































Part	 of	 the	 findings	 of	 my	 research	 on	 Circulating	 Lymphocytes	 (Chapter	 3	 of	 this	
thesis)	was	published	in	the	following	article:	
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Natuley	 Smalle,	 Thomas	 A.	 Hughes,	 Clive	 RD.	 Carter, Lymphocyte	 depletion	 and	
repopulation	 after	 chemotherapy	 for	 primary	 breast	 cancer.	 Breast	 Cancer	 Res.	
2016;18:10.		
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Chemotherapy	 is	 used	 for	 treatment	 of	 breast	 cancer.	 However,	 relatively	 little	 is	
known	about	the	extent	or	the	time	course	of	immune	dysfunction	caused	by	it.	The	aim	
of	this	study	was	to	evaluate	the	circulating	lymphocytes	and	tetanus	&	pneumococcal	
antibody	 titers	 pre	 and	 at	 various	 time	 points	 post-chemotherapy	 and	 check	 for	












There	 were	 significant	 depletions	 of	 circulating	 B,	 CD4+T,	 CD8+T	 and	 NK	 cells	 at	 2	
weeks	post-chemotherapy	(p<0.001),	with	B	cells	showing	maximum	depletion.	Levels	
of	 B	 cells	 and	 CD4+	 T	 cells	 remained	 significantly	 low	 even	 at	 9	 months	 post-
chemotherapy	 (p<0.001).	Repopulating	B	and	CD4+	T	 cell	phenotypes	were	different	




Chemotherapy	 regimen	 and	 the	 extent	 of	 depletion	 of	 lymphocytes	 had	 a	 significant	
influence	on	overall	and	disease-free	survival.		
	
Analysis	 of	 TILs	 showed	 significant	 correlations	 between	 the	 stromal	 and	 intra-
tumoural	 levels	 of	 each	of	 the	 lymphocytes	 and	between	different	 lymphocytes.	TILs	
correlated	with	hormone	negative,	 triple	negative	and	grade	3	tumours.	Only	 tumour	
infiltrating	CD8+	 lymphocytes	 correlated	with	 its	matched	 circulating	 levels,	 and	 this	
positive	 correlation	 was	 stronger	 in	 hormone	 negative	 and	 triple	 negative	 tumours.	
High	 CD4+	 stromal	 infiltrate	 was	 associated	 with	 better	 disease-free	 survival	 and	
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Breast	 cancer	 chemotherapy	 has	 significant	 long-term	 effects	 on	 the	 immune	
parameters	 and	 this	 should	 be	 taken	 into	 consideration	 during	 clinical	management.	
TILs	are	associated	with	poor	prognostic	features	and	also	show	some	correlation	with	
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Breast	 cancer	 is	 the	most	 common	 cancer	 in	 the	 UK	and	 is	 by	 far	 the	most	 common	




BRCA1	 or	 BRCA2	 genes.	 Other	 risk	 factors	 include	 early	menarche,	 late	menopause,	
nulliparity,	and	exogenous	oestrogens	such	as	hormone	replacement	therapy	(Lacey	et	





‘grade’.	 Each	 of	 these	 factors	 impacts	 on	 prognosis	 and,	 to	 a	 certain	 extent,	
recommended	 treatment	 (see	 section	 1.1.3).	 Virtually	 all	 breast	 cancers	 are	
adenocarcinomas.	These	may	be	classified	as	in-situ	carcinoma	(tumour	cells	confined	
to	 ducts/acini)	 or	 invasive	 carcinoma	 (tumour	 cells	 invaded	 through	 the	 basement	
membrane	 into	surrounding	 tissues).	 Invasive	carcinomas	are	classified	histologically	
as	 infiltrating	 ductal	 (85%	 of	 the	 total),	 infiltrating	 lobular	 (10%),	 mucinous	 (2%),	
tubular	 (2%)	 or	 medullary	 (<1%)	 (Dillon,	 2014).	 Infiltrating	 ductal,	 lobular	 and	
medullary	 cancers	 have	 worse	 prognoses	 compared	 to	 mucinous	 or	 tubular	 types	
(Soerjomataram	et	al.,	2008).	Inflammatory	breast	cancer	is	a	further	classification	that	
can	 be	 superimposed	 on	 these	 subtypes.	 It	 is	 a	 rare	 and	 very	 aggressive	 disease	 in	
which	cancer	cells	block	lymph	vessels	in	the	breast	skin.	It	presents	as	a	swollen,	red	
or	 “inflamed”	 breast.	 Invasive	 inflammatory	 breast	 cancer	 cases	 are	 associated	with	
particularly	poor	prognoses	 (Dawood	et	al.,	 2011).	Breast	 cancer	 staging	 is	 based	on	
tumour	size,	lymph	node	status	and	metastases	(TNM)	(Table	1)	(Hortobagyi,	2017).		 	
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Stage	 Tumour	size	 Lymph	 node	
metastasis	
Distant	metastasis	
Stage	1A	 ≤2	cm	 N0	 No	















































Prognosis	 varies	 dramatically	 depending	 on	 stage	 at	 diagnosis	 with	 5	 year	 survival	
rates	of	99%	for	stage	1	to	only	15%	for	stage	4	(CRUK,	2016).	Tumour	grade	depends	
on	 the	 appearance	 of	 cancer	 cells	 and	 is	 defined,	 at	 least	 in	 the	 UK,	 by	 the	modified	
Bloom–Richardson–Elston	system	(Elston	and	Ellis,	1991).	This	is	used	to	assign	scores	
to	three	tumour	characteristics:	the	number	of	mitoses	(more	gives	a	higher	grade),	the	
degree	 of	 nuclear	 pleomorphism	 (more	 pleomorphic	 gives	 higher	 grade),	 and	 the	
degree	 to	 which	 the	 cells	 attempt	 to	 form	 normal	 tissue-like	 structures	 (more	 gives	
lower	grade).	The	result	is	a	grading	of	1,	2	or	3.	Patients	with	grade	1	tumours	show	




Breast	 cancer	 is	 a	 heterogenous	 disease	with	many	 biological	 subtypes	 that	 respond	
differently	to	various	treatment	modalities.	Histological	classification	of	breast	cancers	
includes	 in-situ	 cancers	 and	 invasive	 cancers	 as	 described	 above.	 However,	 newer	
classification	 systems	 using	 molecular	 markers	 such	 as	 estrogen	 receptor	 (ER),	
progesterone	 receptor	 (PR),	 human	 epidermal	 growth	 factor	 receptor	 2	 (ErbB2	 or	
Her2/neu)	and	p53	are	used	more	commonly	as	these	enable	to	predict	the	response	to	
newer	 targeted	 therapies.	 Molecular	 classification	 includes	 Luminal	 A,	 Luminal	 B,	
Triple-negative/	Basal-like,	Her2-enriched	and	Normal-like.	Luminal	A	breast	cancers	
are	hormone	receptor	positive,	Her2	negative	and	have	low	levels	of	Ki-67.	They	tend	
to	 grow	 slowly	 and	 have	 the	 best	 prognosis.	 Luminal	 B	 breast	 cancers	 are	 hormone	




have	 worse	 prognosis.	 They	 however	 can	 be	 successfully	 treated	 with	 targeted	




In	 the	 past,	 breast	 cancer	 was	 not	 considered	 to	 be	 immunogenic.	 However,	 many	
breast	 cancer	 antigens	 have	 now	 been	 identified.	 These	 immunogenic	 proteins	 in	
breast	cancer	can	stimulate	a	systemic	immune	response.	These	immunogenic	proteins	
or	breast	cancer	antigens	are	transcribed	by	breast	cancer	related	genes.	Examples	of	
breast	 cancer	 antigens	 include	 Her2/neu,	 Mucin	 (MUC)-1,	 CEA,	 p53,	 Telomerase	 -
associated	 proteins	 (Disis,	 2004).	 MUC-1	 is	 one	 of	 the	 most	 extensively	 evaluated	
immunological	marker	of	breast	cancer.	It	is	a	membrane	bound	glycoprotein	and	is	a	
component	of	ductal	cell	surface	of	most	glandular	cells.	MUC-1	is	both	over	expressed	





immunotherapy	 treatments	 being	 used	 in	 breast	 cancer	 patients.	 The	 advantage	 of	
immunotherapy	 over	 other	 treatment	 modalities	 is	 the	 specificity	 of	 the	 immune	
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The	 molecular	 pathology	 and	 classification	 of	 breast	 cancers	 determine	 their	
treatments,	 with	 some	 therapies	 targeted	 at	 cancers	 with	 only	 particular	 molecular	
characteristics,	while	other	therapies	are	indicated	in	high	grade/stage	disease.	Surgery	
is	 the	 primary	 treatment	 in	 the	 vast	 majority	 of	 cases	 (mastectomy,	 or	 breast	
conserving	surgery	where	possible)	and	is	usually	combined	with	adjuvant	treatments	




wide	 local	 excision	 and	 surgery	 to	 the	 axilla.	 Axillary	 surgery	may	 be	 in	 the	 form	 of	
sentinel	node	biopsy	(SLNB)	or	axillary	lymph	node	clearance	(ANC)	or	SLNB	followed	
by	ANC.	While	former	causes	minimal	disruption	of	lymphatics	and	removes	only	1-2	
nodes;	 the	 latter	 involves	 removing	 all	 lymph	 nodes	 from	 the	 axilla	 and	 thereby	
disrupting	 the	 lymphatics	 on	 that	 side.	 Since	 lymph	 nodes	 are	 important	 peripheral	




infections	 involving	 the	 arm.	 Repeated	 infections	 can	 also	 lead	 to	 backing	 up	 of	
lymphatic	fluid	leading	to	lymphoedema.	Axillary	node	clearance	carries	a	significantly	
higher	 risk	of	 lymphoedema	 compared	 to	 sentinel	node	biopsy	 (Mansel	 et	al.,	 2006).	
There	 is	 however	 no	 evidence	 in	 literature	 that	 axillary	 surgery	 affects	 systemic	
immunity.		
1.1.3.2 	Chemotherapy	
Chemotherapy	 can	 be	 administered	 in	 the	 adjuvant	 (post-surgery)	 or	 neo-adjuvant	
setting	 (pre-surgery).	 The	 clinical	 goal	 of	 chemotherapy	 is	 to	 improve	 disease	
free/overall	 survival.	 Neo-adjuvant	 chemotherapy	 (NACT)	 can	 enable	 breast	
conservation	 surgery,	 as	 opposed	 to	 mastectomy,	 and	 thereby	 improve	 cosmetic	
outcomes	(Kaufmann	et	al.,	2012).	It	also	allows	for	assessing	the	response	of	tumour	
to	 chemotherapy	 and	 switching	 of	 therapy	 in	 case	 of	 non-response,	 thus	 allowing	 a	
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more	 patient	 or	 tumour	 specific	 regimen	 in	 order	 to	 improve	 the	 outcome,	 although	
this	has	been	questioned	recently	(Vaidya	et	al.,	2018).	 	Indications	for	chemotherapy	
include	nodal	 involvement,	 large/high-grade	 tumours,	 triple	negative	 tumours	 (those	
not	 expressing	 oestrogen	 receptor	 alpha,	 progesterone	 receptor,	 or	 Her2),	 Her2+	
tumours,	 inflammatory	 breast	 cancers	 and	 metastatic	 cancers.	 Anthracycline	 based	
chemotherapy	 is	 generally	 recommended	 and	 taxanes	 are	 added	 where	 additional	
benefit	outweighs	risk.	Actual	choice	of	chemotherapy	is	usually	guided	by	local	policy	
(NICE,	 2009).	 The	 2005	 Oxford	 overview	 analysis	 showed	 that	 combination	
chemotherapy	reduces	proportional	annual	risk	of	recurrences	by	almost	25%	and	risk	
of	 death	 by	 around	 17%	 (Early	 Breast	 Cancer	 Trialists'	 Collaborative,	 2005,	 Early	
Breast	Cancer	Trialists'	 Collaborative	 et	 al.,	 2012).	 Study	 reported	 results	 from	4756	
women	in	10	randomised	trials	that	began	before	2005	and	compared	NACT	with	the	
same	chemotherapy	given	post	op.	A	recent	meta-analysis	on	the	use	of	chemotherapy	
in	 adjuvant	 and	 neo-adjuvant	 setting	 showed	 that	 NACT	was	 associated	 with	 breast	
conservation	but	also	an	absolute	increase	in	15-year	risk	of	local	recurrence	by	5.5%	
(21.4%	 for	NACT	 versus	 15.9%	 for	 adjuvant	 chemotherapy	 (ACT),	 p=0.0001).	 There	
was	 however,	 no	 significant	 difference	 in	 15-year	 distant	 recurrence	 in	 patients	
undergoing	NACT	versus	ACT	(38.2%	for	NACT	versus	38.0%	for	ACT,	RR	1.02,	p=0.66),	
breast	 cancer	death	 (34.4%	vs	33.7%,	 relative	 risk	 (RR)	1.18,	 p=0.31)	or	death	 from	
any	 cause	 (40.9%	 vs	 41.2%,	 RR	 1.04,	 p=0.45)	 (Early	 Breast	 Cancer	 Trialists'	
Collaborative,	2018).	Prior	to	this,	Mieog	et	al.,	 	had	shown	that	mastectomy	rate	was	
lower	in	patients	treated	with	NACT	versus	those	having	ACT	(RR	0.71)	(Mieog	et	al.,	
2007).	Overall	 survival	was	same	 in	both	groups	(HR	0.98,	95%	CI	0.87	 to	1.09)	and	
there	was	no	significant	difference	in	local	recurrence	rates	in	the	two	groups	(HR	1.12,	
95%	 CI	 0.92	 to	 1.37).	 This	 meta-analysis	 also	 reported	 decreased	 rate	 of	 infectious	
complications	 in	 the	NACT	 group	 (RR	 0.69,	 95%	CI	 2.3-5.6).	 The	 authors	 postulated	
that	the	decrease	in	the	infectious	complications	in	NACT	group	was	possibly	due	to	the	
fact	that	patient	who	had	surgery	after	chemotherapy	had	a	chance	to	recover	from	the	
immune	 suppressive	 effects	 of	 chemotherapy.	 However,	 if	 patients	 had	 surgery	 first,	
the	immune	system	was	perhaps	depressed	due	to	the	stress	of	surgery	and	following	a	




mastectomy	 in	 high-risk	 patients	 (large/high-grade	 tumours,	 positive	 resection	
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margins,	 lymph	 node/pectoralis	 major	 involvement).	 Overall,	 radiotherapy	 reduces	
risk	of	loco-regional	or	distant	first	recurrence	from	35%	to	19.3%	and	reduces	the	15-
year	 risk	of	 breast	 cancer	death	 from	25.2%	to	21.4%	 (Early	Breast	Cancer	Trialists'	
Collaborative	et	al.,	2011).	
1.1.3.4 	Endocrine	treatments	
Endocrine	 treatments	are	used	 for	tumours	 that	express	oestrogen	receptor	alpha,	as	
assessed	by	clinical	pathology	analysis	of	tumour	samples.	Options	include	Tamoxifen	
for	 pre-menopausal	 women,	 and	 aromatase	 inhibitors	 for	 post-menopausal	 women.	
Tamoxifen	has	been	shown	to	improve	breast	cancer	patient	survival	rates	from	65%	
to	74%	over	15	years	 and	 reduces	 recurrence	 rates	 from	44%	 to	33%	 (Early	Breast	
Cancer	Trialists'	Collaborative,	2005).	When	given	as	first	line	adjuvant	therapy	in	post-
menopausal	 women,	 aromatase	 inhibitors	 (AIs)	 improve	 disease	 free	 survival	 (DFS)	
compared	 to	 tamoxifen,	 therefore	 AIs	 are	 now	 the	 preferred	 endocrine	 treatment	 in	
this	group	(Coates	et	al.,	2007,	Forbes	et	al.,	2008).		
1.1.3.5 	Trastuzumab	
Trastuzumab	 is	 a	 humanised	 monoclonal	 antibody	 against	 the	 human	 epidermal	
growth	 factor	 receptor	 2.	 	 Tumours	 are	 routinely	 tested	 for	 Her2	 over-expression.	
Her2/neu	 or	 ErbB-2	 is	 over	 expressed	 in	 20-30%	 of	 breast	 carcinomas	 and	 is	
associated	 with	 aggressive	 disease	 (Slamon	 et	 al.,	 1987,	 Slamon	 et	 al.,	 1989,	 Hudis,	
2007,	Engelstaedter	et	al.,	2012).	Trastuzumab	is	thought	to	act	by	down	regulating	the	
expression	 of	 this	 receptor	 and	 thus	 blocking	 growth	 signals	 for	 tumour	 cells.	 Of	
interest	 in	 the	 context	 of	 my	 immune-related	 work	 is	 the	 fact	 that	 some	 of	
trastuzumab’s	anti-tumour	effects	also	involve	innate	and	adaptive	immune	responses	
such	 as	antibody	dependent	 cell-mediated	 cytotoxicity	 (ADCC)	 (Arnould	 et	 al.,	 2006).	
Large	 trials	have	 shown	 that	adjuvant	 trastuzumab	 improves	disease	 free	 survival	 in	
Her2	positive	breast	cancer	patients	(Romond	et	al.,	2005,	Smith	et	al.,	2007,	Perez	et	
al.,	 2011).	 Trastuzumab	 induced	 tumour	 regression	 is	 T	 cell	 dependent	 and	 has	 also	
been	 found	 to	be	 associated	with	 long-term	 immune	memory,	which	 can	protect	 the	
host	 against	 relapses	 (Park	 et	 al.,	 2010).	 Studies	 in	 mice	 have	 shown	 that	 although	




My	 research	 is	 focused	 on	 influence	 of	 therapies	 for	 breast	 cancer	 on	 the	 adaptive	
immune	system.	I	will	therefore	describe	relevant	components	of	this	system	related	to	
my	work.	There	are	two	distinct	systems,	the	innate	and	the	adaptive.	Innate	immunity	





functional	 cells,	 but	 they	 also	 interact	with	 each	 other	 at	 several	 levels	 to	 develop	 a	
more	complete	defence	against	invading	pathogens.	The	cellular	components	of	innate	
immunity	 include	 natural	 killer	 (NK)	 cells,	 polymorphonuclear	 neutrophils,	





The	primary	 lymphoid	organs	 are	 the	bone	marrow	and	 thymus	where	 lymphocytes	
are	 formed	and	mature.	The	secondary	 lymphoid	organs	are	the	 lymph	nodes,	spleen	
and	 the	mucosal	 lymphoid	 tissue.	Most	 of	 the	 interactions	between	 lymphocytes	 and	
other	 non-lymphoid	 cells,	 to	 generate	 an	 immune	 response	 against	 the	 pathogens,	
occurs	 in	 the	 secondary	 lymphoid	 organs.	 Since	 treatment	 of	 breast	 cancer	 involves	
removal	of	axillary	nodes	(discussed	 in	section	1.1.3.1),	 it	 is	 important	to	understand	




carries	 pathogens	 and	 antigen	 bearing	 cells	 from	 the	 periphery	 to	 the	 lymph	 nodes.	
Free	antigens	diffuse	through	the	extra	cellular	fluid	to	the	lymph	node	while	dendritic	
cells	 and	 lymphocytes	 are	 attracted	 there	 via	 chemokines.	 B	 cells	 are	 localised	 in	
follicles	in	the	outer	cortex	while	T	cells	are	more	diffusely	spread	in	the	para	cortical	
areas.	 The	 presence	 of	 antigen,	 antigen	 presenting	 cells	 (dendritic	 cells	 and	




Lymphoid	 lineage	 cells	 (B,	 T	 and	 NK	 cells)	 are	 derived	 from	 common	 lymphoid	
progenitors,	 which	 in	 turn	 are	 derived	 from	 multipotent	 hematopoietic	 stem	 cells.	
Lymphopoiesis	 takes	place	 in	 the	 central	 lymphoid	 tissues:	 bone	marrow	 for	most	B	






cell.	 The	 early	 stages	 of	 B	 cell	 development	 are	 dependent	 on	 bone	marrow	 stromal	
cells.	The	cytokine	IL-7	secreted	by	bone	marrow	stromal	cells	is	essential	for	growth	
and	survival	of	developing	B	cells	(Parrish	et	al.,	2009).	Further	important	factors	for	





of	 B	 cell	 development	 is	 depicted	 in	 Figure	 1.	 A	 definitive	 B	 cell	 fate	 is	 specified	 by	






















at	 the	 cell	 surface.	Mature	 B	 cells	 produce	 δ	 heavy	 chain	 as	well	 as	 μ	 heavy	 chain	 and	 are	
marked	 by	 the	 additional	 appearance	 of	 IgD	 on	 the	 cell	 surface.	 (Illustration	 adapted	 from	
Janeway’s	Immunobiology,	8th	ed,	figure	8.4).	
	
Immature	 B	 cells	 are	 tested	 for	 auto	 reactivity	 before	 they	 leave	 the	 bone	 marrow.	 The	
tolerance	 produced	 at	 this	 stage	 of	 B	 cell	 development	 is	 called	 central	 tolerance.	 Self-
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tissue,	 the	marginal	sinus	of	spleen.	The	daily	output	of	new	B	cells	 from	bone	marrow	 is	
roughly	5-10%	of	the	total	B	lymphocyte	population.	The	self-reactive	immature	B	cells	has	
one	 of	 these	 4	 outcomes:	 death	 by	 apoptosis,	 production	 of	 new	 receptor	 by	 receptor	
editing,	 induction	 of	 a	 permanent	 state	 of	 unresponsiveness,	 or	 a	 state	 of	 immunological	
tolerance.	 Immature	B	cells	proceed	 through	two	defined	transitional	stages	 in	 the	spleen,	
termed	T1	and	T2,	before	they	mature	into	naive	B-lymphocytes.	Normally,	lymphocytes	will	





















a	 different	 developmental	 stage	 and	 have	 a	 specific	 function.	 The	 current	 model	 of	
human	 peripheral	 B	 cell	 development	 involves	 four	 major	 consecutive	 stages:	
transitional	B	 cells	 that	have	 just	 emerged	 from	bone	marrow	but	 are	 still	 unable	 to	
respond	 to	 antigens,	 naïve	 B	 cells	 that	 are	 fully	 mature	 but	 have	 not	 encountered	
antigen,	 memory	 B	 cells	 that	 have	 encountered	 antigen	 and	 survive	 for	 extended	









































B	cells	 that	 are	 recently	derived	 from	bone	marrow	are	 referred	 to	 as	 transitional	B	
cells.	They	can	be	identified	using	various	markers	such	as	CD10+,	CD24+,	CD38+,	CD23+,	
CD21+/35hi	(Srivastava	et	al.,	2005,	Palanichamy	et	al.,	2009,	Cuss	et	al.,	2006).	 In	our	





Adult	 circulating	 B	 cells	 can	 be	 separated	 into	 3	 subtypes	 based	 on	 CD27	 and	 IgD	
expression	and	naïve	B	cells	are	marked	by	the	lack	of	expression	of	CD27	(Agematsu	et	







After	an	 encounter	with	 a	 specific	pathogen	and	generation	of	 an	antibody	 response,	
levels	 of	 specific	 antibodies	 to	 that	 particular	 antigen	 decrease	 in	 serum	 over	 a	
relatively	short	period	of	time.	However,	immunological	memory	persists	in	the	B	cell	
population,	which	 is	capable	of	 rapid	clonal	expansion	upon	re-exposure	 to	 the	same	
antigen.	Memory	 B	 cells	 represent	 up	 to	 40%	 of	 circulating	 B	 cells.	Memory	 B	 cells,	
identified	 by	 their	 expression	 of	 CD27,	 can	 be	 divided	 into	 switched	 (IgD-)	 and	non-
switched	(IgD+)	based	on	the	immunoglobulin	expression	(Agematsu	et	al.,	2000,	Shi	et	
al.,	2003).		
1.2.2.3.1  Non-switched Memory B cells (CD19+CD27+IgD+) 
These	are	also	known	as	IgM	memory	B	cells	and	are	produced	in	the	splenic	marginal	
zone.	 They	 form	 a	 B	 cell	 subset	 that	 is	 distinct	 from	 the	 classical	 germinal	 centre	
derived	 memory	 B	 cells	 (Weller	 et	 al.,	 2004).	 They	 initiate	 early	 low	 affinity	 IgM	
antibody	 responses.	 Clinically,	 low	 IgM	 memory	 B	 cell	 levels	 are	 associated	 with	




1.2.2.3.2 Switched Memory B cells (CD19+CD27+IgD-) 
This	 cell	 type	 is	 formed	 in	 germinal	 centres	within	 lymph	 nodes	 or	 spleen	 following	
encounter	with	antigen	and	stimulation	from	CD4+	T	helper	cells	(Steiniger	et	al.,	2005).	




These	are	 terminally	differentiated	B	cells	 that	are	 formed	 in	 the	germinal	centres	of	
secondary	 lymphoid	 organs	 (spleen	 and	 lymph	 nodes)	 and	 finally	 reside	 in	 bone	
marrow.	They	can	be	identified	by	expression	of	high	levels	of	CD27,	CD38	and	CD138	
and	 absence	 (or	 low	 expression)	 of	 CD20	 (Rawstron,	 2006).	 They	 secrete	 large	
amounts	of	antibody.	Normally	these	cells	represent	a	minor	population	in	peripheral	





the	 immune	 response,	 although	 the	 phenotypes	 of	 these	 ‘regulatory’	 B	 cells	 are	 still	





























heavy	 chains	 and	 two	 identical	 light	 chains	 joined	 together	 by	 disulphide	 bonds.	 Each	
heavy	and	 light	 chain	has	a	 constant	 and	a	 variable	 region.	A	 light	 chain	and	a	heavy	
chain	form	each	arm	of	the	antibody	molecule	such	that	the	variable	regions	of	both	these	
come	together	to	from	the	antigen	binding	site.	The	part	of	the	immunoglobulin	that	has	


























within	 the	 thymus,	 also	 called	 thymocytes,	 undergo	 a	 series	of	maturation	 steps	 and	
can	be	identified	based	on	the	expression	of	different	cell	surface	markers.	The	majority	
develop	 into	 αβ	 T	 cells	 while	 about	 5%	 develop	 into	 γδ	 T	 cells.	 Notch	 signalling	 is	
required	throughout	the	development	of	T	cells	and	helps	differentiation	into	αβ	versus	
γδ	 and	 also	 CD4	 versus	 CD8.	 The	 αβ	 and	 γδ	 T	 cells	 are	 developed	 early	 in	 the	
differentiation	period	when	the	progenitor	cells	enter	the	thymus.	Later,	the	αβ	T	cells	
develop	 into	 CD4	and	 CD8	 T	 cells.	 The	 initial	 thymocytes	 however,	 lack	 CD4	 or	 CD8	
receptors	and	are	called	double	negative	(DN)	cells.	They	are	further	subdivided	based	
on	 the	 expression	of	CD44	(an	 adhesion	molecule)	 and	CD25	(IL-2	 receptor	α	 chain)	
and	 successive	 stages	 in	 the	 development	 of	 thymocytes	 are	 marked	 by	 changes	 to	






peripheral	 lymphoid	 organs	 where	 they	 may	 become	 activated	 on	 encountering	 an	
antigen.	 This	 leads	 to	 clonal	 expansion	 and	 differentiation	 into	 effector	 T	 cells.	 The	
effector	T	cells	are	attracted	to	the	sites	of	infection	where	they	kill	the	infected	cells	or	












T	 cell	 progenitors	 that	migrate	 to	 the	 thymus	are	 called	 thymocytes.	 These	 thymocytes	
undergo	a	series	of	maturation	steps	in	the	thymus	and	are	identified	by	the	presence	of	
different	cell	surface	markers.	The	earliest	thymocytes	lack	CD4	and	CD8	and	are	called	
double	 negative	 cells	 (DN).	 The	 earlier	 DN	 cells	 express	 CD44	while	 the	 later	 DN	 cells	




β	 chain	 gene	 arrangements	 and	 expression	 of	 both	 CD4	 and	 CD8.	 Once	 the	 immature	
double	positive	thymocytes	(DP)	that	form	a	vast	majority	of	thymocytes,	have	ceased	to	
proliferate,	 and	 become	 small	 double	 positive	 cells,	 the	 α	 chain	 locus	 begins	 to	
rearrange.These	cells	express	either	CD4	or	CD8	only.	These	single	positive	thymocytes	are	
gradually	 exported	 from	 the	 thymus	 into	 circulation	 as	 peripheral	 T	 cells.	 (Illustration	
adapted	from	Janeways’s	Immunobiology,	8th	ed,	figure	8.20).	
1.2.5 	T	lymphocyte-	subtypes	and	function	
T	 lymphocytes	 consist	 of	 naïve	 T	 cells	 that	 have	 not	 yet	 encountered	 their	 cognate	
antigen,	effector	T	cells	that	actively	respond	to	any	stimulus,	and	a	pool	of	long-lived	
memory	 T	 cells	 that	 can	 respond	 immediately	 in	 case	 of	 re-infection.	 The	 effector	 T	
cells	consist	of	the	CD4+	helper	T	cells,	CD8+	cytotoxic	T	cells,	and	FoxP3+	regulatory	T	
cells	(Tregs).	
























are	 considered	mature	 T	 cells	 and	 unlike	 the	memory	 T	 cells	 have	 not	 encountered	
their	cognate	antigen	in	the	periphery.	They	are	recognised	by	the	absence	of	memory	
CD45RO	 and	presence	 of	 CD45RA	 isoform	 and	 are	 also	 characterised	 by	 the	 surface	
expression	 of	 L-selectin	 (CD62L)	 (Beverley	 et	 al.,	 1992,	 van	 den	 Broek	 et	 al.,	 2018).	
Naïve	 T	 cells	 constantly	 circulate	 through	 the	 secondary	 lymphoid	 organs	 and	
circulating	 blood	 until	 they	 encounter	 their	 cognate	 antigen.	 Once	 activated,	 they	
proliferate	and	migrate	to	the	site	of	infection	as	effector	T	cells.		
	
A	 surface	molecule	 CD31	 has	 been	 used	 to	 identify	 2	 subsets	 of	 naïve	 T	 cells	 in	 the	
peripheral	 blood	of	 humans:	CD31+	and	CD31-.	The	CD31+	 cells	 have	been	 found	 to	
have	 significantly	higher	 levels	 of	T	 cell	 receptor	 excision	 circle	 (TREC).	 Since	TRECs	
are	 not	 replicated	 during	 mitoses,	 with	 each	 cell	 division,	 there	 is	 reduction	 in	 the	
content	of	TREC.	The	quantification	of	TREC	has	been	used	to	assess	the	proliferative	
history	of	T	cells.	CD31+	T	cells	have	been	 found	to	have	high	TREC	content	which	 is	
only	slightly	 lower	 than	 that	seen	 in	 thymocytes,	 indicating	that	 these	cells	represent	
recent	thymic	emigrants.	The	levels	of	CD31+	and	CD31-	naïve	cells	change	during	life.	





naïve	 T	 cells	 before	 an	 encounter	 of	 naïve	 T	 cells	with	 their	 cognate	 antigen.	 Others	
believe	 that	naïve	T	 cells	 turn	 into	 effector	T	 cells	 after	 encounter	with	 antigen.	The	
effector	T	cells	migrate	to	the	inflamed	tissue	and	kill	the	infected	cells.	Following	this	
most	 effector	 cells	 die.	 However,	 there	may	 remain	 a	 small	 pool	 of	 residual	 effector	
cells	called	memory	cells	which	are	ready	to	proliferate	after	a	second	encounter	with	
the	 same	 antigen	 (Pepper	 and	 Jenkins,	 2011,	 Kaech	 and	 Cui,	 2012,	 Omilusik	 and	
Goldrath,	2017).	They	can	be	differentiated	from	naïve	T	cells	by	their	specific	surface	










extra-cellular	pathogens	(Romagnani,	 1999).	Both	Th1	and	Th2	 cells	 help	 in	priming	
the	CD8+	T	cells	and	in	the	development	of	memory.	The	effector	properties	of	CD8+	T	





maintaining	 tolerance	 to	 self-antigens	 and	 preventing	 autoimmune	 diseases.	 They	
develop	either	during	 the	normal	development	of	T	cells	 in	the	 thymus	at	the	double	
positive	 stage	 (natural	 regulatory	 T	 cells)	 or	 they	develop	 in	 the	periphery	 from	 the	
CD4+	naïve	T	cells	(adaptive	regulatory	T	cells)	(Curotto	de	Lafaille	and	Lafaille,	2009).	
The	 expression	 of	 a	 nuclear	 transcription	 factor	 forkhead	 box	 protein	 3	 (FoxP3)	
determines	the	natural	development	and	function	of	Tregs	(Miyara	et	al.,	2009,	Li	et	al.,	
2015).	 FoxP3	 is	 a	 protein	 involved	 in	 immune	 responses	 and	 belongs	 to	 the	
forkhead/winged	helix	family	of	transcription	regulators.	It	has	a	DNA-binding	domain	
that	can	recruit	both	transcriptional	activator	and	repressor	complexes	to	target	genes.	
It	 plays	 a	 crucial	 role	 in	 generation	 of	 CD4+CD25+	 regulatory	 T	 cells,	 which	 act	 as	
suppressive	 agents,	 and	 can	 be	 used	 as	 a	 biomarker	 to	 identify	 regulatory	 T	 cells	
(Fontenot	 et	 al.,	 2003).	 They	 are	 essential	 for	 maintaining	 immune	 tolerance	 (Zou,	
2006).	One	of	the	ways	by	which	they	maintain	immune	tolerance	is	by	inhibiting	the	




B	 and	 T	 cells	 occupy	 two	 distinct	 zones	 in	 peripheral	 lymphoid	 tissues.	 For	 linked	




chemokines.	 When	 circulating	 naïve	 B	 cells	 migrate	 into	 the	 lymphoid	 tissues,	 they	
enter	 the	 primary	 lymphoid	 follicles	 attracted	 by	 the	 chemokine	 CXCL13.	Within	 the	
follicle,	 stromal	 cells	 and	 follicular	 dendritic	 cells	 secrete	 CXCL13	 while	 naïve	 cells	
express	 the	 receptor	 for	 this	 chemokine,	 CXCR5.	When	 the	naïve	B	 cell	 in	 the	 follicle	
encounters	its	specific	antigen,	the	antigen	is	bound	to	the	B	cell	receptor,	the	complex	
is	internalized,	and	the	antigen	is	degraded	into	peptides	and	then	presented	on	the	cell	
surface	 bound	 to	 MHC	 class	 II	 molecules	 (Figure	 5).	 Encounter	 with	 antigen	 also	
induces	 expression	 of	 chemokine	 receptor	 CCR7.	The	 B	 cell	 then	moves	 towards	 the	
boundary	between	the	T	cell	area	and	 the	 follicle	where	chemokine	 ligands	 for	CCR7,	
such	as	CCL21,	are	expressed	by	stromal	cells	and	dendritic	cells.	Naïve	T	cells	express	
CCR7	 but	 not	 CXCR5	 and	 so	 are	 localised	 to	 the	 T	 cell	 areas.	 When	 a	 naïve	 T	 cell	
encounters	 its	 cognate	 peptide	 antigen	 presented	 by	 a	 dendritic	 cell,	 expression	 of	
CXCR5	 is	 induced	 as	 the	 T	 cell	 begins	 to	 proliferate.	 Some	 T	 cells	 differentiate	 into	
effector	T	cells	and	leave	the	lymphoid	tissue	but	others	become	TFH	cells	(T	follicular	
helper	cells)	and	migrate	to	the	boundary	between	T	cell	area	and	a	follicle	attracted	by	
the	 chemokine	 CXCL13.	 TFH	cells	 that	 have	 already	 differentiated	 in	 response	 to	 the	
same	antigen	presented	to	them	by	dendritic	cells,	recognize	the	peptide:MHC	class	II	












Antigen	 that	 binds	 to	 the	 B	 cell	 antigen	 receptor	 is	 internalized	 and	 processed	 into	
peptides.	 These	 are	 returned	 to	 the	 B	 cell	 surface	 bound	 to	 MHC	 class	 II	 molecules.	




Binding	 of	 CD40	 by	 CD40	 ligand	 helps	 to	 drive	 the	 resting	 B	 cell	 into	 cell	 cycle	 and	 is	
essential	 for	 B	 cell	 response	 to	 thymus	 dependant	 antigens.	 T	 cells	 provide	 additional	
signals	 to	 B	 cells	 in	 the	 form	 of	 secreted	 cytokines	 (IL4,	 IL5,	 IL6)	 that	 regulate	 B	 cell	
proliferation	 and	 antibody	 production.	 BCR:	 B	 cell	 receptor;	 TCR:	 T	 cell	 receptor.	
(Illustration	adapted	from	Janeways’s	Immunobiology,	8th	ed,	figure	10.3).	
	
Antibody	 responses	 to	 protein	 antigens	 that	 require	 antigen-specific	 T	 cell	 help	 as	
described	 above	 are	 known	 as	 thymus	 dependent	 antigens.	 Some	 microbial	
constituents	such	 as	bacterial	polysaccharides	 can	 induce	 antibody	production	 in	 the	
absence	of	 helper	T	 cells.	 These	 are	known	as	 thymus	 independent	 antigens.	 In	both	
instances,	B	cells	require	two	signals	for	activation.	The	first	signal	is	delivered	by	the	B	
cell	 receptor	when	 it	binds	an	antigen.	 In	the	case	of	 thymus	dependent	antigens,	the	
second	signal	 is	delivered	by	 the	helper	T	cell	 that	 recognises	degraded	 fragments	of	
antigens	as	peptides	bound	to	MHC-class	II	molecules	on	the	B	cell	surface.	For	thymus	



















cancer	cells	 that	arise	 in	 the	body.	Frank	MacFarlane	Burnett	and	Lewis	Thomas	 first	
introduced	the	concept	of	 ‘Immune	Surveillance’	 in	 the	1950’s	(Burnet,	1964,	Burnet,	
1970,	Thomas,	1982).	Further	developments	in	this	field	led	to	the	development	of	the	





2004,	Murphy,	 2012d,	Mittal	 et	 al.,	 2014).	 The	 innate	 and	 adaptive	 immune	 systems	
work	 together	 to	 detect	 developing	 tumours	 and	 ideally	 destroy	 them	 before	 they	
become	clinically	detectable	(Dunn	et	al.,	2004,	Schreiber	et	al.,	2011).	In	an	immune-
competent	 individual,	 tumour	 cells	 are	 continuously	 removed	 during	 the	 elimination	
and	 the	 equilibrium	 phases,	 thus	 delaying	 tumour	 growth.	 If	 the	 immune	 system	 is	
compromised,	the	equilibrium	phase	rapidly	turns	into	escape	phase	and	tumour	cells	
are	removed	 less	effectively.	This	process	 is	evident	 from	the	occurrence	of	cancer	 in	
recipients	 of	 organ	 transplants	 on	 immunosuppressive	 therapy	 (Penn	 and	 Starzl,	
1973).	 Incidence	 of	 cancer	 in	 these	 patients	 has	 been	 found	 to	 be	 twice	 that	 of	 the	
general	 population	 (Collett	 et	 al.,	 2010).	 A	 study	 of	 1,75,732	 solid	 organ	 transplant	
patients	 showed	 an	 elevated	 incidence	 of	 32	 different	 cancers,	 with	 non-Hodgkin’s	
lymphoma	being	commonest	(Engels	et	al.,	2011)	
	
Tumours	 avoid	 immune	 recognition	 in	 a	 number	 of	 ways.	 They	 may	 have	 low	
immunogenicity.	Low	 immunogenicity	 implies	that	 the	cytotoxic	T	cells	are	unable	 to	
recognize	 the	 tumour	 antigens	 (Maeurer	 and	 Lotze,	 1997).	 Some	 tumours	 lose	
expression	of	MHC	class	I	molecules	or	co-stimulatory	proteins,	and	therefore	they	are	
not	 recognized	 by	 cytotoxic	 T	 cells	 (Garrido	 et	 al.,	 1997).	 Tumours	 often	 produce	
immunosuppressive	 cytokines	 such	 as	 TGF-b	 and	 IL-10	 that	 can	 suppress	 immune	
responses	directly	(Maeda	and	Shiraishi,	1996)	or	can	recruit	regulatory	T	cells	(Tregs)	
that	 secrete	 immunosuppressive	 cytokines	 (Jacobs	 et	 al.,	 2012).	 Regulatory	 T	 cell	
represent	 an	 important	 subset	 of	 CD4+	 T	 cells	 that	 helps	 to	maintain	 immunological	
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self-tolerance,	and	comprises	about	5-10%	of	CD4+	T	cells	in	the	peripheral	circulation	
(Sakaguchi	 et	 al.,	 2007,	 Baecher-Allan	 et	 al.,	 2004).	 Levels	 of	 regulatory	 T	 cells	 have	
been	found	to	be	elevated	in	a	variety	of	cancers	(Curiel	et	al.,	2004,	Kobayashi	et	al.,	
2007,	 Shen	et	 al.,	 2010).	The	 innate	 and	adaptive	 immune	 systems	work	 together	 to	
detect	 developing	 tumours	 and	 ideally	 destroy	 them	 before	 they	 become	 clinically	
apparent	 (Dunn	et	 al.,	 2004,	 Schreiber	 et	 al.,	 2011).	Both	CD4+	and	CD8+	T	 cells	are	
important	 in	 achieving	 immunological	 control	 of	 tumours.	 CD4+	 T	 cells	 activate	 the	




discussion	 of	 how	 chemotherapy	 interacts	 with	 the	 immune	 system	 is	 relevant.	
Conventionally,	 chemotherapy	 is	 considered	 to	 be	 immune	 suppressive,	 through	
damaging	key	immune	cells	(see	section	1.4).	However,	there	is	evidence	that	cell	death	










et	 al.,	 2003).	 This	 could	 potentially	 cause	 long	 lasting	 remissions	 in	 some	 types	 of	
cancer.	The	dying	cancer	cells	can	also	stimulate	immune	responses	which	in	turn	can	








in	 cancer	 patients	 adversely	 affects	 the	 response	 to	 chemotherapy	 in	 multiple	 solid	
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cancers	 including	 breast	 cancer	 (Ray-Coquard	 et	 al.,	 2009)	 implying	 that	 the	
immunosuppressed	patient	is	probably	unable	to	mount	an	adequate	immune	response	
after	 chemotherapeutic	 agents.	 It	 has	 also	 been	 suggested	 that	 letrozole	 used	 in	 the	
treatment	of	hormone	receptor	positive	breast	cancer	may	also	have	an	indirect	anti-






The	 tumour	 microenvironment	 contains	 various	 types	 of	 cells	 including	 leukocytes,	
macrophages	 and	 dendritic	 cells.	 These	 cells	 help	 to	 modulate	 the	 tumour	
microenvironment	 to	 an	 immune	 stimulatory,	 anti-tumour	 or	 immune	 suppressive,	
tumour-promoting	 environment.	The	 initial	 reports	 failed	 to	distinguish	between	 the	
different	 types	 of	 cells	 in	 the	 tumour	 environment	 but	 with	 the	 development	 of	
monoclonal	antibodies,	it	became	easier	to	characterise	the	infiltrate	more	specifically	
(Whitford	 et	 al.,	 1990).	 Although	 the	 composition	 of	 cells	 involved	 in	 innate	 and	








The	majority	 of	 tumour-infiltrating	 lymphocytes	 (TILs)	 in	 solid	 tumours	 are	 CD3+	 T	
cells,	which	includes	cytotoxic	CD8+	T	cells	and	helper	CD4+	T	cells	(Ahn	et	al.,	2015,	
Ruffell	 et	 al.,	 2012).	 Tumour	 microenvironment	 has	 also	 been	 found	 to	 contain	
molecules	that	are	capable	of	increasing	the	proportion	of	FoxP3+	Tregs	by	causing	the	
CD4+	T	helper	cells	to	develop	into	FoxP3+	Tregs,	by	recruiting	existing	FoxP3+	Tregs	
to	 the	 tumour	 site,	 and	 by	 causing	 the	 proliferation	 of	 existing	 Tregs	 in	 the	 tumour	
tissue	 (Zou,	 2006,	 Pardoll,	 2012).	 Another	 subtype	 of	 T	 cell	 that	may	 have	 a	 role	 in	
influencing	 the	 tumour	 microenvironment	 includes	 the	 CD45RO+	 memory	 T	 cells.	
There	 is	some	evidence	 that	high	 levels	of	CD45RO+	T	cells	 in	 tumour	 tissue	may	be	
associated	with	good	prognosis	(Pages	et	al.,	2009,	Pages	et	al.,	2010).	The	precise	role	
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Given	 the	 proposed	 role	 of	 immunity	 in	 immunosurveillance	 along	 with	 the	
requirement	 for	 an	 intact	 immune	 system	 for	 a	number	 of	 treatment	modalities,	 the	
effect	of	chemotherapy	on	immunity	is	of	some	importance.	A	high	level	of	cytotoxic	T	
cells	in	peripheral	circulation	has	been	shown	to	be	a	significant	independent	predictor	
of	 longer	 survival	 in	 patients	 with	 metastatic	 breast	 cancer	 (Blake-Mortimer	 et	 al.,	
2004).	Chemotherapeutic	agents	are,	however,	associated	with	adverse	effects	on	 the	






or	 all	 of	 these	 cells	 leading	 to	 leukopenia,	 anaemia	 or	 thrombocytopenia.	 Symptoms	
depend	on	the	cell	type	affected	and	may	include	increased	susceptibility	to	infections,	
excessive	 fatigue	 and	 increased	 susceptibility	 to	 bruising	 or	 bleeding.	 Chemotherapy	
induced	 neutropenia,	 although	 transient,	 can	 be	 associated	 with	 life	 threatening	





of	 chemotherapy	 for	 breast	 cancer.	 Chemotherapy	 regimens	 used	 in	 the	 past	 (5-FU,	
Methotrexate,	 Chlorambucil	 or	 Cyclophosphamide),	 with	 treatment	 lasting	 for	 more	
than	12	months,	have	been	shown	to	cause	progressive	lymphopenia	with	a	reduction	
in	total	lymphocytes	to	50-60%	of	pre-chemotherapy	levels	(Strender	et	al.,	1982),	and	
a	 greater	 reduction	 in	 non-T	 lymphocytes	 than	 the	 T	 lymphocytes	 (Strender	 et	 al.,	
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up	 to	 3	months	 after	 the	 last	 chemotherapy	 cycle)	 on	 lymphocytes	 in	 breast	 cancer	




al.,	 1997,	 Kotsakis	 et	 al.,	 2000).	 An	 exception	 is	 a	 study	 by	Melichar	 et	 al.,	 in	which	
significant	 increases	 (p<0.05)	 in	 levels	 of	 CD3+,	 CD4+	 and	 CD8+	 T	 cells	 following	
chemotherapy	 for	 breast	 cancer	 were	 found	 (Melichar	 et	 al.,	 2001).	 The	 authors	
attributed	this	conflict	with	much	of	the	literature	to	differences	in	chemotherapeutic	





Much	 less	 is	 known	 about	 the	 longer-term	 effects	 of	 chemotherapy	 on	 lymphocytes,	
especially	 on	 B-lymphocytes	 and	 especially	 with	 respect	 to	 the	 more	 detailed	
phenotypes	of	lymphocytes	beyond	the	simple	B	and	T	cell	distinction.	Evidence	with	
regards	 to	 recovery	 of	 immune	 parameters	 following	 chemotherapy	 is	 limited	 and	
often	conflicting	(Mackay	et	al.,	1984,	Mozaffari	et	al.,	2009,	Hakim	et	al.,	1997).	Mackay	
et	al	reported	depressed	T	and	B	cell	numbers	even	at	12	months	following	completion	
of	 chemotherapy.	 On	 the	 other	 hand,	 Hakim	 et	 al	 studied	 effects	 of	 dose	 intense	
chemotherapy	 consisting	 of	 5	 cycles	 of	 5-Fluorouracil,	 Leucovorin,	 Adriamycin,	 and	
Cytoxan	followed	by	5	cycles	of	Paclitaxel.	During	12	months	follow	up,	all	lymphocyte	









Fagnoni	 et	 al.,	 2002).	 There	 was	 a	 progressive	 increase	 in	 naïve	 CD4	 T	 cells	 during	
follow	 up	 and	 these	 reached	 pre-treatment	 levels	 only	 at	 18	 months	 (Hakim	 et	 al.,	
1997).	However,	in	general	it	remains	very	difficult	to	extrapolate	from	these	findings	
the	 likely	 effects	 of	 current	 chemotherapy,	 as	 regimens	used	were	 typically	different	
from	each	other	and	from	current	regimens.		
	
There	 are	 very	 limited	 data	 with	 regards	 to	 effects	 of	 chemotherapy	 on	 memory	
response	 and	 humoural	 immunity	 (antibody	 mediated	 immunity).	 Damage	 to	 long-
term	 immune	memory	 to	 small	 pox	 and	 influenza	 following	 chemotherapy	 has	 been	
reported	 (Wiser	 et	 al.,	 2010,	 Chakraborty	 et	 al.,	 1999).	 Zielinski	 et	 al	 reported	 an	
impaired	primary	but	not	secondary	immune	response	against	tick	borne	encephalitis	
following	breast	cancer	chemotherapy	(Zielinski	et	al.,	1986).	
1.5 	Significance	 of	 tumour	 infiltrating	 lymphocytes	 in	
breast	cancer-	a	review	of	literature	
Tumour	 infiltrating	 lymphocytes	 (TILs)	 have	 been	 extensively	 evaluated	 in	 breast	
cancer	and	found	to	be	associated	with	various	clinico-pathological	characteristics.	The	
most	 commonly	 associated	 factors	 appear	 to	 be	 high	 tumour	 grade	 and	 hormone	
negative	tumours	(Baker	et	al.,	2011,	West	et	al.,	2011a,	Liu	et	al.,	2012,	Adams	et	al.,	
2014,	 Loi,	 2013,	 Lee	 et	 al.,	 2013a,	 Loi	 et	 al.,	 2014,	 Salgado	 et	 al.,	 2015b,	 Dieci	 et	 al.,	
2015,	 Ingold	 Heppner	 et	 al.,	 2016).	 Other	 tumour	 related	 factors	 that	 appear	 to	 be	
associated	with	high	TILs	include	lymph	node	involvement	(Ladoire	et	al.,	2008,	Lee	et	
al.,	 2013a,	 Loi	 et	 al.,	 2014,	 Adams	 et	 al.,	 2014,	 Ingold	 Heppner	 et	 al.,	 2016),	 ductal	
histology	and	larger	tumours	(Loi	et	al.,	2014).		
	
TILs	have	been	evaluated	both	 in	 the	 adjuvant	 setting	 as	well	as	 in	 the	neo-adjuvant	
setting	 and	 several	 studies	 have	 found	 that	 lymphocytic	 infiltrate	 in	 cancer	 tissue	 is	
associated	 with	 better	 outcome.	 Besides	 reports	 of	 TILs	 in	 H&E	 stained	 cancer	
specimens,	as	initially	recommended	by	the	International	TILs	Working	Group	(Salgado	
et	 al.,	 2015b),	 there	 are	now	multiple	 reports	based	on	 immunohistochemistry	(IHC)	
that	has	led	to	further	characterisation	of	the	TILs.	CD8+	T	cells	have	been	extensively	
evaluated	 and	 greater	 infiltration	 of	 CD8+T	 cells	 has	 been	 found	 to	 be	 a	 prognostic	
marker	for	better	survival	(Mahmoud	et	al.,	2011a,	Baker	et	al.,	2011,	Liu	et	al.,	2012,	




this	 is	 not	 entirely	 clear	 but	 it	 is	 possible	 that	 the	 methodology	 used	 to	 assess	
lymphocytic	infiltrate,	being	different	from	what	is	normally	used,	contributed	to	it	or	
the	other	possibility	 is	 that	the	results	were	not	 interpreted	correctly.	Macchetti	et	al	
used	dual	flow	cytometry	for	detection	of	selected	lymphocyte	subsets,	and	they	did	not	
find	 a	direct	 association	 between	 lymphocytic	 tumour	 infiltrates	 and	 outcome.	 They,	
however,	found	that	CD4+	T	lymphocyte	counts	were	significantly	higher	in	the	group	
of	 patients	 with	 nodal	 metastasis	 compared	 to	 those	 without	 nodal	 disease.	
Considering	 the	 fact	 that	nodal	metastasis	 is	associated	with	poor	prognosis,	authors	
extrapolated	 their	 findings	 to	 report	 an	 association	 of	 high	 CD4+	 T	 cell	 infiltrate	 in	
tumours	 with	 poor	 prognosis.	 Similar	 associations	 of	 tumour	 infiltrating	 CD3+	
lymphocytes	with	nodal	metastasis	were	 found	 in	another	 independent	 study,	where	
IHC	was	used	to	assess	the	TILs	(Georgiannos	et	al.,	2003).	Matkowski	et	al	evaluated	
CD4+	and	CD8+	T	lymphocytes	in	the	centre	of	tumour,	at	the	margin	and	in	the	nodes	
and	 found	 high	 expression	 of	 CD4+	 and	 CD8+	 T	 lymphocytes	 to	 be	 associated	 with	
worse	overall	survival.	However,	it	is	unclear	if	this	high	expression	of	CD4+	and	CD8+	












(iTL)	 and	 total	 FoxP3+	 T	 cell	 infiltrate	 was	 associated	 with	 poor	 prognosis	 in	 ER	
positive	 breast	 cancers	 that	 lacked	 CD8+	 T	 cell	 infiltrate,	 and	 better	 survival	 in	 ER	
negative/Her2+	patients	with	high	CD8+	infiltrate	(Liu	et	al.,	2014).		
	
There	 is	 also	 evidence	 in	 literature	 that	a	high	CD8+/	CD4+	T	 cell	 ratio	 is	associated	
with	favourable	prognosis	indicating	the	CD4+	T	cells	may	have	a	detrimental	effect	on	
the	beneficial	effects	of	CD8.	The	unfavourable	effects	of	CD4	on	prognosis	was	found	to	





system	 (pathological-immunological	 scoring	 system:	 PathIm)	 incorporating	 the	
pathological	 AJCC	 classification	 and	 CD8/FoxP3	 ratio	 and	 used	 this	 as	 a	 prognostic	
marker	for	survival.	Those	with	high	PathIm	scores	were	found	to	have	reduced	overall	
and	 recurrence	 free	 survival	 (Ladoire	 et	 al.,	 2011b).	 Similar	 results	 were	 seen	 in	
another	recent	study	where	high	CD8/FoxP3	TIL	ratio	was	found	to	be	associated	with	
better	pCR	and	better	prognosis	 compared	 to	 low	CD8/FoxP3	 ratio	 (Miyashita	 et	 al.,	
2014,	Asano	et	al.,	2016).		
	
Besides	 their	 role	 as	 prognostic	 biomarkers,	 TILs	 have	 also	 been	 proposed	 as	 a	
diagnostic	biomarker	to	differentiate	between	a	new	primary	and	a	true	recurrence	in	
the	 case	of	 ipsilateral	 breasts	 tumour	 recurrence	 (West	 et	al.,	 2011b).	Authors	 found	
that	the	tumour	infiltrating	CD3+,	CD8+	and	CD25	+	lymphocytes	were	reduced	in	new	
primary	lesions	but	 increased	 in	 the	case	of	a	true	recurrence	when	compared	to	 the	
original	tumour.	There	are	limited	results	concerning	TILs	in	primary	and	concurrent	
metastasis;	data	available	suggests	that	 the	 immune	response	seen	 in	 the	 two	 lesions	
are	 similar	 (McGrath	 et	 al.,	 2010),	 or	 are	 reduced	 in	 the	metastasis	 compared	 to	 the	
primary	 lesion	 (Cimino-Mathews	 et	 al.,	 2013).	 However,	 due	 to	 paucity	 of	 data,	 no	
definite	conclusions	can	be	made.	
1.5.1 	Role	of	TILs	in	the	adjuvant	and	neo-adjuvant	setting	
There	 are	multiple	 reports	 supporting	 the	use	of	 TILs	 as	 a	prognostic	marker	 in	 the	
neo-adjuvant	 and	 adjuvant	 setting.	 A	 summary	 of	 many	 of	 these	 reports	 is	 listed	 in	









to	 be	 associated	 with	 pCR	 (Oda	 et	 al.,	 2012,	 Seo	 et	 al.,	 2013,	 Lee	 et	 al.,	 2013a).	 A	
multicentre	 neo-adjuvant	 pilot	 study	 showed	 CD8+	 T	 cell	 infiltrate	 to	 be	 a	 strong	
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predictor	of	pCR	in	triple	negative	breast	cancer	patients	(Nabholtz	et	al.,	2014).	There	




In	 the	 neo-adjuvant	 setting,	 there	 is	 also	 the	 added	 advantage	 of	 availability	 of	 2	
specimens	–	pre	and	post-chemotherapy	-	to	assess	the	response	to	chemotherapy	or	
other	systemic	treatments.	A	few	studies	have	compared	lymphocyte	infiltrate	in	breast	
tumour	 pre	 and	 post-chemotherapy.	 Demaria	 et	 al	 assessed	 TILs	 in	 pre	 and	 post-	







high	 or	 low	 lymphocytic	 infiltrate	 pre	 and	 post-chemotherapy.	 The	 group	 with	 low	














































































































Table	 shows	 summary	 of	 studies	 on	 tumour-infiltrating	 lymphocytes	 in	 the	 adjuvant	
setting.	 (DFS:	 Disease	 free	 survival,	 DDFS:	 Distant	 disease-free	 survival,	 ER:	 Estrogen	





































































































































































































setting.	 (BCCS:	Breast	cancer	 specific	 survival,	DFS:	Disease	 free	 survival,	DDFS:	Distant	
disease-free	 survival,	 ER:	 Estrogen	 Receptor,	 H&E:	 Hematoxylin	 and	 Eosin,	 HR:	 hazard	
ratio,	 iTL:	 intra-tumoural	 lymphocytes,	 IHC:	 Immunohistochemistry,	 LPBC:	 Lymphocyte	






of	breast	 cancers	 are	 triple-negative	 and	 these	 cancers	 are	 generally	 associated	with	
worse	prognosis	(Anders	and	Carey,	2009).	TILs	have	consistently	been	found	in	highly	
proliferative	breast	cancers	like	triple	negative	breast	cancer	(TNBC)	and	Her2+	breast	
cancer	 and	 their	 presence	 at	 diagnosis	 is	 associated	 with	 pCR	 following	 NACT	
(Nabholtz	et	al.,	2014,	Miyashita	et	al.,	2014,	Denkert	et	al.,	2015,	Denkert	et	al.,	2018)	




for	 assessing	 TILs	 (Salgado	 et	 al.,	 2015b),	 Pruneri	 et	 al	 conducted	 a	 retrospective	
analysis	of	TILs	in	897	TNBCs	in	order	to	assess	the	clinical	validity	of	the	guidelines.	
TILs	 were	 found	 to	 be	 associated	 with	 better	 DFS,	 DDFS	 and	 OS	 using	 the	
recommended	 methodology	 for	 assessing	 TILs	 (Pruneri	 et	 al.,	 2016).	 Use	 of	 IHC	 to	
determine	the	nature	of	lymphocytic	infiltrate	in	TNBC	has	shown	high	CD4+	and	high	
CD8+	T	cell	infiltrates	as	significant	factors	associated	with	pCR	and	better	DFS	or	BCSS	
(Rao	et	al.,	2017,	Liu	et	al.,	2012).	Based	on	 the	published	reports,	 the	results	 for	 the	
prognostic	value	of	TILs	in	TNBC	could	potentially	be	considered	as	Level	1	evidence	
(evidence	based	on	systematic	reviews	of	RCTs	or	individual	RCTs)	(Simon	et	al.,	2009).	




Her2+	 breast	 cancer	 constitutes	 20-30%	 of	 all	 breast	 cancers	 and	 is	 found	 to	 be	
associated	with	worse	prognosis	compared	to	Her2	negative	breast	cancers	(Slamon	et	
al.,	 1987,	Madell,	 2017).	 Similar	 to	 the	 association	of	TILs	with	ER	negative	or	 triple	
negative	 breast	 cancers,	 there	 is	 evidence	 that	 TILs	 are	 associated	 with	 better	
prognosis	in	Her2+	breast	cancers.	A	recent	meta-analysis	of	randomized	control	trials	
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has	 reported	 the	 association	 of	 high	 TILs	 with	 increased	 pCR	 in	 Her2+	 patients	
irrespective	 of	 the	 chemotherapy	 or	 anti	 Her2	 agents	 used	 (Solinas	 et	 al.,	 2017).	
Although	multiple	studies	have	reported	the	prognostic	effect	of	TILs	in	Her2+	breast	
cancers	(West	et	al.,	2011a,	Ladoire	et	al.,	2011a,	Loi	et	al.,	2014,	Salgado	et	al.,	2015a),	
there	 are	 a	 few	 exceptions.	 Heppner	 et	 al	 failed	 to	 confirm	 TILs	 as	 an	 independent	
prognostic	marker	 in	Her	2+	patients.	They	evaluated	stromal	TILs	 in	Her2+	patients	
from	 the	 neo-adjuvant	 GeparQuattro	 (G4)	 and	 GeparQunito	 (G5)	 trials.	 All	 Her2+	
positive	 patients	 in	 G4	were	 treated	with	 Trastuzumab	 in	 addition	 to	 chemotherapy	
while	in	G5	they	were	randomised	to	receive	either	Trastuzumab	or	Lapatinib.	Her2+	
LPBC	 cases	 had	 a	 significantly	 increased	 pCR	 rates	 in	 the	 complete	 cohort	 and	 G4	
subgroup	but	not	 in	 the	G5	subgroup.	LPBC	cases	tended	to	have	better	DFS	but	 this	
was	 again	 not	 statistically	 significant	 (Ingold	 Heppner	 et	 al.,	 2016).	 The	 N9831	
Adjuvant	 trial	 involving	 early	 stage	Her2+	 breast	 cancer	 patients	 failed	 to	 show	 any	
association	 between	 stromal	 lymphocyte	 infiltrate	 and	 Trastuzumab	 treatment	
although	TILs	were	prognostically	associated	with	recurrence	free	survival	in	patients	





1.5.2 	A	 review	 of	 the	 methodology	 used	 for	 detecting	 and	
quantifying	TILs	
Routine	 use	 of	 TILs	 as	 a	 biomarker	 has	 not	 been	 incorporated	 into	 routine	practice,	
despite	multiple	 publications	 showing	 association	 of	 TILs	with	 prognosis.	 Significant	
heterogeneity	 in	 the	methodology	 for	detecting	 lymphocytes	and	determining	the	cut	
offs	used	for	analysis	could	be	factors	preventing	use	of	this	biomarker	in	a	consistent	
manner.	 The	 International	 TILs	 Working	 Group	 published	 detailed	 guidelines	 to	
facilitate	 uniformity	 in	 evaluation	 of	 TILs	 in	 H&E	 stained	 specimens	 and	 thereby	
improve	the	reliability	and	validity	of	this	upcoming	biomarker	(Salgado	et	al.,	2015b).	
One	of	the	most	contentious	issues	is	probably	the	area	to	be	evaluated,	with	options	
including	 analysis	 of	 full-faced	 sections	 or	 tissue	microarray	 (TMA)	 cores,	 and	 using	
random	areas	under	high	power	 field	(HPF)	or	selectively	assessing	the	areas	of	high	
lymphocytic	 infiltration.	Full-faced	sections	have	been	evaluated	 in	numerous	studies	
(Denkert	 et	 al.,	 2010,	 Loi	 et	 al.,	 2013,	Adams	et	 al.,	 2014,	Dieci	 et	 al.,	 2015,	Herrero-
Vicent	et	al.,	2017).	TMAs	were	not	originally	recommended,	as	there	was	no	reliable	
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way	 of	 ensuring	 that	 the	 TMA	 cores	 reflect	 the	 heterogeneity	 of	 lymphocyte	
distribution	 across	 the	 tumour.	 However,	 there	 have	 subsequently	 been	 multiple	
reports	based	on	TMAs	(Bates	et	al.,	2006,	Mahmoud	et	al.,	2011a,	Baker	et	al.,	2011,	
West	 et	 al.,	 2011a,	 Liu	 et	 al.,	 2012,	 Ali	 et	 al.,	 2014,	 Denkert	 et	 al.,	 2010)	 and	 results	






The	 recommendation	 by	 the	 International	 Working	 Group	 was	 to	 use	 H&E	 stained	
specimens	to	assess	the	lymphocyte	infiltrate	and	there	are	multiple	reports	based	on	
this	(Denkert	et	al.,	2010,	Loi	et	al.,	2013,	Adams	et	al.,	2014,	Dieci	et	al.,	2015,	Herrero-
Vicent	 et	 al.,	 2017).	 Although	 this	 appears	 to	 be	 a	 reliable	 way	 of	 assessing	 the	
lymphocytic	infiltrate,	it	does	not	allow	differentiation	between	the	various	lymphocyte	




CD8+	 T	 cell	 infiltrate	 has	 been	 associated	 with	 good	 prognosis,	 FoxP3	 infiltrate	 has	






compared	 to	 the	 intra-tumoural	 lymphocyte	 counts	 (Loi	 et	 al.,	 2014,	 Salgado	 et	 al.,	






was	 conducted	 using	 more	 advanced	 digital	 image	 evaluation	 software	 in	 order	 to	




example	 of	 the	 selected	 tumour	 infiltrating	 lymphocyte	 density.	With	 the	 use	 of	 this	
specialised	software,	there	was	an	ICC	of	0.89	(Denkert	et	al.,	2016)	implying	that	it	is	
possible	 to	 reproduce	 the	 results	 in	 daily	 practice	 as	 long	 as	 strict	 guidelines	 and	
stringent	 criteria	 are	 adhered	 to	 for	 evaluation	 of	 TILs.	 Generally,	 studies	 that	 have	
used	 IHC	 have	 reported	 both	 stromal	 and	 intra-tumoural	 lymphocytes.	 Use	 of	 IHC	
probably	makes	it	easier	to	assess	the	specific	lymphocytes	in	both	stromal	and	intra-
tumoural	 compartment	 as	 opposed	 to	H&E	 staining.	Except	 for	 occasional	 reports	 of	
intra-tumoural	 lymphocytes	 being	 better	 predictors	 of	 survival	 compared	 to	 stromal	




Besides	 the	 heterogeneity	 in	 the	 staining	 of	 the	 slides	 and	 the	 area	 assessed	 to	
determine	 the	 tumour	 infiltrating	 lymphocytes,	 there	 are	 differences	 in	 the	 cut	 off	
values	 used	 to	 determine	 lymphocyte	 predominance	 and	 the	 subsequent	 analysis	 to	





a	 Receiver	 Operating	 Characteristic	 (ROC)	 curve	 to	 determine	 the	 cut-off	 point	






cut	 off	 value	used	 for	determining	 lymphocyte	predominance	 appears	 to	be	different	
when	 IHC	 has	 been	 used	 to	 assess	 specific	 lymphocytes,	 and	 especially	 lower	 when	
TMAs	 or	 biopsy	 specimens	 have	 been	 used,	 presumably	 because	 of	 the	 smaller	 area	
assessed	and	low	lymphocytic	infiltrate.	A	median	cut	off	value	of	15	lymphocytes	was	
used	in	two	studies,	one	of	which	used	TMAs	and	the	other	randomly	selected	3	high	
power	 fields	 (x400)	 of	 breast	 cancer	 specimens	 to	 assess	 TILs	 (Bates	 et	 al.,	 2006,	
Bohling	 and	 Allison,	 2008).	 Other	 studies	 that	 have	 used	 IHC	 to	 identify	 specific	









offs	 used	 for	 analysis	 shows	 the	 lack	 of	 uniformity	 and	 raises	 concerns	 regarding	




al.,	 2015).	 Subsequently	 the	 International	 TILs	 Working	 Group	 published	 a	
standardised	methodology	for	assessing	TIL	in	H&E	stained	specimens	in	an	attempt	to	





association	 of	 TILs	 with	 pCR	 or	 better	 outcome	 and	with	 rapidly	 growing	 evidence	
related	 to	 TILs,	 there	 is	 a	 definite	 possibility	 that	 TILs	 can	 be	 used	 as	 a	 prognostic	
marker	in	the	near	future.	
1.5.3 	Clinical	 implications	 of	 altered	 lymphocyte	 levels	 and	
sub-populations		
Immune	 deficiency	 following	 chemotherapy	 has	 important	 potential	 clinical	
implications	 due	 to	 increased	 susceptibility	 to	 infections.	 Increased	 incidence	 of	
pneumocystitis	 carini,	 adenovirus	 pneumonia,	 pulmonary	 histoplasmosis	 and	 herpes	
zoster	 has	 been	 seen	 in	 various	 studies	 (Chakraborty	 et	 al.,	 1999)	 (Brunvand	 et	 al.,	
1991,	Mackall	et	al.,	1994).		A	study	by	Kotsakis	et	al	showed	that	17%	of	patients	with	
solid	 malignancies	 treated	 with	 Docetaxel,	 developed	 non-neutropenic	 infections	
(Kotsakis	et	al.,	2000).	Increased	incidence	of	Varicella-zoster	virus	(VZV)	reactivation	
has	 been	 found	 following	 high	 dose	 chemotherapy	 and	 autologous	 stem	 cell	 rescue	
(Bilgrami	 et	 al.,	 1999),	 and	 its	 incidence	 has	 also	 been	 found	 to	 increase	with	more	
severe	 immune-suppression	 (Arvin,	 1996).	A	suppressed	 immune	 system	during	 and	
after	 treatment	 can	 also	 lead	 to	 relapse	of	 the	underlying	malignancy.	This	has	been	
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Circulating	 and	 tumour	 infiltrating	 lymphocytes	 have	 been	 suggested	 as	 prognostic	
biomarkers.	 Although	 there	 are	 some	 data	 regarding	 the	 short-term	 effects	 of	
chemotherapy	 on	 circulating	 lymphocytes,	 there	 is	 paucity	 of	 data	 regarding	
chemotherapy	 regimens	 used	 currently	 and	 longer-term	 effects	 of	 chemotherapy	 on	
circulating	 lymphocytes,	 especially	 B-lymphocytes.	 There	 is	 also	 limited	 evidence	
regarding	the	repopulating	subtypes	of	B	and	T-lymphocytes	and	their	effect	if	any,	on	
the	 immune	 system.	 My	 aim	 was	 to	 analyse	 the	 levels	 of	 circulating	 B	 and	 T-
lymphocytes	and	their	sub-types	before	and	at	various	time	points	after	chemotherapy	






2007,	 Hiraoka	 et	 al.,	 2006,	 Shen	 et	 al.,	 2010).	 As	 discussed	 in	 section	 1.5,	 there	 is	
abundant	 evidence	 regarding	 the	 prognostic	 role	 of	 TILs	 in	 breast	 cancer.	 There	 is	
however,	 no	 published	 report	 comparing	 circulating	 and	 tumour	 infiltrating	
lymphocytes	 in	 breast	 cancer.	 Ling	 et	 al	 reported	 increased	 frequency	 of	 regulatory	
FoxP3	cells	both	 in	 the	 tumour	environment	as	well	as	in	circulation	 in	patients	with	
colorectal	 cancer	 (Ling	 et	 al.,	 2007).	 There	 is	 also	 very	 little	 evidence	 regarding	 the	
prognostic	 significance	 of	 lymphocytic	 infiltrate	 at	 different	 tumour	 locations,	 and	
specifically	 at	 the	 tumour	 edge.	 Besides	 consolidating	 what	 is	 already	 known	 about	
TILs,	I	aimed	to	assess	CD4+,	CD8+,	CD20+	and	FoxP3+	lymphocytes	in	the	stroma,	in	
the	 intra-tumoural	 compartment	 and	 at	 the	 tumour	 edge	 of	 the	 breast	 cancer	
















• To	 assess	 whether	 levels	 of	 Pneumococcal	 and	 Tetanus	 antigen-specific	
antibodies	vary	before	and	after	chemotherapy	






























2.1 Ethics,	 patient	 selection,	 blood	 sampling	&	 clinical	
data	collection	
2.1.1 	Ethical	issues	
Ethical	 approval	 for	 recruitment	 of	 patients	 and	 subsequent	 analyses	 of	 their	 blood,	





meeting	 as	 a	 component	 of	 clinical	 duties	 as	 a	 research	 fellow	 and	 surgical	 trainee.	
Patients	 with	 a	 diagnosis	 of	 operable	 breast	 cancer	 diagnosed	 at	 Leeds	 Teaching	
Hospitals	 NHS	 Trust	 (LTHT)	 from	 June	 2011	 to	 January	 2012	 and	 due	 to	 have	
chemotherapy	were	approached	to	participate.	Patients	were	deemed	to	be	potentially	
suitable	if	they	were	female	patients,	<75	years	old	with	tumour	characteristics	such	as	
high	 grade,	 node	 positive,	 triple	 negative	 or	 Her2+	 breast	 cancer	 requiring	
chemotherapy.	Figure	6	shows	the	flow	diagram	summarising	the	patient	recruitment	
process.	 Following	MDT	 discussion,	 all	 breast	 cancer	 patients	 were	 reviewed	 in	 the	
breast	clinic	when	they	were	given	the	biopsy	results.	Patients	potentially	suitable	for	
the	 study	 were	 reviewed	 by	 the	 author	 or	 one	 of	 the	 breast	 research	 nurses	 in	 the	
breast	 clinic.	 This	 was	 done	 either	 at	 the	 time	 of	 initial	 diagnosis,	 if	 tumour	
characteristics	at	the	time	of	diagnosis	indicated	a	definitive	need	for	adjuvant	or	neo-
adjuvant	chemotherapy	or	at	the	time	of	first	clinic	review	following	surgical	treatment	
and	 MDT	 decision	 regarding	 the	 need	 for	 adjuvant	 chemotherapy.	 Patients	 were	
assessed	 with	 regards	 to	 the	 exclusion	 criteria:	 males,	 age	 >75	 years;	 long-term	
steroids/immunosuppressive	 drug	 use;	 previous	 history	 of	 breast	 cancer;	 previous	
chemotherapy	within	 the	 last	 10	 years.	 Patients	 over	 75	 years	 of	 age	were	 excluded	
from	the	study	as	these	patients	were	less	likely	to	receive	chemotherapy	and	even	if	
they	did	get	chemotherapy,	the	chemotherapy	regimen	was	generally	different	and	the	
dosage	 tailored	 to	 their	 ability	 to	 tolerate	 the	 chemotherapy.	 Patients	were	 given	 an	












Baseline	 samples	 were	 taken	 prior	 to	 the	 start	 of	 chemotherapy	 (Cohort	 A,	 n=65).	
There	 was	 generally	 a	 gap	 of	 3-4	 weeks	 between	 surgery	 and	 the	 actual	 start	 of	
chemotherapy.	Chemotherapy	 then	 lasted	 for	4-5	months	and	the	post-chemotherapy	
blood	 samples	 were	 taken	 2	 weeks,	 3	 months,	 6	 months	 and	 9	 months	 after	 the	
completion	 of	 chemotherapy.	 During	 the	 initial	 period	 of	 recruitment,	 there	 was	
obviously	 a	 delay	 in	 getting	 the	 blood	 samples.	 Some	 patients	 who	 were	 already	
undergoing	 chemotherapy	 but	 otherwise	 eligible	 for	 the	 study	 based	 on	 the	 same	
inclusion/exclusion	 criteria	 were	 therefore	 approached.	 Information	 leaflets	 were	
provided	to	them	usually	during	their	visits	to	the	oncology	unit	for	chemotherapy.	If	
willing	to	participate,	they	were	consented	and	recruited	to	the	study	(cohort	B,	n=28).	
Although	 baseline	 (pre-chemotherapy)	 blood	 sample	 was	 not	 available	 for	 these	
Number of patients 
identified in MDT as 
potentially eligible for study, 
n=175
Number of patients 
approached
n= 106 (cohort A), n=45 
(cohort B)
Number agreed to 
participate (cohort A)
n=65
Number agreed to participate 
(cohort B) n=28
Eliminated/withdraw









Cohort A: patients due 
to start chemotherapy 
(NACT or ACT)






detailed review of 
patients/notes  
n=24
Missed 1 or 
more blood 
samples, n=5






subsequently	 eliminated	 from	 the	 study	 since	 their	 chemotherapy	 regimens	 were	
highly	 atypical	 (one	 received	 only	 2	 cycles	 of	 chemotherapy,	 while	 the	 other	 had	
chemotherapy	 delayed	 because	 of	 reactivation	 of	 Hepatitis	 B).	 One	 further	 patient	
asked	to	leave	the	study	at	an	early	stage.	One	or	more	sample	time-points	were	missed	
for	8	patients	in	cohort	A.	From	cohort	B,	1	patient	was	subsequently	eliminated	as	her	
treatment	was	modified	 in	 response	 to	having	developed	a	 recurrence	 and	1	patient	
asked	 to	 leave	 the	 study	 after	 the	 1st	 sample	 was	 taken.	 One	 or	more	 sample	 time-
points	were	missed	for	5	patients	in	this	cohort.		
A	 one-off	 blood	 sample	 was	 also	 taken	 from	 healthy	 controls	 (n=17).	 These	 were	
generally	patients	who	presented	to	the	breast	clinic	with	breast	related	symptoms	but	
were	 found	 to	 have	no	 obvious	 breast	pathology.	All	 patients	 gave	written	 informed	
consent.		
2.1.3 	Clinical	data	collection	
Detailed	history	was	 taken	 from	patients	 at	 recruitment	by	 the	 author.	Demographic	
and	clinical	details	of	patients,	especially	details	regarding	the	tumour,	were	collected	
from	electronic	databases	held	at	LTHT.	Smoking	history	was	collected	from	patients	at	
recruitment.	 I	 defined	 ‘smokers’	 as	 all	 current	 smokers	 (irrespective	 of	 number	 of	
cigarettes	 and	 duration	 of	 smoking);	 ‘Non-smokers’	 were	 all	 ex-smokers	 and	 non-
smokers.	 Data	 regarding	 vaccination	 record	 of	 patients	was	 not	 collected.	 It	was	 felt	
that	data	would	be	inaccurate	due	to	recall	bias	and	moreover,	the	post-chemotherapy	
titres	were	 being	 compared	 to	 pre-chemotherapy	 titres	which	would	 act	 as	 baseline	
level	 irrespective	 of	 previous	 vaccinations.	 Follow-up	 data	 with	 regards	 to	 survival	
(tumour	recurrence	or	death)	was	collected	from	a	prospectively	maintained	electronic	
database	 held	 at	 LTHT.	 All	 breast	 cancer	patients	 are	 routinely	 followed	 on	 a	 yearly	
basis	for	5	years	following	cancer	treatment	at	LTHT.	Survival	data	were	collected	from	
the	 electronic	 database	 in	August	2015	and	 the	 date	 of	 last	 visit	 to	 the	 hospital	was	










which	 patients	were	 recruited.	 	 If	 recruited	 before	 initiating	 chemo	 (n=65),	 samples	
were	 taken	 prior	 to	 chemotherapy	 and	 then	 at	 2	weeks,	 3	months,	 6	months	 and	 9	




Blood	 samples	 consisted	 of	 8mL	 venous	 blood,	 taken	 in	 two	 separate	 tubes:	 one	 in	
EDTA	 (ethylene-diamine-tetra	 acetic	 acid)	 vacutainer	 tubes	 (Greiner	 Bio-one,	
Stonehouse	UK)	for	lymphocyte	analyses,	and	another	in	a	clot	activator	and	gel	tube	











Basic	 lymphocyte	 analyses	 were	 performed	 using	 Trucount	 tubes	 and	Multitest	IMK	
Kits	(Becton	Dickinson,	BD).	Majority	of	the	lymphocyte	analysis	was	performed	in	the	
immunology	 lab	at	St	 James’s	Univerity	Hospital	by	one	of	my	supervisors.	 I	did	one-
fifth	 of	 the	 analyses	 under	 his	 supervision.	 BD	 Trucount	 tubes	 containing	 a	 specific	
number	of	fluorescent	beads	were	used	to	determine	absolute	lymphocyte	subset	cell	
counts.	 BD	Multitest	IMK	 Kit	 is	 a	 four-colour	 direct	 immunofluorescence	 reagent	 kit	
used	 to	 identify	 and	determine	percentages	 and	absolute	numbers	of	mature	human	
lymphocyte	 subsets	 in	 erythrocyte-lysed	whole	blood.	The	kit	 consists	 of	 2	 reagents,	
each	 containing	 a	 specific	 antibody	 panel	 (anti-CD3/anti-CD8/anti-CD45/anti-CD4	 or	
anti-CD3/anti-CD16/anti-CD56/anti-CD45/anti-CD19)	 provided	 in	 1mL	 of	 buffered	
saline	with	0.1%	sodium	azide.	The	concentration	values	of	the	conjugated	antibodies	
are	 listed	 in	 Table	 4.	 Reagent	 1	 contained	 fluorescein	 isothiocyanate	 (FITC)	 labelled	
	 45	
anti-CD3	 (clone	 SK7),	 phycoerythrin	 (PE)	 labelled	 anti-CD8	 (clone	 SK1),	 peridinin	
chlorophyll	protein	(PerCP)	labelled	anti-CD45	(clone	2D1-HLe-1)	and	allophycocyanin	
(APC)	labelled	anti-CD4	(clone	SK3).	Reagent	2	contained	FITC	labelled	anti-CD3	(clone	














CD3/anti-CD16/anti-CD56/anti-CD45/anti-CD19	 (reagent	 2)	 was	 added	 to	 tube	 B.	
50μL	of	EDTA-blood	was	added	to	each	tube.	Both	tubes	were	incubated	for	15	min	at	
room	 temperature	 in	 the	 dark.	 450μL	 of	 1	 X	 BD	Multitest	 lysing	 solution	 (catalogue	
number	349202)	was	added	to	both	 tubes	and	they	were	subsequently	 incubated	 for	
15	min,	 protected	 from	 light.	 The	 lysing	 solution	 lyses	 all	 the	 red	 blood	 cells	 while	




M,	 Transitional-T).	 7.5μL	 of	 various	 reagents	 were	 added	 to	 each	 tube	 as	 follows:	 C	
tube:	 IgG2b-PercP	 (A95-1),	 IgG1-Pe	 (X40)	 and	 IgG2a-FITC	 (G155-178);	M	 tube:	 anti-
CD19-PercP	(SJ25C1),	anti-CD27-Pe	(M-T271)	and	anti-IgD-FITC	(IA6-2);	T	tube:	anti-
CD19-PercP	 (SJ25C1),	 anti-CD24-Pe	 (ML-5),	 anti-CD27-FITC	 (M-T271)	 and,	
exceptionally,	5μL	of	anti-CD38-APC	(HB7).	
75μL	of	blood	from	EDTA	tube	was	then	added	and	tubes	were	incubated	in	the	dark	
(20	min,	 room	 temperature).	3mL	of	BD	 lysis	buffer	 (BD	Facs	 lysing	 solution,	 cat	no.	










tube	 1:	 CD3PerCP	 (SK7),	 CD4-APC	 (SK3),	 CD45RA-Pe	 (HI100)	 and	 CD62L-FITC	
(Dreg56);	tube	2:	CD3PerCP	(SK7),	CD4-APC	(SK3),	CD45RA	–Pe		(HI100)	and	CD45RO	-
FITC	(UCHL-1);	tube	3:	CD4-APC	(SK3),	CD31-Pe	(L133.1),	CD45RO-FITC	(UCHL-1);	tube	
4:	 CD4-APC	 (SK3),	 CD25-Pe	 (2A3),	 FoxP3-Pe	 (259D/C7).	 7.5μL	 of	 each	 of	 these	
reagents	were	added	to	the	tubes	except	in	the	case	of	CD4-APC,	where	only	2.5μL	of	
the	 reagent	was	used	per	 tube.	 Following	 this,	 the	procedure	 as	described	 in	 section	
2.2.3	for	extended	B	cell	phenotyping	was	followed.	
2.2.5 	FoxP3	phenotyping	







set,	BD,	 catalogue	no.	 560098).	 	All	 samples	were	 then	 centrifuged	(400g	 for	5	min).	
The	supernatant	was	then	discarded,	and	the	pellets	were	re-suspended	in	0.5mL	of	BD	
Solution	 C	 (prepared	 from	 BD	 human	 FoxP3	 Buffer	 set,	 catalogue	 no.	 560098)	 and	
incubated	at	room	temperature	for	30	min	protected	from	light.	Solutions	A	and	C	fix	
and	 permeabilize	 the	 cells	 to	 facilitate	 the	 FoxP3	 antibody	 to	 penetrate	 the	 cells	 as	
FoxP3,	unlike	other	cell	surface	antigens,	is	intracellular.	The	pellets	were	then	washed	
twice	 in	 3mL	 Phosphate	 buffered	 saline	 (PBS)	 (Gibco)	 and	 1%	 foetal	 bovine	 serum	
(FBS)	(Gibco)	to	remove	the	excess	Solution	C.	The	pellets	were	then	re-suspended	in	
FoxP3	 antibody	 (BD,	 catalogue	 no.	 560047,	 concentration	 25μg/mL, 20μL of FoxP3 
antibody and 80μL of PBS) and incubated at room temperature for 30 min. Following the 
final incubation, cells were washed twice in PBS/FBS solution and then re-suspended in 
	 47	




The	 absolute	 numbers	 of	 lymphocyte	 subsets	 were	 determined	 using	 BD	 Multiset	
software	and	using	the	following	equation:	Absolute	count	=	(number	of	events	in	the	
cell	 population	 /	number	 of	 events	 in	 the	 absolute	 count	 bead	 region)	 x	 (number	 of	
beads	 per	 test).	 Using	 this	 method,	 the	 various	 cell	 types	 were	 quantified	 using	 the	



























Whole	 blood	was	 stained	with	 fluorescently	 tagged	antibodies	 against	 CD19/CD27/IgD	
































and	 lymphocytes	 were	 analysed	 by	 flow	 cytometry.	 Lymphocytes	 were	 identified	 by	
scatter	profile	(panel	A)	and	B	cells	were	identified	according	to	their	expression	of	CD19	











































































Whole	 blood	 was	 stained	 with	 fluorescently	 tagged	 antibodies	 against	
CD3/CD4/CD45RA/CD45RO	 and	 lymphocytes	 were	 analysed	 by	 flow	 cytometry.	
Lymphocytes	 were	 identified	 by	 scatter	 profile	 (panel	 A)	 and	 T	 cells	 were	 identified	
according	to	their	expression	of	CD3	(B).	CD4+	T	cells	were	identified	by	the	expression	of	

































Whole	 blood	 was	 stained	 with	 fluorescently	 tagged	 antibodies	 against	
CD3/CD4/CD45RA/CD62L	 and	 lymphocytes	 were	 analysed	 by	 flow	 cytometry.	
Lymphocytes	 were	 identified	 by	 scatter	 profile	 (panel	 A)	 and	 T	 cells	 were	 identified	
according	to	their	expression	of	CD3	(B).	CD4+	T	cells	were	identified	by	the	expression	of	
CD3/CD4	(C).	The	expression	of	CD45RA	and	CD62L	from	these	cells	were	evaluated	with	































Whole	 blood	 was	 stained	 with	 fluorescently	 tagged	 antibodies	 against	
CD4/CD45RO/CD31	 and	 lymphocytes	 were	 analysed	 by	 flow	 cytometry.	 Lymphocytes	
were	identified	by	scatter	profile	(panel	A)	and	T	cells	were	identified	according	to	their	
expression	 of	 CD4	 (B).	 The	 expression	 of	 CD45RO	 and	 CD31	 from	 these	 cells	 were	






























and	 lymphocytes	 were	 analysed	 by	 flow	 cytometry.	 Lymphocytes	 were	 identified	 by	
scatter	profile	(panel	A)	and	T	cells	were	identified	according	to	their	expression	of	CD4	
(B).	 The	 expression	 of	 CD25	 and	 FOXP3	 from	 these	 cells	 were	 evaluated	 with	 high	
expression	 of	 CD25	 and	 positive	 FOXP3	 representing	 the	 regulatory	 T	 cells	
(CD4+CD25hiFOXP+)	(C).	FSC	(forward	scatter),	SSC	(side	scatter).	
2.3 	Serum	antibody	analysis	
Tetanus	 and	 Pneumococcal	 antibody	 titres	 were	 determined	 by	 enzyme-linked	
immunoassay	 using	 kits	 supplied	 by	 The	 Binding	 Site	 (Edgbaston,	 Birmingham)	
following	 the	 manufacturer’s	 protocols.	 The	 specific	 kits	 used	 were	 cat	 numbers:	
MK010	for	Tetanus	and	MK012	for	Pneumococcus.	Helen	Dixon,	a	biomedical	scientist	
at	the	department	of	Clinical	Immunology	(Leeds	General	Infirmary,	Leeds)	performed	
this	 assay.	 This	 clinical	 laboratory	 also	 supplied	 the	 thresholds	 used	 here	 for	
“suboptimal”	and	“inadequate”	levels,	based	on	clinical	usage.	
	























For	 the	 anti-Pneumococcal	 antibody	assay,	 the	microwells	were	pre-coated	with	PCP	
(Pneumococcal	 Capsular	 Polysaccharide)	 antigen.	 Calibrators	 and	 controls	were	 pre-
adsorbed	 against	 capsular	 polysaccharide	 and	 samples	 were	 diluted	 in	 a	 diluent	
containing	 C-Polysaccharide	 (CPS).	 The	 calibrators,	 controls	 and	 diluted	 patient	
samples	 were	 added	 to	 the	 wells	 and	 antibodies	 recognising	 the	 PCP	 antigen	 bind	
during	 the	 first	 incubation.	 After	washing	 the	wells	 to	 remove	 all	 unbound	 proteins,	
purified	peroxidase	labelled	rabbit	anti	IgG	(γ	chain	specific)	conjugate	was	added.	The	
conjugate	 binds	 to	 the	 captured	 human	 antibody	 and	 the	 excess	 unbound	 conjugate	
was	 removed	 by	 a	 further	 wash	 step.	 The	 bound	 conjugate	 is	 visualised	 with	
3,3’,5,5’tetramethylbenzidine	(TMB)	substrate	which	gives	a	blue	reaction	product,	the	
intensity	 of	 which	 is	 proportional	 to	 the	 concentration	 of	 antibody	 in	 the	 sample.	
Phosphoric	 acid	was	added	 to	 each	well	 to	stop	 the	 reaction.	This	produces	a	 yellow	
end	point	colour,	which	was	read	at	450nm	on	a	spectrophotometer.	
2.4 	Tumour	 infiltrating	 lymphocyte	 analysis	 using	
immunohistochemistry		
Immunohistochemistry	 was	 used	 to	 assess	 number,	 type	 and	 location	 of	 tumour	
infiltrating	 lymphocytes.	Formalin	Fixed	Paraffin-embedded	(FFPE)	blocks	containing	
tumour	tissue	from	the	study	patients	were	identified	and	retrieved	from	the	pathology	
department	of	Leeds	Teaching	Hospitals	NHS	Trust.	 Sections	were	 taken	and	 stained	
for	the	antibodies	to	be	analysed	(section	2.4.1)	using	IHC	protocol	(section	2.4.3).	The	
initial	 study	 population	 described	 in	 section	 2.1.2	 consisted	 of	 2	 cohorts,	 cohort	 A	
where	pre	and	post-chemotherapy	blood	samples	were	available	(n=62)	and	a	cohort	B	
where	only	post-chemotherapy	bloods	were	available	(n=26).	For	this	part	of	the	study,	
only	 cohort	 A	 patients	 were	 used	 as	 I	 aimed	 to	 compare	 the	 results	 of	 tumour	
infiltrating	 lymphocytes	 with	 circulating	 lymphocytes.	 For	 patients	 who	 underwent	
NACT	 in	 cohort	 A	 (n=13),	 blocks	 representing	 tissue	 from	 both	 pre-chemotherapy	
(initial	diagnostic	biopsy	tissue)	and	the	post-chemotherapy	(surgical	resection	tissue)	





(lymph	 node	 or	 tonsil	 tissue).	 Various	 concentrations	 of	 the	 antibodies	 were	 tested	
based	 on	 the	 manufacturer’s	 recommendation	 and	 other	 reports	 in	 literature.	 The	
	 56	
maximum	dilution	of	the	antibody	that	gave	easily	assessable	and	apparently	specific	
staining	 of	 the	 tissue	 antigen,	 with	 the	 least	 possible	 background	 and	 non-specific	
interaction	was	 selected.	The	 incubation	 times	 and	 temperatures	were	 also	 varied	 to	
improve	the	staining	quality.			
	
Antibodies	 against	 the	 following	 markers	 were	 assessed	 in	 the	 tissues	 using	 IHC,	
targeting	 CD8,	 CD4,	 CD20	 and	 FoxP3.	 The	 clones	 of	 these	 antibodies	 used	 and	 the	
dilutions	used	are	listed	in	Table	6.	
Antibody	 CD8	 CD4	 CD20	 FoxP3	
Supplier	 Dako	 Dako	 Dako	 Abcam	
Catalogue	










Clone	 C8/144B	 4B12	 L26	 236A/E7	
































small	 squirrel	 hair	 brush.	 Once	 floated	 in	 the	 heated	 water	 bath,	 the	 sections	 were	
separated	from	each	other	gently	using	fine	pointed	or	curved	forceps.	Gentle	teasing	
using	 forceps	 rectified	 any	 folds	 in	 sections	 and	 if	 unsuccessful	 such	 sections	 were	
discarded.	 Once	 separated,	 the	 sections	 were	 drawn	 on	 to	 a	 SuperFrost	 plus	 slide	
(SuperFrost,	VWR)	and	were	consecutively	numbered.	The	slides	were	 then	held	 in	a	






Tris-Buffered	 saline	 (TBS)	 (60	mL	2.5M	NaCl	 and	20	mL	1M	Tris	HCl	 (pH	7.4);	2.5M	
NaCl,	Tris-Buffered	 saline	with	 tween	 (TBST)	 (1%	v/v	Tween	20	 in	TBS)	and	10mM	
citric	acid	buffer	(pH	6.0)	
2.4.3.2 	Dewaxing,	antigen	retrieval	and	blocking	
The	 slides	 were	 first	 placed	 on	 a	 hot	 plate	 for	 30	min	 prior	 to	 the	 procedure.	 This	
helped	to	dewax	and	prevent	tissue	loss	during	staining.		The	slides	were	then	passed	





acid	buffer	pH	6.0.	The	 slides	were	 completely	 immersed	 in	 the	buffer	 solution.	This	
container	was	then	placed	in	the	pressure	cooker,	which	was	then	closed	and	placed	in	
a	microwave	on	full	power	for	20	min.	When	the	yellow	gauge	on	the	pressure	cooker	
indicated	 that	 the	 cooker	 is	 fully	 pressurised,	 timer	 was	 set	 for	 5	min.	 At	 4	min	 40	




The	 slides	 were	 subjected	 to	 peroxidase	 block	 to	 inhibit	 endogenous	 peroxidase	
activity	by	immersing	in	3%	hydrogen	peroxide	(H2O2)	(180mL	of	distilled	water	and	
20mL	 of	 30%	 v/v	 H2O2)	 for	 15	 min.	 The	 slides	 were	 then	 washed	 in	 tap	 water	 by	
dipping	it	 in	a	container	with	tap	water	and	then	placed	in	a	container	with	TBS.	The	
slides	were	then	placed	in	a	humidified	chamber	(container	with	wet	paper	towels)	and	




added	 to	 the	 slides.	 Overnight	 incubation	 was	 done	 in	 a	 humidified	 chamber	 at	 4°,	
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whereas	 1h	 incubation	 was	 done	 at	 room	 temperature.	 The	 details	 of	 the	 primary	
antibody	used	for	each	biomarker,	the	concentration	used,	and	the	incubation	times	are	
described	 in	 Table	 6.	 Positive	 (lymph	 node)	 and	 negative	 controls	 (with	 antibody	
diluent	 only)	 were	 performed	 with	 each	 batch.	 After	 incubation	 with	 primary	
antibodies,	slides	were	washed	with	TBST	(2	x	5	min)	and	with	TBS	(5	min).	
2.4.3.4 	Secondary	Antibody	





The	slides	were	 then	placed	 in	the	humidified	 tray	again.	To	visualise	 the	reaction	of	
the	 biomarker	 with	 that	 of	 the	 antibody,	 100µL	 of	 3,	 3’-	 diaminobenzidine	 (DAB)	
working	 solution	 (Vector	 Laboratories)	 was	 applied	 to	 each	 section	 (prepared	 by	
adding	1	drop	of	DAB	to	1mL	of	DAB	substrate).	After	10	min,	the	excess	of	DAB	was	
removed	 from	 the	 slides.	 They	 then	 were	 washed	 in	 running	 tap	 water	 for	 2	 min.	
Passing	the	slides	through	Mayer’s	haematoxylin	for	30	seconds	performed	the	counter	
staining.	This	was	followed	by	a	wash	under	running	water	for	1	min	and	then	placing	






The	 scanned	 slides	 were	 viewed	 and	 manually	 scored	 using	 Webscope,	 which	 is	 a	
browser	based	digital	microscope	and	allows	viewing	and	scoring	of	slides.	The	scoring	
regimen	was	developed	in	close	consultation	with	Dr	Eldo	Verghese	(EV),	a	consultant	
breast	 histopathologist	 from	 LTHT.	 Dr	 Verghese	 also	 acted	 as	 a	 second	 scorer	 as	
described	 -	 10%	 of	 the	 slides	 for	 each	 of	 the	 four	 antibodies	 were	 double	 scored.	
Scoring	was	done	in	accordance	with	the	guidelines	recommended	by	the	International	




The	 entire	 slide	 was	 first	 scanned	 at	 low	 magnification	 to	 check	 for	 distribution	 of	
tumour	cells,	tumour	edge	and	the	lymphocytic	infiltrate.	The	lymphocytic	infiltrate	at	
the	 tumour	 edge	 was	 assessed	 and	 graded	 as	 mild,	 moderate	 or	 heavy	 infiltrate	 of	
lymphocytes.	Three	areas	per	slide	were	then	selected	at	10x	magnification	on	virtual	
slides	on	a	screen	resolution	of	1280	x	800	megapixel.	The	size	of	the	area	selected	was	
equivalent	 to	 the	size	of	 the	computer	screen	used	 for	scoring	 the	slides	(13	 inches).	
This	was	 consistent	 for	 all	 slides	 as	 the	 same	 computer	was	 used	 for	 scoring	 all	 the	




lymphocytes	 were	 not	 selected.	 The	 areas	 selected	 were	 digitally	 marked	 at	 10x	
magnification	using	a	pen	 tool	 available	 in	 the	Webscope	 software.	The	 area	marked	





density	 areas.	 Since	 the	 annotations	 could	not	be	saved	 in	 the	Webscope	 software,	 a	
screen	 shot	 of	 the	 area	 counted	 was	 taken	 and	 the	 second	 scorer	 (EV,	 a	 consultant	
breast	pathologist)	used	the	screen	shots	to	double	score	or	to	verify	the	scores	when	
in	 doubt	 regarding	 the	 nature	 of	 cells.	 For	 biopsy	 specimens,	 only	 2	 areas	 per	 slide	
were	scored	due	to	limited	tumour	tissue	in	these.	If	no	tumour	was	found	(especially	
post-chemotherapy	 where	 there	 was	 no	 residual	 disease)	 then	 that	 slide	 was	 not	
scored	 but	 the	 degree	 of	 lymphocyte	 infiltrate	was	 noted	 for	 analysis.	 The	 following	
parameters	 were	 scored	 in	 each	 selected	 area	 except	 the	 lymphocytic	 infiltrate	 at	
tumour	edge,	which	was	assessed	under	low	magnification	for	each	slide.	
1. Proportion	of	stromal	area	occupied	by	stained	lymphocytes	(%)	





Intra-tumoural	 lymphocytes	 (iTL)	 were	 defined	 as	 lymphocytes	 within	 the	 tumour	





tumoural	 lymphocytes.	 The	 stromal	 lymphocytes	 were	 defined	 as	 those	 within	 the	
stromal	area	between	the	tumour	nests	and	not	in	contact	with	any	tumour	cells.	The	
stromal	 proportion	 of	 lymphocytes	 was	 defined	 as	 the	 proportion	 of	 stromal	 area	




Figure	 shows	 tumour-infiltrating	 CD8	 lymphocytes	 in	 stroma	 and	 the	 intra-tumoural	
compartment	at	5x	magnification(A).	The	slides	were	first	scanned	at	low	magnification	












Figure	 shows	 tumour-infiltrating	 CD4	 lymphocytes	 in	 stroma	 and	 the	 intra-tumoural	
compartment	 at	 5x	magnification	 (A).	 The	 tumour	 islands	 are	marked	with	 pink.	 Inset	
with	black	arrow	shows	high	power	magnification	at	10x	of	a	tumour	island	with	iTLs	(B).	






Figure	shows	 tumour-infiltrating	CD20	 lymphocytes	 in	 stroma	and	 the	 intra	–tumoural	
















compartment	 at	 5x	magnification	 (A).	 Stromal	 areas	 are	marked	with	 pink.	 Inset	with	
black	arrow	shows	high	power	magnification	at	10x	of	a	tumour	island	with	iTLs	(B).	A	
typical	 iTL	 is	marked	with	 red	 block	 arrow.	 Inset	with	 green	 arrow	 shows	 high	 power	




stratified	 as	 mild	 moderate	 and	 heavy	 infiltrate	 based	 on	 the	 density	 of	 stained	
lymphocytes	at	the	tumour	edge.	In	some	cases,	the	tumour	edge	was	not	included	in	










As	 mentioned	 above,	 3	 areas	 per	 slide	 were	 scored	 in	 the	 case	 of	 main	 surgical	
specimen	 and	2	 areas	 in	 the	 case	 of	 biopsy	 specimens.	 Average	 of	 the	 3	 scores	 or	 2	
scores	(in	case	of	biopsies)	was	documented	for	stromal	proportion	of	lymphocytes	and	






version-22	 software.	 P-values	of	≤	 0.05	were	 considered	 significant	 in	most	 cases.	 In	
case	of	multiple	variables	being	tested	together,	a	Bonferroni	correction	was	applied	to	
adjust	 the	 p	 value	 by	 dividing	 the	 p	 value	 by	 the	 number	 of	 tests	performed.	 Power	
calculation	 to	 determine	 the	 sample	 size	 was	 not	 performed,	 as	 this	 study	 was	




circulating	 lymphocytes	 were	 assessed	 as	 absolute	 counts	 or	 as	 a	 proportion	 of	 the	
respective	T	or	B	cells	in	the	case	of	lymphocyte	subsets.	Lymphocyte	count	relative	to	
the	 pre-chemotherapy	 count	 was	 calculated	 by	 dividing	 the	 post-chemotherapy	
lymphocyte	 count	 by	 the	 pre-chemotherapy	 lymphocyte	 count	 and	 expressed	 as	 a	
percentage.	 The	 distribution	 of	 the	 data	was	 schematically	 checked	 for	 normality	 by	
using	 a	 histogram	 or	 by	 using	 the	 normality	 test	 (Kolmogorov-Smirnov).	 This	 was	
performed	 to	determine	 the	 statistical	 tests	 to	be	 used	 for	 subsequent	data	 analysis.	
Since	most	of	the	data	related	 to	 the	circulating	lymphocytes	did	not	 follow	a	normal	
distribution,	median	values	and	interquartile	range	(IQR)	was	used	as	a	measure	of	the	
central	 tendency	 and	 non-parametric	 tests	 were	 used	 for	 further	 data	 analysis.	 The	
difference	 in	 lymphocyte	counts	 in	different	groups	of	patients	based	on	 the	 tumour;	
patient	or	the	treatment	related	factors	were	tested	using	Independent-	Samples	Mann-
Whitney	U	test	(in	case	of	2	categories)	or	Kruskall-Wallis	test	(in	case	of	>2	categories)	
and	 the	 difference	 between	 the	 specific	 lymphocytes	 at	 different	 time	 points	 was	
assessed	 using	 the	 Related-samples	Wilcoxan’s	 signed	 rank	 test	 (when	 assessing	 the	
difference	 in	 lymphocytes	 between	 2	 specific	 time	 points)	 or	 Friedman’s	 two-way	
Analysis	of	Variance	by	Ranks	(ANOVA)	(in	the	case	of	>2	time	points).		
	
Correlations	 between	 different	 circulating	 lymphocytes	 or	 between	 clinico-	
pathological	 factors	 and	 circulating	 lymphocytes	 were	 assessed	 using	 correlation	
coefficients.	Pearson’s	correlation	coefficient	was	used	to	assess	correlations	between	
two	 normally	 distributed	 continuous	 variables.	 A	 Spearman’s	 correlation	 coefficient	
was	used	to	assess	correlations	between	two	categorical	variables	or	when	continuous	
variables	were	not	normally	distributed.	The	 strength	of	 association	between	 clinical	
and	 pathological	 variables	 and	 circulating	 lymphocytes	 was	 ascertained	 using	
univariate	 and	 multivariate	 regression	 analysis.	 Related-samples	 Wilcoxan’s	 signed	
rank	 test	 or	 Friedman’s	 two-way	 Analysis	 of	 Variance	 Ranks	 (ANOVA)	 was	 used	 to	
assess	 the	 difference	 in	 antibody	 titres	 at	 different	 time	 point’s	 pre	 and	 post-
chemotherapy.		
	
Tumour	 infiltrating	 lymphocytes	 were	 assessed	 as	 absolute	 counts	 (continuous	
variables),	as	a	proportion	of	the	stromal	area	(percentage)	or	as	a	proportion	relative	
to	 the	 intra-tumoural	 cells	 (percentage).	 Categorical	 and	 continuous	 variables	 were	
distinguished,	 and	 the	 distribution	 of	 the	 data	 was	 schematically	 checked	 using	 a	
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histogram	and	normality	tests	as	above.	 	For	IHC	analyses,	the	measure	of	association	
between	 the	 two	 independent	 scorers	was	assessed	using	 correlation	 coefficient	and	
the	measure	of	agreement	between	two	independent	scorers	was	calculated	using	and	
Kappa	 (κ)	 statistics.	 The	 continuous	 data	 was	 changed	 to	 categorical	 in	 order	 to	
perform	 this	 test.	 Wilcoxan’s	 signed	 rank	 test	 or	 Friedman’s	 two-way	 Analysis	 of	
Variance	by	Ranks	 (ANOVA)	was	used	 to	assess	 the	differences	 in	 the	distribution	of	
various	tumour-infiltrating	lymphocytes	in	the	stroma	or	intra-tumoural	compartment.	
The	 correlation	 between	 stromal	 and	 intra-tumoural	 lymphocytes,	 between	 TIL	 and	
various	 clinic-pathological	 factors	 and	 between	 TIL	 and	 circulating	 lymphocytes	was	
assessed	using	Spearman’s	correlation	coefficient.	
	
A	 ROC	 curve	 was	 used	 to	 determine	 a	 cut	 off	 point	 for	 circulating	 and	 tumour	
infiltrating	lymphocytes	 to	divide	 the	cohort	 into	groups	with	high	(above	 the	cut	off	
value)	and	 low	 levels	 of	 lymphocytes	 (below	 the	 cut	 off).	 The	 strength	of	 association	
between	clinical	and	pathological	variables,	circulating	lymphocytes,	TIL	and	outcome	
was	 ascertained	 using	 Cox	 regression	 analysis.	 The	 prognostic	 variables	 that	 were	


















Breast	 cancer	 is	 the	most	 common	malignancy	 in	women	and	approximately	30%	of	
breast	 cancer	 patients	 receive	 chemotherapy.	 Although	 chemotherapy	 is	 known	 to	
cause	considerable	 immune	dysfunction,	 relatively	little	is	known	about	the	extent	or	
the	 time	 course	 of	 immune	 dysfunction	 for	 current	 chemotherapy	 regimens.	My	 aim	








There	were	 significant	depletions	of	B,	 CD4+T,	CD8+T	and	NK	 cells	 at	 2	weeks	post-
chemotherapy	(p<0.001),	with	B	cells	showing	a	dramatic	depletion	to	a	median	5.4%	
of	 pre-chemotherapy	 level	 with	 some	 cases	 showing	 complete	 depletion.	 Post-
chemotherapy,	 CD8+	 T	 cell	 and	 NK	 cells	 showed	 significant	 recovery	 returning	 to	
almost	normal	pre-chemotherapy	levels	by	9	months	but	levels	of	B	cells	and	CD4+	T	
cells	remained	significantly	low	(p<0.001).	Repopulating	B	and	CD4+	T	cell	phenotypes	
were	 different	 from	 the	 pre-chemotherapy	 profile.	 B	 cells	 showed	 progressive	
increases	in	the	proportions	of	naïve	cells	and	a	decrease	in	the	proportions	of	memory	
cells.	Proportions	of	transitional	B	cells	were	increased	at	3	months	post-chemotherapy	
compared	 to	 pre-chemotherapy	 levels,	 but	 these	 progressively	 decreased	 towards	
more	 typical	 levels	from	6	to	9	months	while	 the	regulatory	B	cells	showed	an	 initial	
decrease	followed	by	progressive	increase	over	the	9-month	follow-up.	Repopulating	T	
cells	 showed	 a	 progressive	 increase	 in	 CD45RA-CD45RO+	 memory	 T	 cells	 with	 a	
progressive	 decrease	 in	 the	 naïve	 CD45RA+CD45RO-	 and	 CD4+CD45RA+CD62L+	 T	 cells.	
There	was	a	progressive	decrease	 in	the	CD4+CD45RO-CD31+	recent	 thymic	emigrants,	
while	 the	 CD25+FoxP3+	 regulatory	 T	 cells	 showed	 progressive	 increases	 over	 the	 9-
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month	 follow-up	 period	 post-chemotherapy.	 Titers	 of	 anti-pneumococcal	 and	 anti-
tetanus	 antibodies	 were	 significantly	 reduced	 post-chemotherapy	 and	 these	 did	 not	
return	 to	 normal	 even	 at	 9	 months	 post-chemotherapy	 (p<0.001).	 Smoking	 and	
chemotherapy	 regimen	 had	 significant	 correlations	 with	 degrees	 of	 depletion	 and	
repopulation	of	B	and	T	cells	and	were	independent	predictors	of	post-chemotherapy	B	




Breast	 cancer	 chemotherapy	 has	 significant	 long-term	 effects	 on	 the	 immune	








free/overall	 survival.	 Anthracycline	 based	 chemotherapy	 is	 generally	 recommended	
and	 taxanes	 are	 added	 where	 additional	 benefit	 outweighs	 risk.	 Actual	 choice	 of	
chemotherapy	is	usually	guided	by	local	policy	(NICE,	2009).	Chemotherapeutic	agents	
are	 associated	with	 adverse	 effects	 on	 the	 immune	 system.	Neutropenia	 is	 the	most	
serious	haematological	toxicity	and	can	be	associated	with	life	threatening	infections	or	
may	 force	 chemotherapy	 dose	 reductions	 or	 delays	 that	 compromise	 treatment.	
Chemotherapy	has	also	been	shown	to	affect	the	adaptive	immune	system	(reviewed	in	
Ch1,	section	1.4).	Many	studies	have	reported	the	short-term	effects	of	chemotherapy	
(during	 and	 up	 to	 3	 months	 after	 the	 last	 chemotherapy	 cycle)	 on	 lymphocytes	 in	
breast	 cancer	 patients,	 with	 a	 consensus	 that	 chemotherapy	 reduces	 circulating	
lymphocyte	levels.	Much	less	is	known	about	the	longer-term	effects	of	chemotherapy	
on	 lymphocytes,	 especially	 on	 B-lymphocytes.	 	 Evidence	with	 regards	 to	 recovery	 of	
immune	parameters	following	chemotherapy	is	limited	and	often	conflicting	(reviewed	
in	 Ch1,	 section	 1.4).	 There	 are	 very	 limited	 data	 with	 regards	 to	 effects	 of	
chemotherapy	 on	 memory	 response	 and	 humoral	 immunity	 (antibody	 mediated	
immunity)	 and	 no	 reports	 of	 detailed	 phenotyping	 of	 B	 cells	 post-chemotherapy.	My	
aim	was	 to	 plug	 these	 gaps	 in	 the	 literature	 by	 assessing	 the	 levels	 of	 B	 and	 T	 cells	




To	 understand	 the	 effects	 of	 chemotherapy	 on	 immune	 factors	 I	 conducted	 a	
longitudinal	 study	 to	 analyse	 the	 levels	 of	 lymphocytes	 before	 and	 at	 various	 time	
points	 up	 to	 9	months	 after	 completion	 of	 chemotherapy	 in	 patients	 diagnosed	with	
primary	breast	cancer.	There	were	2	patient	cohorts:	
Group	A	(n=62):	Analyses	were	performed	pre-chemotherapy,	and	at	2	weeks	and	3,	6	
and	9	months	 after	 the	 end	of	 chemotherapy.	One	or	more	 sample	 time-points	were	
missed	for	8	patients.	The	mean	age	of	patients	in	Group	A	was	54.33	years.	
	 70	




Bloods	 were	 also	 taken	 from	 healthy	 females	 in	 a	 similar	 age	 range	 as	 the	 study	
patients	 but	 not	 suffering	 from	 breast	 cancer	 or	 other	 immunological	 conditions	
(control	 group,	 n=17).	 Results	 from	 88	 study	 patients	 were	 included	 in	 the	 final	
analysis.	 Extensive	 clinico-pathological	 data	 concerning	 the	 patients	 were	 collected	
(Table	7).	
	













































































































Pre-treatment	lymphocyte	 levels	 in	 the	study	breast	cancer	cohort	were	compared	to	
the	published	normal	range	(Table	8)	and	to	the	control	group	recruited	for	the	study	
(Table	9).	The	pre-treatment	levels	of	 lymphocytes	were	within	 the	normal	range	 for	
adults	prior	to	chemotherapy.	The	normal	reference	range	for	all	lymphocytes	is	taken	
from	the	 literature	(Comans-Bitter	et	al.,	1997)	and	 is	used	as	reference	range	 in	the	
clinical	laboratory	at	St	James’s	University	Hospital	NHS	Trust.	The	lymphocyte	counts	
in	 the	 majority	 of	 patients	 were	 in	 the	 normal	 or	 above	 normal	 range.	 A	 small	
proportion	of	patients	(4/62	in	the	case	of	CD8	and	NK	cells,	and	2/62	in	the	case	of	B	



















CD4	 1034.50	(675)	 71%	 0%	 29%	 300-1400	
CD8	 426.00	(371)	 90%	 6%	 4%	 200-900	
B		 243.00	(179)	 86%	 3%	 11%	 100-500	
NK		 233.50	(118)	 92%	 6%	 2%	 90-600 
Table	8.	Baseline	lymphocytes	counts	in	study	patients	and	normal	range	
Pre-chemotherapy	bloods	were	 taken	 from	62	patients	in	 the	study	cohort	and	assessed	
for	levels	of	CD4,	CD8,	B	and	NK	cells.	The	normal	reference	range	for	all	lymphocytes	was	
taken	 from	 the	 literature	 and	 used	 as	 reference	 range	 in	 the	 clinical	 laboratory	 at	 St	
James’s	 University	 Hospital	 NHS	 Trust.	 The	 baseline	 (pre-chemotherapy)	 levels	 of	
lymphocytes	were	compared	with	the	normal	range	for	each	of	the	lymphocytes.	Column	3	




The	 baseline	 level	 of	 B	 cells,	 CD4+	 and	 CD8+	 T	 cells	 and	 NK	 cells	 were	 also	 not	










CD4	 1034.50	(675.00)	 992.00	(262.50)	 0.262	
CD8	 426.00	(371.00)	 529.00	(347.00)	 0.139	
B		 243.00	(179.00)	 272.00	(221.50)	 0.576	
NK		 233.50	(118.00)	 231.00(152.00)	 0.962 
Table	9.	Comparison	of	baseline	lymphocytes	in	study	patients	and	control	group	





shown	 in	 Figure	 19-A.	 In	 addition,	 post-chemotherapy	 levels	 are	 expressed	 as	 a	
proportion	 of	 the	matched	 pre-chemotherapy	 level	 in	 order	 to	 highlight	 longitudinal	
changes	 (Figure	 19-B).	 The	 latter	 analysis	 was	 performed	 only	 in	 Group	 A	 patients,	
since	only	in	these	patients	were	pre-chemotherapy	levels	available.	The	median	values	
and	 IQRs	are	shown	 in	Table	23	and	24	(Appendix	2,	 section	6.2.1	and	6.2.2).	 	There	
was	a	 significant	depletion	of	B	 cells,	 CD4+	T,	 CD8+	T	 and	NK	 cells	at	2	weeks	post-
chemotherapy	 (p<0.001,	 for	 each	 of	 the	 cell	 types),	with	 B	 cells	 showing	 a	 dramatic	
depletion	 to	 a	 median	 level	 of	 5.4%	 of	 pre-chemotherapy	 level.	 In	 the	 majority	 of	
patients	 (55.68%),	 B	 cell	 were	 reduced	 to	 <2%	 of	 their	 original	 levels.	 In	 some	
individual	cases,	there	was	an	almost	complete	depletion	of	B	cells	(8	patients	showed	
an	absolute	B	cell	count	of	<1/μL	at	2	weeks	post-chemotherapy).	There	was	gradual	
recovery	 of	 each	 of	 these	 lymphocyte	 types	 over	 the	 9-month	 period	 following	
chemotherapy.	 There	 was	 almost	 complete	 recovery	 of	 CD8+	 T	 and	 NK	 cells	 by	 9	
months	post-chemotherapy,	but	there	was	only	partial	recovery	of	B	and	CD4+	T	cells	
(reaching	a	median	value	of	69%	and	60%	of	the	pre-chemotherapy	level	respectively)	













of	 the	data	with	medians	 (lines),	 interquartile	ranges	 (whiskers)	and	 individual	outliers	
(circles).	All	statistically	significant	differences	(p<0.05)	selected	and	marked	in	the	figure	
using	*	(pre-	2w	and	pre-	9m).	Related-Samples	Wilcoxan	signed-rank	test	used	to	assess	
statistical	 significance.	 This	 figure	 is	 adapted	 from	my	 published	 figure	 in	 Verma	 et	 al	
2016.	






of	 reconstitution	of	 these	 cells	at	 3	months	and	6	months,	 except	between	B	 and	NK	
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and	CD8+	T	cells	and	also	between	CD8+	T	cells	and	NK	cells	where	there	was	strong	
correlation	 (rs=	0.478-0.715,	 p<0.001).	 At	9	months	 post-chemotherapy,	 there	was	 a	
positive	 correlation	 only	 between	 proportions	 of	 CD4+	 and	 CD8+	 T	 cells	 (rs=	 0.591,	
p<0.001)	 as	well	 as	CD8+	T	 cells	 and	NK	 cells	 (rs=	0.498,	 p<0.001).	 I	 concluded	 that	
repopulation	of	the	different	lymphocyte	compartments	was	highly	related	across	the	
subtypes,	and	particularly	so	for	the	two	T	cell	subtypes,	and	for	CD8+	T	cells	and	NK	
cells.	 Since	 multiple	 tests	 were	 performed,	 and	 there	 was	 a	 risk	 of	 multiple	 testing	
problems,	 the	Bonferroni	correction	was	applied	to	 the	p	value.	Using	 the	Bonferroni	
correction,	 the	significant	p	value	was	0.002.	Using	 this	p	value,	only	 the	correlations	
between	 lymphocytes	 at	 2	weeks	 and	 correlations	 between	 CD4	 and	 CD8	at	 all	 time	
points	were	significant.	
	 2	weeks	 3	months	 6	months	 9	months	
	 As	a	proportion	of	pre-chemotherapy	level	(%)	
B	&	CD4	 0.738	 0.375	(p=0.003)	 0.315	(p=0.014)	 NS	
B	&	CD8	 0.751	 0.267	(p=0.039)	 0.332	(p=0.010)	 NS	
B	&	NK	 0.780	 0.383	(p=0.002)	 	NS	 NS	
CD4	&	CD8	 0.844	 0.478	 0.715	 0.591	
CD4	&	NK	 0.564	 0.357	(p=0.005)	 0.333	(p=0.009)	 NS	
CD8	&	NK	 0.751	 0.513	 0.472		 0.498	 
Table	10.	Positive	correlation	between	extent	of	depletion	and	repopulation	of	
lymphocytes	
Table	 shows	 the	 Spearman’s	 correlation	 coefficient	 values	 between	 the	 lymphocytes	 as	
listed	in	the	first	column.	P	values	were	<0.001	for	all	except	where	p	values	listed	in	the	




Since	 B	 and	 CD4+	 T	 cells	 showed	 the	 maximum	 depletion	 and	 least	 repopulation	
compared	 to	 the	 pre-chemotherapy	 levels,	 I	wanted	 to	 assess	whether	 the	 degree	 of	





depletion	 and	 repopulation	 following	 chemotherapy	 (Figure	 20-A).	 Independent	 -
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samples	Mann	Whitney	 U	 test	 was	 used	 to	 assess	 if	 the	 difference	 in	 the	 degree	 of	
depletion	 or	 repopulating	 B	 and	 CD4+	 T	 cells	 in	 the	 upper	 and	 lower	 tertiles	 was	
statistically	 significant.	 In	 the	 case	 of	 CD4+	 T	 cells,	 the	 degree	 of	 depletion	 between	
those	with	high	or	low	initial	counts	were	similar,	but	there	was	a	significant	difference	
in	 the	 level	 of	 repopulation	 between	 the	 two	 groups	 at	 6	 months	 (p=0.008).	





significant	difference	 in	 the	proportions	of	CD4+	T	cells	 in	between	the	 low	and	high	













(A-left)	 and	 CD4+	 T	 cells	 (B-left).	 The	 depletion	 and	 repopulation	 of	 B	 cells	 post-
chemotherapy	 was	 then	 assessed	 in	 the	 lower	 and	 upper	 tertiles.	 Relative	 numbers	 of	
these	cells	are	shown	at	 time	points	2	weeks	 (2w)	and	3,	6	and	9	months	 (3m,	6m,	9m)	
post-chemotherapy	on	the	right-side	plots.	Boxes	represent	50%	of	the	data	with	medians	
(lines),	 interquartile	 ranges	 (whiskers)	 and	 individual	 outliers	 (circles).	 	 All	 statistically	
significant	differences	 (p<0.05)	 selected	and	marked	 in	 the	 figure	using	*	 (6m	and	9m).	
Mann-Whitney	U	test	used	to	assess	statistical	significance.	This	figure	is	adapted	from	my	
published	figure	in	Verma	et	al	2016.	
3.4.4 	Chemotherapy	 increases	 proportions	 of	 naïve	 and	
decreases	proportions	of	memory	B	cells	
In	 order	 to	 determine	 the	 source	 of	 the	 cells	 repopulating	 the	 B-lymphocyte	
compartment	 after	 chemotherapy-induced	 depletion,	 I	 performed	 detailed	
phenotyping	 of	 the	 cells	 in	 terms	 of	 surface	 markers	 indicating	 immunological	
maturity.	 The	 different	 B	 cell	 subsets	 examined	 were	 naïve	 cells	 (CD27-IgD+),	 non-
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IgD+)	 from	 54%	prior	 to	 chemotherapy	 to	80%	at	 3	months	post-chemotherapy	 and	









post-chemotherapy	 (p<0.001).	 Transitional	 (CD24hiCD38hi)	 and	 “regulatory”	
(CD24hiCD27+)	 B	 cells	 behaved	 differently.	 There	 was	 a	 significant	 increase	 in	 the	
proportions	of	 transitional	B	cells	 (p<0.001)	 from	5%	pre-chemotherapy	 to	23%	at	3	
months	 post-chemotherapy	 followed	 by	 a	 progressive	 drop	 in	 the	 proportions,	
reaching	14%	by	9	months.	The	CD24hiCD27+	B	cells,	which	have	been	reported	to	have	
some	regulatory	function	(Iwata	et	al.,	2011),	reduced	significantly	after	chemotherapy	











cells	 (A),	 CD27+IgD+	non-switched	 B	 cells	 (B),	 CD27+IgD-	 switched	 (C)	 memory	 B	 cells,	
transitional	 cells	 (CD24hiCD38hi)	 (D)	 and	 “regulatory”	 B	 cells	 (CD24hiCD27+)	 (E).	 Boxes	





Representative	 dot-plots	 from	 an	 individual	 patient	 showing	 the	 variation	 in	
proportions	of	various	B	cell	subsets	pre	and	3	months	post-chemotherapy	is	shown	in	
Figures	22-24.	Figure	22	 shows	 the	 increase	 in	 the	proportions	of	naïve	B	 cells	 from	
68%	prior	to	chemotherapy	to	93%	at	3	months	post-chemotherapy	and	decreases	in	
the	 non-switched	 memory	 B	 cells	 from	 10%	 (pre)	 to	 3%	 (3m	 post)	 and	 switched	
memory	B	cells	from	19%	(pre)	to	4%	(3m	post)	in	this	representative	patient.	Figure	



































































































Dot	 plots	 shows	 distribution	 of	 CD24+CD38+	 B	 cells	 (upper	 outer	 quadrant)	 prior	 to	
chemotherapy	 (left)	 and	 at	 3	 months	 post-chemotherapy	 (right)	 in	 a	 representative	




























25%	 and	 25%	 at	 3,	 6	 and	 9	 months	 respectively	 (p<0.001)	 (Figure	 25	 A).	 Similar	
results	were	 seen	 even	when	using	an	alternative	marker	 for	 identifying	 the	naïve	T	
cells	 (CD45RA+CD62L+)	 (Figure	 25	 B).	 Prior	 to	 chemotherapy,	 CD45RA+CD62L+	 cells	
constituted	47%	of	the	circulating	CD4+	cells	and	this	reduced	to	35%	at	2	weeks	post-
chemotherapy	 (p<0.001)	 and	 remained	 low	 at	 33%	 even	 at	 9	 months	 follow	 up	
(p=0.004).		Conversely,	 the	proportion	of	memory	T	cells	(CD45RA-CD45RO+)	 increased	
from	 63%	 pre-chemotherapy	 to	 68%	 at	 2	 weeks	 post-chemotherapy	 (p<0.001)	 and	
continued	to	increase	to	75%	at	9	months	post-chemotherapy	(p<0.001)	(Figure	25	C).	
The	ratio	of	naïve/memory	CD4+T	cells	dropped	from	0.6	pre-chemotherapy	to	0.47	at	




Preferential	 impact	 of	 chemotherapy	 on	 immature	 T	 cells	 was	 also	 evident	 from	 its	
effect	on	CD45RO-CD31+T	cells.	CD31	has	been	 found	to	be	a	marker	of	recent	 thymic	
emigrants	 (Kohler	 and	 Thiel,	 2009,	 Tanaskovic	 et	 al.,	 2010).	 Prior	 to	 chemotherapy	
these	cells	constituted	22%	of	the	CD4+	T	cell	population.	2	weeks	post-chemotherapy;	
there	was	a	significant	drop	in	their	levels	to	18%	(p<0.001).	Their	levels	continued	to	
decrease	 subsequently	 and	 at	 9	 months	 post-chemotherapy,	 these	 cells	 constituted	
12%	of	the	CD4+	T	cell	population	(p<0.001)	(Figure	25	D).	
	
CD25+FoxP3+	 cells	 are	 a	 subset	 of	 CD4+	 T	 cells	 that	 are	 thought	 to	 have	 regulatory	
function	and	high	levels	of	CD4+FoxP3+	cells	have	been	associated	with	poor	outcome	in	
cancer	patients.	 I	assessed	 the	 levels	of	CD25+FoxP3+	and	CD25hiFoxP3+	cells	pre	and	
post-chemotherapy	(Figure	25	E	and	F).	Although	there	was	a	progressive	increase	in	
the	 levels	 of	 CD25+FoxP3+	 and	 CD25hiFoxP3+	 post-chemotherapy,	 the	 difference	 was	









cells	 (A),	 CD45RA+CD62L+	Naïve	T	 cells	 (B),	 CD45RA-CD45RO+	Memory	T	 cells	 (C),	 CD45RO-
CD31+	Recent	 thymic	 emigrants	 -RTE	 (D),	 CD25+FoxP3+	 and	CD25hiFoxP3+	 regulatory	T	
cells	 (E-F).	 Boxes	 represent	 50%	 of	 the	 data	with	medians	 (lines),	 interquartile	 ranges	
(whiskers)	and	individual	outliers	(circles).	All	statistically	significant	differences	(p<0.05)	





29.	 Post-chemotherapy	 there	was	 a	decrease	 in	 the	 proportion	 of	naïve	 T	 cells	 from	
37%	to	32%	(upper-inner	quadrant)	and	an	increase	in	the	memory	T	cells	from	45%	
to	 60%	 (lower-outer	 quadrant)	 in	 this	 representative	 patient.	 Figure	 26	 shows	 a	
decrease	 in	 the	 proportions	 of	 naïve	 T	 cells	 using	 an	 alternate	 marker	

















































































































Dot	 plots	 shows	 the	 distribution	 of	 naïve	 T	 cells	 using	 an	 alternate	 marker	
(CD4+CD45RA+62L+)	(upper-right	quadrant)	prior	to	chemotherapy	and	at	3	months	post-










































3.4.6 Recovery	 of	 CD4+	 T	 cells	 correlates	 with	 recovery	 of	
switched	 memory	 B	 cells,	 and	 recovery	 of	 B	 cells	
correlates	with	naïve	CD45RA+CD62L+	T	cells		
CD4+T	 cells	play	a	 substantial	 role	 in	B	 cell	 activation	 and	maturation	by	stimulating	
class	switching	(Ch1,	section	1.2.6).	The	analyses	presented	above	(Figure	19)	showed	
that	 there	 was	 significant	 depletion	 and	 incomplete	 recovery	 of	 both	 these	 cells	
following	 chemotherapy.	 	 There	 was	 also	 a	 significant	 correlation	 between	 the	
proportions	 of	 repopulating	 B	 and	 CD4+	T	 cells	 compared	 to	 their	 pre-chemotherapy	
levels	(Table	11).		





























cells	 was	 stronger	 between	 the	 specific	 subsets	 of	 B	 or	 CD4+	 T	 cells.	 There	 was	 a	
positive	correlation	between	the	switched	memory	B	cells	and	CD4+T	cells	at	3,	6	and	9	
months	post-chemotherapy	and	a	negative	correlation	between	naïve	B	cells	and	CD4+	
T	 cells	 as	 well	 as	 the	 ratio	 of	 naïve/memory	 B	 cells	 and	 CD4+	 T	 cells	 at	 these	 time	
points.	 On	 comparing	 the	 CD4+	 T	 cell	 subsets	 with	 B	 cells,	 there	 was	 a	 negative	
correlation	between	the	naïve	CD45RA+CD62L+	T	cells	and	B	cells	at	3,	6	and	9	months	
post-chemotherapy	 and	 also	 prior	 to	 chemotherapy.	 This	 was	 however	 not	 the	 case	
between	 the	 CD45RA+CD45RO-	 naïve	 T	 cells	 and	 B	 cells.	 There	 was	 also	 a	 negative	
correlation	 between	 CD4+CD45RO-CD31+	 RTE	 and	 B	 cells	 at	 6	 and	 9	 months	 post-

































































circulating	 lymphocytes.	 I	 therefore,	 tested	 whether	 any	 of	 the	 patient,	 tumour	 or	




showed	 correlations	 with	 the	 levels	 of	 lymphocytes	 pre	 or	 post-chemotherapy	
(Appendix	 2,	 section	 6.2.4,	 Tables	 27-28).	 However,	 chemotherapy	 regimens	 and	
smoking	status	showed	significant	correlations	with	 these	 levels	 (discussed	 in	3.4.7.1	
and	 3.4.7.2).	 At	 9	 months	 post-chemotherapy,	 there	 was	 also	 a	 weak	 negative	
correlation	 between	 radiotherapy	 treatment	 and	CD4+	 T	 cell	 proportions	 (r=	 -0.292,	
p=0.034)	and	a	weak	positive	correlation	between	tumour	size	and	B	cell	proportions	
(r=	 0.300,	 p=0.029).	 When	 absolute	 counts	 of	 B	 and	 CD4+	 T	 cells	 were	 used	 for	
	 88	
analysis,	 there	 was	 a	 weak	 correlation	 between	 Her2	 status	 and	 B	 cell	 counts	 at	 2	
weeks,	 3	 months,	 and	 9	 months	 post-chemotherapy	 and	 between	 B	 cell	 count	 at	 2	
weeks	 post-chemotherapy	 and	 tumour	 recurrence	 (Appendix	 2,	 section	 6.2.5,	 Table	
29).	Similarly,	when	absolute	counts	of	CD4+	T	cells	were	analysed,	there	was	a	weak	
correlation	 between	 patient’s	 age	 and	 CD4+	 T	 cells	 at	 2	 weeks	 post-chemotherapy	




Patients	 included	 in	 the	 study	 were	 treated	 with	 anthracycline-based	 regimes	
(epirubicin	 and	 cyclophosphamide	 (EC),	 or	 5-Flurouracil,	 epirubicin	 and	
cyclophosphamide	 (FEC)	 for	 6	 cycles,	 or	 –	 alternatively	 -	 they	 had	 2	 cycles	 of	 EC	
followed	by	4	cycles	of	taxane	in	the	form	of	docetaxel	(EC+TAX)	if	they	failed	to	show	
response	to	the	initial	regimen.	Patients,	who	received	docetaxel,	were	routinely	given	
Granulocyte	 Colony	 Stimulating	 Factor	 (GCSF)	 to	 combat	 the	 neutropenia	 associated	








p<0.01).	 This	 difference	 was	 no	 longer	 significant	 at	 3,	 6	 or	 9	 months	 post-
chemotherapy	 in	 the	 case	 of	 CD4+	 T	 cells,	 CD8+	 T	 cells	 and	 NK	 cells.	 However,	 the	
repopulation	of	B	cells	at	6	and	9	months	in	the	EC/FEC	group	was	significantly	greater	
compared	to	the	EC+TAX	group.	Although	the	group	that	received	Taxanes	showed	less	
depletion	 of	 cells	 compared	 to	 EC/FEC	 group	 at	 2	 weeks	 post-chemotherapy,	
subsequent	 recovery	of	B	 cells	 in	 the	EC+TAX	group	was	much	 less	 compared	to	 the	
EC/FEC	group.	At	9	months	post-chemotherapy,	the	level	of	B	cells	in	the	EC/FEC	group	
was	 no	 different	 from	 the	 pre-chemotherapy	 level	 (p=0.248)	 suggesting	 complete	
recovery	of	B	cells	in	this	group.	However,	their	levels	in	the	EC+TAX	group	remained	














represent	 50%	 of	 the	 data	 with	 medians	 (lines),	 interquartile	 range	 (whiskers)	 and	











































































































represent	 50%	 of	 the	 data	 with	 medians	 (lines),	 interquartile	 range	 (whiskers)	 and	
individual	 outliers	 (circles).	 All	 statistically	 significant	 differences	 (p<0.05)	 selected	and	
marked	in	the	figure	using	*.	Mann-Whitney	U	test	used	to	assess	statistical	significance.	
	
Even	 though	 B	 cells	 in	 EC/FEC	 group	 showed	 better	 repopulation	 compared	 to	 the	
EC+TAX	 group,	 the	 CD24hiCD27+	 B	 cell	 subset	 with	 ‘regulatory’	 function	 showed	




regimen	 and	 showed	 lower	 levels	 in	 EC/FEC	 group	 was	 the	 CD27+IgD-	 Switched	


















































































cells	prior	 to	chemotherapy	(20%	versus	28%,	p=0.014).	The	 levels	 in	EC/FEC	group	
persisted	to	be	significantly	low	at	3	months	(8%	versus	10%,	p=0.045),	6	months	(5%	
versus	8%,	p=0.015)	and	9	months	(4%	versus	7%,	p=0.030)	compared	to	 the	group	







were	 used	 to	 treat	 the	 study	 patients.	 B	 cell	 subsets	 were	 quantified	 in	 the	 peripheral	
blood	of	the	study	patients	prior	to	chemotherapy	(pre)	and	at	3,	6	and	9	months	(3m,	6m,	
9m)	 post-chemotherapy.	 Levels	 of	 CD24hiCD27+	 ‘regulatory’	 B	 cell	 pre	 and	 post-
chemotherapy	are	shown	on	 the	 left	 (32-A)	and	 levels	of	CD27+IgD-	 switched	memory	B	




3.4.7.2 Patients	 who	 smoke	 reconstitute	 B	 cells	 more	 slowly	 post-
chemotherapy			
The	only	other	factor	that	appeared	to	influence	the	levels	of	lymphocytes	was	smoking	
status	of	patients.	There	was	no	significant	difference	 in	 the	 levels	of	B	cells	between	
the	non-smokers	 and	smokers	prior	 to	 chemotherapy.	Post-chemotherapy	 there	was,	
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chemotherapy	 (Figure	33).	The	 extent	 of	 depletion	of	B	 cells	was	 similar	 in	 smokers	







(n=43)	 and	 smokers	 (n=19).	 Circulating	 levels	 of	 B	 cells	 were	 assessed	 using	 flow	
cytometry	pre-chemotherapy	(pre)	and	at	2	weeks	(2w),	3,	6	and	9	months	(3m,	6m,	9m)	
post-chemotherapy.	 Data	 is	 shown	 as	 absolute	 counts	 (left	 panel)	 and	 as	 proportions	
relative	to	the	matched	pre-chemotherapy	level	(right).	Boxes	represent	50%	of	the	data	
with	medians	 (lines),	 interquartile	 range	(whiskers)	and	 individual	outliers	 (circles).	All	





‘regulatory’	 B	 cells.	 Baseline	 levels	 of	naïve	 B	 cells	were	 similar	 in	non-smokers	 and	
smokers.	 Repopulation	 of	 naïve	 B	 cells	 was	 significantly	 lower	 in	 the	 smokers	
compared	to	non-smokers	(67%	versus	81%	at	3m,	p<0.001;	71%	versus	87%	at	6m,	
p=0.002	 and	 77%	 versus	 86%	 at	 9	 m,	 p=0.002).	 Conversely,	 the	 levels	 of	 switched	
memory	B	cells	were	higher	in	the	smokers	compared	to	non-smokers	at	all	time	points	
including	prior	to	chemotherapy	(30%	versus	22%	at	pre,	p=0.009;	21%	versus	8%	at	
























































memory	 (B)	 and	 CD27+IgD+	non-switched	memory	 (C)	 B	 cells	were	 assessed	using	 flow	
cytometry	at	pre-chemotherapy	(pre),	2	weeks	(2w),	3,	6	and	9	months	(3m,	6m,	9m)	post-
chemotherapy.	 The	 levels	 of	 these	 cells	 are	 expressed	 as	 a	 proportion	 of	 B	 cells.	 Boxes	
represent	 50%	 of	 the	 data	 with	 medians	 (lines),	 interquartile	 range	 (whiskers)	 and	
individual	 outliers	 (circles).	 All	 statistically	 significant	 differences	 (p<0.05)	 selected	and	
marked	in	the	figure	using	*.	Mann-Whitney	U	test	used	to	assess	statistical	significance.	
	
Naïve/mem	B	ratio	 Non-smoker	 Smoker	 P	value	
Pre	 1.47	 0.89	 0.171	(NS)	
3m	 6.09	 2.74	 0.001	
6m	 9.51	 2.97	 0.002	




























Naïve (CD27-IgD+)  Non-Sw Mem (CD27+IgD+) Sw Mem (CD27+IgD-)















Prior	 to	 chemotherapy,	 smokers	had	a	significantly	higher	 level	 of	CD4+	 lymphocytes	
(1432	versus	965	cells/μL,	p=0.008)	(Figure	35	A)	and	this	difference	was	maintained	
in	 the	 repopulating	 CD4+	 lymphocytes,	 reaching	 a	 statistical	 significance	 at	 3	 and	 9	
months	 (703	 versus	 523	 cells/μL,	 p=0.039	 and	 849	 versus	 cells/μL,	 p=0.004	
respectively)	 (Figure	 35	 C).	 The	 proportion	 of	 repopulating	 CD4+	 lymphocytes	
compared	to	the	pre-chemotherapy	level	was	however	not	different	in	the	smokers	and	







(n=43)	and	 smokers	 (n=19).	 Circulating	 levels	 of	 CD4+	T	 cells	were	assessed	using	 flow	
cytometry	pre-chemotherapy	(pre)	and	at	2	weeks	(2w),	3,	6	and	9	months	(3m,	6m,	9m)	
post-chemotherapy.	Data	is	shown	as	absolute	counts	(A	&	C)	and	as	proportions	relative	
to	 the	 matched	 pre-chemotherapy	 level	 (B).	 Boxes	 represent	 50%	 of	 the	 data	 with	
medians	 (lines),	 interquartile	 range	 (whiskers)	 and	 individual	 outliers	 (circles).	 	 All	
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3.4.8 Predictors	 of	 B	 and	 CD4+	 T	 cell	 depletion	 and	
repopulation	post-chemotherapy	
Since	 chemotherapy	 regimen	 and	 smoking	 had	 significant	 effects	 on	 the	 extent	 of	
depletion	 and	 reconstitution	 of	 B	 cells	 and	 CD4+	 T	 cells,	 I	 performed	 a	 regression	
analysis	 to	 check	 the	 extent	 of	 association	 between	 these.	 I	 included	 the	 pre-
chemotherapy	 B	 and	 CD4+	 T	 cell	 level	 in	 the	 model,	 since	 there	 were	 significant	
correlations	between	these	at	all	time	points	and	also	to	check	if	the	pre-chemotherapy	
level	of	these	cells	could	be	used	to	predict	the	levels	of	B	cells	post-chemotherapy.	On	







B	 cell	 level	 at	 all	 time	 points	 except	 at	 2	weeks	 (p<0.05)	 (Appendix	 2,	 section	 6.2.6,	
Table	 31).	 Similarly,	 these	 covariates	 predicted	 post-chemotherapy	 levels	 of	 CD4+T	
cells	at	2	weeks,	and	3,	6	and	9	months	(p<0.001	at	each	time	point),	but	only	pre-op	





To	 assess	 the	 effects	 of	 chemotherapy	 on	 antibody-mediated	 immunity,	 I	 next	
evaluated	the	levels	of	tetanus	and	pneumococcal	antibodies.	Since	people	in	the	UK	get	
routinely	immunised	against	pneumococcal	and	tetanus	as	per	the	national	guidelines,	I	




4.03	 IU/mL)	 for	 tetanus	 antibodies.	 8/52	 patients	 had	 levels	 of	 pneumococcal	
antibodies	defined	clinically	as	suboptimal	(<30	IU/mL)	and	1/52	had	inadequate	level	
(<10	 IU/mL).	 11/52	 patients	 had	 suboptimal	 tetanus	 antibody	 levels	 (<0.15	 IU/mL)	
	 96	
and	 0/52	 had	 inadequate	 level	 (<0.010	 IU/mL).	 Possible	 causes	 for	 low	 baseline	




tetanus	 and	 pneumococcal	 antibody	 levels	 post-chemotherapy	 (Figure	 36).	 The	
antibody	levels	at	all	time	points	were	significantly	different	(p<0.001,	Friedman’s	two-
way	ANOVA).	When	antibody	levels	at	each	time	point	was	compared	to	the	baseline,	




6%	 had	 inadequate	 levels.	 Tetanus	 antibody	 levels	 also	 dropped	 significantly	 at	 2	
weeks	 post-chemotherapy	 to	 72%	 of	 the	 baseline	 level	 (p<0.001)	 and	 remained	














anti-tetanus	(<0.15	 IU/mL)	antibodies	and	 inadequate	 level	of	anti	-pneumococcal	 (<10	
IU/mL)	and	anti-tetanus	(<0.10	IU/mL)	are	marked	by	dotted	lines.	Boxes	represent	50%	
of	 the	data	with	medians	 (lines),	 interquartile	 range	 (whiskers)	 and	 individual	 outliers	
(circles).	All	statistically	significant	differences	(p<0.05)	selected	and	marked	in	the	figure	
using	 *.	 Wilcoxan	 Signed	 Rank	 test	 and	 Friedman’s	 two-way	 ANOVA	 used	 to	 assess	
statistical	 significance.	 This	 figure	 is	 adapted	 from	my	 published	 figure	 in	 Verma	 et	 al	
2016.	
Since	B	and	CD4+	T	 cells	are	 responsible	 for	 antibody	productions,	 I	 checked	 if	 there	
was	any	 correlation	between	 these	 cells	 and	 the	 levels	 of	 tetanus	 and	pneumococcal	
antibodies.	There	was	no	correlation	between	the	circulating	B	cells,	CD4+	T	cells	or	B	
cell	 subtypes	described	 earlier	 and	 the	 levels	 of	 tetanus	 or	 pneumococcal	 antibodies	

































































































tetanus	 or	 anti	 pneumococcal	 antibody	 levels	 (Appendix	 2,	 section	 6.2.7,	 Table	 33).	
Smoking,	however,	appeared	to	have	some	influence	on	the	antibody	levels.	There	were	
no	 differences	 in	 the	 tetanus	 antibody	 levels	 in	 smokers	 and	 non-smokers	 prior	 to	
chemotherapy	(Figure	37-A)	but	 the	proportions	of	anti-tetanus	antibody	levels	were	
significantly	 lower	 in	 the	 smokers	 compared	 to	 the	 non-smokers	 at	 2	 weeks	 (62%	
versus	83%	of	pre-chemotherapy	 level,	 p=0.018)	and	9	months	 (72%	versus	94%	of	
pre-chemotherapy	 level,	 p=0.012)	 post-chemotherapy	 (Figure	 37-B).	 Pneumococcal	








9	 months	 (9m)	 in	 non-smokers	 (n=36)	 and	 smokers	 (n=16).	 Data	 is	 shown	 as	 serum	
concentration	 of	 anti-tetanus	 antibody	 (A)	 as	 absolute	 levels	 and	 relative	 to	 their	
respective	pre-chemotherapy	levels	(B)	in	non-smokers	and	smokers.	Boxes	represent	50%	
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Pneumococcal	 antibody	 titres	were	determined	 in	 peripheral	 blood	 samples	 taken	 from	
breast	cancer	patients	 before	 (pre)	 and	after	 chemotherapy	at	 2	weeks	 (2w),	 3	months	
(3m)	and	9	months	 (9m)	 in	non-smokers	 (n=36)	and	smokers	 (n=16).	Data	 is	 shown	as	
serum	concentration	of	anti-pneumococcal	antibody	as	absolute	levels	(A),	and	relative	to	
their	 respective	 pre-chemotherapy	 levels	 (B)	 in	 non-smokers	 and	 smokers.	 Boxes	
represent	 50%	 of	 the	 data	 with	 medians	 (lines),	 interquartile	 range	 (whiskers)	 and	




Having	seen	 the	effect	of	chemotherapy	on	 the	lymphocytes,	 I	wanted	to	assess	if	the	
extent	of	lymphocyte	depletion	or	other	treatment	related	factors	had	any	influence	on	
the	survival	of	breast	cancer	patients.	Follow	up	data	relating	to	survival	was	collected	
for	 the	 cohort.	 The	median	 follow-up	 time	 following	 first	 treatment	 was	 50	months	
(minimum	17,	maximum	63	months,	IQR	7).	A	ROC	curve	was	used	to	determine	a	cut	
off	 for	 the	different	 lymphocytes	and	survival	was	compared	 in	patients	with	high	or	
low	levels	of	lymphocytes	based	on	the	cut	off	value.		
3.4.10.1 Significant	 predictors	 of	 patient	 outcome	 on	 univariate	 and	
multivariate	analysis	




















































(EC/FEC	 versus	 EC+Taxane,	 p=0.014,	 CI	 0.029	 to	 0.672,	 HR	 0.140),	 implying	 better	
outcome	 in	 those	 who	 had	 EC/FEC	 compared	 to	 those	 who	 had	 EC+Taxane.	 	When	
lymphocyte	 levels	 were	 tested,	 B	 cell	 levels	 at	 2	 weeks	 post-chemotherapy	 as	 a	
continuous	 variable	 (p=0.014,	 CI	 1.005	 to	 1.044,	 HR	 1.024,)	 and	 NK	 cell	 levels	 at	 2	
weeks	 post-chemotherapy	 as	 a	 continuous	 variable	 (p=0.040,	 CI	 1.000	 to	 1.009,	 HR	
1.005)	predicted	 risk	of	 recurrence,	 implying	better	outcomes	 in	patients	with	 lower	
levels	 of	 B	 and	NK	 cells	 at	 2	weeks	 post-chemotherapy.	 CD4+	and	 CD8+	 T	 cells	 at	 2	
weeks	post-chemotherapy	were	not	significant	predictors	of	tumour	recurrence.	When	
the	 lymphocytes	were	 used	as	 a	 categorical	 variable	by	 splitting	 the	 cohort	 into	 two	
groups	based	on	high	and	low	levels	of	lymphocytes	using	a	cut	off	value	determined	by	
ROC	 curve	 analysis,	 B	 cells	 (p=0.022,	 CI	 0.080	 to	 0.821,	 HR	 0.257),	 CD4+	 T	 cells	
(p=0.022,	CI	0.080	to	0.821,	HR	0.257),	CD8+	T	cells	 (p=0.036,	CI	0.091	to	0.921,	HR	
0.289)	 and	 NK	 cells	 (p=0.017,	 CI	 0.076	 to	 0.774,	 HR	 0.242)	 at	 2	 weeks	 post-
chemotherapy	 were	 significant	 predictors	 of	 outcome	 (recurrence),	 with	 less	
recurrence	in	those	with	low	levels	of	lymphocytes	at	2	weeks	post-chemotherapy.	On	
multivariate	analysis	however,	none	of	 these	were	 independent	predictors	of	 tumour	
recurrence.		
The	 only	 factors	 that	 were	 predictors	 of	 death	 on	 univariate	 analysis	 were	
chemotherapy	type	(p=0.016,	CI	0.041	to	0.724,	HR	0.172)	and	CD4+	lymphocytes	(as	
categorical	variable)	(p=0.048,	CI	0.048	to	0.989,	HR	0.217),	with	ACT	and	lower	CD4	
levels	 being	 associated	 with	 better	 outcome.	 None	 of	 the	 other	 lymphocytes	 or	
lymphocyte	subtypes	of	B	or	T	cells	at	any	time	point	were	predictors	of	death	on	uni	or	
multivariate	analysis.		




only	 factors	 that	 appeared	 to	 influence	 survival	 in	 the	 study	 cohort	were	 the	 type	of	
chemotherapy	(ACT	versus	NACT)	and	the	chemotherapy	regimen	(EC/FEC	versus	EC	+	
Taxane).	 Those	 who	 had	 adjuvant	 chemotherapy	 had	 better	 DFS	 and	 OS.	 The	
recurrence	 rate	was	13%	 in	 ACT	 group	 compared	 to	 37%	 in	NACT	group	 (p=0.018)	
	 101	
(Figure	 39-A).	 The	mortality	 rate	was	 6%	 in	 ACT	 compared	 to	 26%	 in	 NACT	 group	
(p=0.008)	 (Figure	 39-B).	 This	 can	 be	 explained	 by	 the	 fact	 that	 patients,	 who	 have	
locally	advanced	breast	cancer	with	nodal	involvement	at	the	time	of	diagnosis	tend	to	
have	NACT	first	followed	by	surgery	while	those	with	favourable	prognostic	factors	and	
without	 nodal	 disease	 at	 the	 time	 of	 diagnosis	 have	 surgery	 first	 followed	 by	
chemotherapy	only	if	surgery	shows	nodal	involvement	(ACT).	It	 is	therefore	possible	





Study	 patients	 were	 grouped	 separately	 based	 on	 whether	 they	 had	 adjuvant	
chemotherapy	 (ACT,	 n=69)	 or	 neo-adjuvant	 chemotherapy	 (NACT,	 n=19).	 Disease	 free	
survival	 (DFS)	 and	 Overall	 Survival	 (OS)	 was	 compared	 between	 these	 two	 groups	 of	
patients	 using	 log	 rank	 test.	 Y-axis	 shows	 the	 cumulative	 survival	 and	 x-axis	 shows	 the	
time	 to	 recurrence	 (A)	 and	 time	 to	 death	 (B)	 in	months.	 P	 value	 from	 log-rank	 test	 is	
shown	on	the	plots.	
The	only	other	treatment	related	factor	that	had	a	significant	influence	on	survival	was	
the	 chemotherapy	 regimen	 (Figure	 40).	 Patients	 who	 received	 EF/FEC	 had	 less	
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chemotherapy	 alone	 (EC/FEC)	 (n=39)	 or	 anthracycline	 +	 taxane	 (EC+TAXANE)	 (n=43).		
Disease	 free	survival	 (DFS)	and	Overall	Survival	 (OS)	was	compared	between	these	 two	
groups	 of	 patients	 using	 log	 rank	 test.	 Y-axis	 shows	 the	 cumulative	 survival	 and	 x-axis	
shows	the	time	to	recurrence	(A)	and	time	to	death	(B)	in	months.	P	value	from	log-rank	
test	is	shown	on	the	plots.	
3.4.10.3 Patients	 with	 lymphocyte	 levels	 below	 the	 cut	 off	 value	 at	 2	
weeks	post-chemotherapy	showed	better	DFS	and	OS	
Since	 my	 initial	 results	 showed	 significant	 depletion	 of	 lymphocytes	 post-
chemotherapy	 that	 failed	 to	 recover	 in	 certain	 cases	 even	 after	 9	 months	 post	 -
chemotherapy,	I	assessed	if	the	extent	of	depletion	or	repopulation	of	lymphocytes	had	
any	influence	on	survival.		In	order	to	assess	this,	I	used	ROC	curve	to	find	cut	off	values	
objectively	based	on	 sensitivity	 and	 specificity	 for	each	of	 the	 circulating	 lymphocyte	
types	pre-chemotherapy	and	at	2	weeks	and	9	months	post-chemotherapy	(Zweig	and	
Campbell,	 1993,	 Hajian-Tilaki,	 2013).	 I	 then	 used	 these	 cut	 off	 values	 to	 divide	 the	
cohort	into	2	groups	with	high	and	low	lymphocyte	counts.	Cut	off	values	used	for	each	
of	the	lymphocytes	is	listed	in	Table	35,	Appendix	2,	section	6.2.9.	Survival	in	these	two	
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chemotherapy	 (Figure	 41-A).	 The	 proportion	 of	 patients	 developing	 recurrence	 was	
significantly	 lower	 in	 the	 low	 lymphocyte	 group,	 10%	 vs	32%	 for	 B	 cells	 (p=0.012),	
10%	vs	28%	for	CD4+	T	cells	(p=0.032),	12%	vs	35%	for	CD8+	T	cells	(p=0.008)	and	
16%	 vs	 29%	 for	 NK	 cells	 (p=0.020).	 With	 regards	 to	 OS,	 CD4+	 T	 and	 CD8+	 T	 cells	
showed	 a	 significant	 difference	 at	 2	 weeks	 post-chemotherapy	 (Figure	 41-B)	 with	
lower	mortality	 rates	 in	 patients	 having	 lower	 level	 of	 lymphocytes,	 5%	 vs	 19%	 for	
CD4+	T	cells	 (p=0.024)	and	4%	vs	29%	for	CD8+	T	cells	(p=0.001	(Figure	41-B).	 It	 is	
possible	 that	 those	 who	 suffered	 significant	 depletion	 of	 lymphocytes	 immediately	







less	 mortality	 (6%	 versus	 25%,	 p=0.045)	 when	 outcome	 was	 assessed	 based	 on	
lymphocyte	levels	at	9	months	post-chemotherapy.	Similar	results	were	seen	with	NK	
cells	 with	 those	 above	 the	 cut	 off	 value	 showing	 less	 recurrence	 (10%	 versus	 32%,	
p=0.024)	and	 less	mortality	(3%	versus	26%,	p=0.003)	(Figure	42).	The	difference	 in	
DFS	or	OS	was	not	statistically	significant	in	the	case	of	CD8+	T	cells	although	a	similar	
trend	 appeared	 to	 be	 present,	 with	 those	 with	 higher	 cell	 counts	 (above	 the	 cut	 off	
value)	showing	less	recurrence	and	deaths	compared	to	those	below	the	cut	off	values.	
B	 cells	 at	 9	months	 however	 continued	 to	 show	 the	 opposite	 trend	with	 those	with	
lower	 levels	 of	 B	 cells	 showing	 less	 recurrence	 and	 deaths	 compared	 to	 those	 with	
higher	levels	of	B	cells,	although	the	results	were	not	statistically	significant.	This	was	
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cut	 off	 value	derived	 from	ROC	 curve	analysis	 at	 9	months	post-chemotherapy.	Disease	
free	survival	(DFS)	and	Overall	Survival	(OS)	was	compared	between	these	two	groups	of	
patients	using	log	rank	tests.	Figure	shows	the	results	for	DFS	and	OS	for	CD4+	T	cells	(A)	
and	 for	NK	cells	 (B).	 Y-axis	 shows	 the	cumulative	survival	and	x-axis	 shows	 the	 time	to	
recurrence	(left	panels)	and	time	to	death	(right	panels)	in	months.	P	value	from	log-rank	
test	is	shown	on	the	plots.	




cut	 off	 values	 determined	 using	 ROC	 curve	 analysis.	 Table	 36	 and	 37	 (Appendix	 2,	
section	6.2.10)	shows	the	cut	off	values	used	for	each	of	the	subtypes.	B	cell	subtypes	
did	 not	 have	 a	 significant	 influence	 on	 survival	 except	 for	 naïve	 cells	 prior	 to	
chemotherapy	 on	 DFS	 and	 at	 9	 months	 post-chemotherapy	 on	 OS,	 non-switched	
memory	B	cell	 levels	at	3	months	post-chemotherapy	on	DFS	and	pre	–chemotherapy	
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with	 naïve	 and	 memory	 T	 cell	 subtypes	 in	 high	 and	 low	 cut	 off	 groups	 showed	 a	
significant	difference	 in	DFS	and	OS.	When	outcome	was	 assessed	based	on	 levels	 of	
CD45RA+CD45RO-	naïve	T	cells	at	2	weeks	post-chemotherapy,	there	was	less	recurrence	
in	 the	 high	 cut	 off	 group	 (10%	 vs	 32%,	 p=0.010)	 and	 less	 mortality	 (2%	 vs	 28%,	
p<0.001).	Prior	to	chemotherapy	also,	there	was	a	statistically	significant	difference	in	
OS	(but	not	in	DFS)	between	patients	with	high	and	low	counts	(mortality	5%	vs	24%,	








ROC	 curves	were	used	 to	 determine	 cut	 off	 points	 for	CD45RA+CD45RO-	 naïve	T	 cells	 pre-
chemotherapy	and	at	 2w	and	9m	post-chemotherapy.	 Study	patients	were	 then	divided	
into	those	with	CD45RA+CD45RO-	naïve	T	cells	above	and	below	the	cut	off	value.	DFS	and	
OS	were	 compared	 in	 the	 two	 groups	 of	 patients	 using	 log	 rank	 test.	 Y-axis	 shows	 the	
cumulative	survival	and	x-axis	shows	the	time	to	recurrence	(A)	and	time	to	death	(B)	in	
months.	P	value	from	log-rank	test	is	shown	on	the	plots.	
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in	 the	 group	with	 higher	proportions	 of	naïve	 CD45RA+CD62L+	 cells	 at	 2	weeks	 post-
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Conversely,	 those	 with	memory	 CD45RA-CD45RO+	 T	 cells	 below	 the	 cut	 off	 value	 at	 2	
weeks	post-chemotherapy	showed	lower	recurrence	(10%	versus	19%,	p=0.010)	and	
mortality	 (2%	 versus	 28%,	 p<0.001).	 Using	 lymphocyte	 counts	 at	 9	 months,	 those	






ROC	 curves	were	used	 to	 determine	 cut	 off	 points	 for	CD45RA-RO+	memory	T	 cells	 pre-	
chemotherapy	and	at	 2w	and	9m	post-chemotherapy.	 Study	patients	were	 then	divided	
into	those	with	CD45RA-RO+	memory	T	cells	above	and	below	the	cut	off	value.	DFS	and	OS	






DFS	 using	 pre-chemotherapy	 levels	 (38%	 vs	 9%,	 p=0.005)	 and	 2	 weeks	 post-
chemotherapy	levels	(36%	vs	7%,	p<0.001)	and	for	OS	at	all	time	points.	Mortality	was	
higher	in	the	low	cut	off	group	using	pre-chemotherapy	levels	(26%	vs	5%,	p=0.015),	
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Patients	 with	 higher	 levels	 of	 CD25+FoxP3+	 regulatory	 T	 cells	 showed	 worse	
prognosis.	 Although	 there	 was	 no	 significant	 difference	 in	 DFS	 or	 OS	 based	 on	 pre-
chemotherapy	 levels,	 higher	 levels	 of	 regulatory	 T	 cells	 at	 6	months	was	 associated	
with	higher	recurrence	(30%	vs	11%)	and	higher	mortality	(30%	vs	4%,	p=0.010).	The	
results	for	DFS	were	not	statistically	significant.	Contrary	to	the	results	using	levels	at	6	
months	 post-chemotherapy,	 levels	 at	 2	 weeks	 post-chemotherapy	 showed	 less	
recurrence	in	those	with	high	regulatory	T	cells	(8%	vs	27%,	p=0.030).	The	results	for	
OS	were	not	statistically	significant.	Due	to	lack	of	funds	this	subtype	was	not	analysed	
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chemotherapy	and	at	 2w	and	6m	post-chemotherapy.	 Study	patients	were	 then	divided	
into	those	with	CD25+FoxP3+	regulatory	T	cells	above	and	below	the	cut	off	value.	DFS	and	
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Chemotherapy	 is	 widely	 used	 in	 the	 treatment	 of	 breast	 as	 well	 as	 other	 cancers.	
Despite	widespread	use	of	 chemotherapy,	 knowledge	 about	 its	 effect	 on	 the	 immune	





like	 trastuzumab.	There	 is	 some	evidence	 in	 the	 literature	 that	 chemotherapy	 causes	
adverse	effects	on	circulating	lymphocytes.	With	the	increasing	use	of	a	wide	range	of	
biologic	 therapies	 such	 as	 trastuzumab	 that	 rely	 on	 an	 intact	 immune	 system,	 it	 is	
important	to	consider	the	sequence	and	timing	of	different	treatment	modalities	such	
that	their	effects	can	be	maximised.	While	the	aim	of	treatment	is	getting	rid	of	cancer	
cells,	 its	 effects	 on	other	non-cancerous	 cells	 in	 the	body	 including	 the	 immune	 cells	
cannot	 be	 disregarded.	 With	 advancements	 in	 early	 detection	 and	 better	 treatment	
modalities,	 survival	 from	 breast	 cancer	 appears	 to	 be	 improving,	 and	 it	 is	 probably	
justified	 to	consider	ways	of	 improving	 the	quality	of	 life	post-treatment	by	reducing	
the	 adverse	 effects	 of	 chemotherapeutic	 agents	 on	 the	 immune	 system	 (Fallowfield,	









post-chemotherapy,	 there	 was	 almost	 complete	 depletion	 of	 B	 cells	 with	 >55%	 of	
patients	 showing	 <2%	 of	 their	pre-chemotherapy	 levels	 of	 B	 cells	 at	 this	 stage.	 At	 9	
months	 post-chemotherapy,	 CD8+T	 and	 NK	 cells	 showed	 almost	 complete	 recovery	
(rising	to	93%	and	107%	of	pre-chemotherapy	levels	respectively).	B	cells	showed	only	
partial	 recovery	 at	 9	 months	 post-chemotherapy	 (68%	 of	 pre-chemotherapy	 level).	






2007,	 Wijayahadi	 et	 al.,	 2007).	 The	 mechanism	 of	 this	 however	 is	 still	 unclear.	
Repopulation	 of	 T-lymphocytes	 following	 chemotherapy	 for	 other	 cancers	 has	 also	
showed	a	 rapid	 recovery	of	CD8+	T	 cells	 (Mackall	et	 al.,	 1997).	Reversal	 of	CD4/CD8	
ratio	 indicating	 quicker	 recovery	 of	 CD8+	 T	 cells	 has	 also	 been	 seen	 following	
myeloablative	 chemotherapy	 and	peripheral	 blood	 stem	cell	 transplantation	where	T	








of	B	cells	 following	other	B	cell	depleting	 therapies,	 such	as	Rituximab	shows	similar	
results.	Rituximab	is	a	genetically	engineered	monoclonal	antibody	that	binds	the	B	cell	
surface	 antigen	 CD20	 and	 is	 used	 in	 treatment	 of	 various	 autoimmune	 diseases	 (eg	
Rheumatoid	 Arthritis,	 SLE,	 Autoimmune	 thrombocytopenia)	 and	 also	 B	 cell	
malignancies	 (B	 cell	 non-Hodgkins	 lymphoma).	 Rituximab	 causes	 selective	 loss	 of	
virtually	 all	 peripheral	 CD20+	 B	 cells	 and	 levels	 remain	 depressed	 for	 4-5	 months	
following	therapy,	with	naïve	B	cells	forming	a	major	proportion	of	repopulating	B	cells	
(Leandro	et	al.,	2006).	 	Low	levels	of	memory	B	cells	have	been	seen	 in	repopulating	
lymphocyte	 population	following	 haematopoietic	 BMT	 (D'Orsogna	 et	 al.,	 2009).	 The	
proportions	 of	 transitional	 B	 cells	 showed	 initial	 increase	 following	 chemotherapy,	
followed	 by	 progressive	 decrease	 at	 6	 and	 9	 months	 while	 regulatory	 B	 cells	
(CD24hiCD27+)	 showed	 an	 initial	 decrease	 followed	 by	 progressive	 increase.	 	 It	 has	
been	 reported	 that	 a	proportion	 of	 CD38hiCD24hi	 transitional	 B	 cells	 have	 regulatory	














this	 study	 by	 evaluating	 the	 CD31+	 recent	 thymic	 emigrants.	 These	 cells	 showed	 a	
significant	 decrease	 in	 proportion	 post-chemotherapy.	 My	 results	 with	 regards	 to	
repopulating	naïve	and	memory	T	cells	following	chemotherapy	parallel	other	similar	
studies	 in	 literature	 looking	 at	 reconstitution	 of	 these	 cells	 after	 depletion	 due	 to	
chemotherapy	 (Hakim	 et	 al.,	 1997,	 Fagnoni	 et	 al.,	 2002,	 Mozaffari	 et	 al.,	 2009);	
depletion	 due	 to	 other	 conditioning	 regimens	 prior	 to	 hematopoietic	 stem	 cell	
transplant	 (HSCT)	 (Cox	 et	 al.,	 2005,	 D'Orsogna	 et	 al.,	 2009,	 Thompson	 et	 al.,	 2010,	
Cherukuri	et	al.,	2012,	Macedo	et	al.,	2012)	or	 following	treatment	with	Campath	1H.	
Alemtuzumab	(also	known	as	Campath	1H)	is	a	humanised	monoclonal	antibody	 that	
targets	 the	 cell	 surface	 molecule	 CD52	 present	 on	 the	 surface	 of	 multiple	 cell	
populations	 including	 thymocytes,	 B	 and	 T-lymphocytes	 and	 monocytes,	 but	 not	
plasma	cells	or	haematological	precursors	(Gilleece	and	Dexter,	1993).	It	is	used	in	the	
treatment	 of	multiple	 sclerosis,	 rheumatoid	 arthritis	 and	 leukaemia	 (Zintzaras	 et	 al.,	
2012,	Anderson	et	al.,	2012,	Pettitt	et	al.,	2012).	Although	Campath	1H	does	not	deplete	
haematological	 precursors	 (Hale	 et	 al.,	 2004),	 it	 has	 been	 found	 to	 cause	 immediate	
lymphopenia	which	lasts	for	several	years	(Coles	et	al.,	2006).		All	these	treatments	that	
cause	depletion	of	circulating	lymphocytes	and	reconstitution	of	cells	follow	a	similar	
pattern	 irrespective	 of	 the	 initial	 cause	 of	 depletion.	 In	 fact,	 there	 is	 evidence	 in	







cells	are	required	 for	B	cell	activation/class	switching.	Lack	of	one	of	 these	cell	 types	
could	be	 the	 cause	or	 effect	 of	 a	decrease	 in	 the	other	 cell	 type.	Animal	studies	have	
shown	that	CD4+	T	cells	derived	from	B	cell	deficient	mice	inhibit	the	establishment	of	
peripheral	 B	 cell	 pools	 (Baumgarth	 et	 al.,	 2000).	 It	 is	 therefore	 possible	 that	 the	
significantly	 low	 levels	of	B	cells	 in	my	cohort	post-chemotherapy	was	due	 to	 lack	of	
	 114	
CD4+	T.	Alternatively,	lack	of	repopulation	of	CD4+	T	cells	could	be	the	result	of	lack	of	B	
cells	 post-chemotherapy.	 CD4+	 T	 cell	 deficiency	 is	 known	 to	 persist	 for	 many	 years	
following	hematopoietic	stem	cell	transplantation.	This	in	turn	has	been	found	to	affect	
the	 activation	 of	 B	 cells	 and	 subsequent	 formation	 of	 memory	 and	 plasma	 cells	
(Roberts	et	al.,	1993,	Novitzky	and	Davison,	2001).	
	
Immune	 recovery	 following	 haematopoietic	 stem	 cell	 transplant	 (HSCT)	 may	 also	
parallel	 post-chemotherapy	 immune	 recovery	 in	 terms	 of	 patients’	 susceptibility	 to	
infection.	Post	HSCT,	patients	have	been	found	to	be	at	increased	risk	of	viral	infections	






anti-tetanus	 and	 anti-pneumococcal	 antibody	 levels	 in	 my	 cohort	 to	 assess	 the	
functional	impact	of	low	circulating	lymphocyte	levels	on	the	immune	system.	I	found	
that	 levels	 of	 anti-tetanus	 as	 well	 as	 anti-pneumococcal	 antibody	 levels	 were	





Of	 all	 the	 tumour,	 patient	 or	 breast	 cancer	 treatment	 related	 factors	 that	 could	
potentially	influence	levels	of	circulating	lymphocytes,	only	smoking	and	chemotherapy	
regimen	 showed	 significant	 correlations	 with	 degrees	 of	 B	 cells	 depletion	 or	
repopulation,	and	with	differences	in	B	cell	subtypes.		
Smoking	has	been	found	to	be	adversely	related	to	survival	in	lung	cancer	patients	and	
longer	 abstinence	 from	 smoking	 was	 associated	 with	 less	 mortality	 (Ebbert	 et	 al.,	
2005).	 Similar	 results	 were	 seen	 in	 patients	 with	 head	 and	 neck	 cancers	 who	were	
actively	smoking	at	the	time	of	initiation	of	chemotherapy	and	radiotherapy	(Fortin	et	
al.,	2009).	Smoking	has	also	been	associated	with	increased	symptoms	of	memory	loss,	
depression,	 sleep	 deprivation,	 concentration	 and	 nausea	 during	 and	 after	 cancer	
treatment	(Peppone	et	al.,	2011).	There	 is	 limited	evidence	with	regards	 to	effects	of	
smoking	 on	 lymphocytes.	 While	 some	 studies	 have	 reported	 increased	 B	 and	 T	 cell	
levels	 in	 smokers	 compared	 to	 non-smokers	 (Tanigawa	 et	 al.,	 1998),	 others	 have	
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reported	 no	 difference	 (Schaberg	 et	 al.,	 1997).	 In	 my	 study	 cohort,	 there	 was	 no	





chronic	 obstructive	 pulmonary	 disease	 (COPD)	 who	 smoke	when	 compared	 to	 non-
smokers	 (Brandsma	 et	 al.,	 2012,	 Brandsma	 et	 al.,	 2009).	 It	 is	 possible	 that	 smoke	
induced	neo-antigens	are	 constantly	 induced	 in	 these	patients	 causing	an	 increase	 in	
the	switched	memory	B	cells.		
	
I	 also	 noted	 that	 different	 chemotherapy	 regimens	 had	 differential	 effects	 on	 B	 cell	
depletion	 and	 repopulation.	 Patients	 who	 received	 Epirubicin	 +	 Cyclophosphamide	
(EC)	or	5-Flurouracil	+	Epirubicin	+	Cyclophosphamide	(FEC)	regimen,	had	a	residual	B	
cell	proportion	at	2	weeks	post-chemotherapy	of	2.3%,	while	patients	who	received	EC	
+	 Docetaxel	 had	 a	 residual	 B	 cell	 proportion	 of	 8.2%.	 Those	 who	 received	 EC	 +	
Docetaxel	 regimen,	 however,	 also	 received	 Granulocyte	 Colony	 Stimulating	 Factor	
(GCSF)	and	it	is	possible	that	the	higher	B	cell	level	in	these	patients	are	due	to	effects	
of	GCSF	on	stem	cells.	Besides	stimulating	granulocytes,	GCSF	is	also	known	to	have	an	
effect	 on	 lymphocytes	 (Gurman	 et	 al.,	 2001,	 Korbling,	 1998).	 The	 effect	 of	 GCSF	 on	
lymphocytes	 is	most	 likely	 indirect	 via	 their	 action	on	monocytes	 and	dendritic	 cells	






On	 univariate	 analysis,	 type	 of	 chemotherapy	 (adjuvant	 versus	 neo-Adjuvant),	
chemotherapy	 regimen	 and	 lymphocyte	 levels	 at	 2	 weeks	 post-chemotherapy	 were	
significant	 predictors	 of	 patient	 outcome.	 Patients	 who	 had	 adjuvant	 chemotherapy	
showed	 better	 DFS	 and	 OS	 when	 compared	 to	 those	 who	 had	 neo-adjuvant	
chemotherapy.	 This	 could	 be	 explained	 by	 the	 fact	 that	 patients,	 who	 have	 locally	
advanced	breast	cancer	with	nodal	involvement	at	 the	 time	of	diagnosis	 tend	to	have	
NACT	 first	 followed	 by	 surgery	 while	 those	 with	 favourable	 prognostic	 factors	 and	
without	 nodal	 disease	 at	 the	 time	 of	 diagnosis	 have	 surgery	 first	 followed	 by	
chemotherapy	(ACT),	only	if	surgery	shows	nodal	involvement.	It	is	therefore	possible	
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that	 those	who	 had	NACT	 had	more	 aggressive	 disease	 compared	 to	 those	who	 had	
ACT.	A	recent	meta-analysis	of	10	randomised	controlled	trials	(RCTs)	comparing	long	
term	outcomes	for	NACT	versus	ACT	found	significantly	higher	local	recurrence	in	the	
NACT	group	 (21.4%	versus	15.9%,	p=0.0001)	but	no	 significant	difference	 in	distant	
recurrence	or	mortality	in	the	two	groups	(Early	Breast	Cancer	Trialists'	Collaborative,	






did	not	 respond	very	well	 to	 chemotherapy	 leading	 to	worse	prognosis	 compared	 to	
the	group	of	patients	treated	with	anthracyclines	only.	A	meta-analysis	of	comparison	
between	 different	 poly-chemotherapy	 regimens	 for	 early	 breast	 cancer	 by	 the	 Early	
Breast	 Cancer	 Trialists	 Collaborative	 Group	 (EBCTCG)	 found	 significantly	 less	
recurrence	and	death	in	the	Anthracycline	+	Taxane	group	compared	to	Anthracycline	
only	group	(Early	Breast	Cancer	Trialists'	Collaborative	et	al.,	2012).	Another	phase	3	
trial	 evaluating	 the	 effect	 of	 addition	 of	 paclitaxel	 to	 doxorubicin	 followed	 by	
Cyclophosphamide,	 Methotrexate	 and	 5-FU	 (CMF)	 found	 improved	 survival	 with	 the	
addition	of	Taxanes.	There	was	no	difference	in	survival	when	the	same	regimen	was	
given	before	surgery	(neo-adjuvant	setting)	or	after	surgery	(adjuvant	setting)	(Gianni	
et	 al.,	 2009).	 However,	 this	 was	 a	 randomised	 controlled	 trial	 were	 patients	 were	




I	 also	 compared	 survival	 in	 patients	 based	 on	 high	 and	 low	 lymphocyte	 levels	 post-





patients	 with	 higher	 lymphocyte	 counts	 following	 chemo-radiation	 showed	 better	




radiation	 induced	 lymphopenia	 as	 an	 independent	 predictor	 of	 survival.	 Median	
survival	 in	 patients	 with	 low	 lymphocyte	 counts	 (<500)	 was	 14	 versus	 20	 months,	
p=0.048).	 In	 metastatic	 breast	 cancer	 patients	 treated	 with	 chemotherapy,	 median	
survival	 was	 significantly	 better	 for	 patients	 with	 lymphocyte	 count	 >/=	 1000/µL	
compared	with<	1000/µL.	Progression	free	survival	was	also	shorter	in	patients	with	
lymphocyte	counts	<1000/µL,	p<0.0001	(Ray-Coquard	et	al.,	2009).	However,	there	is	
some	 emerging	 evidence	 that	 lymphopenia	 secondary	 to	 chemotherapy	 can	 actually	






Breast	 cancer	 chemotherapy	 causes	 significant	 depletion	 of	 circulating	 lymphocytes	
and	 serum	 levels	 of	 anti-tetanus	 and	 anti-pneumococcal	 antibodies	 for	 at	 least	 9	
months	post-chemotherapy.	However,	 I	have	not	explored	 the	clinical	 implications	of	
this	 is	 in	 terms	 of	 increased	 susceptibility	 to	 infections.	 	 The	 results	 from	 this	 study	



















showing	 correlations	with	 tumour	 characteristics	 and	 patient	 outcomes.	 The	 aims	 of	
this	 study	were	 to	 assess	 whether	 this	 was	 also	 true	 for	 the	 breast	 cancer	 patients	




positive	 lymphocytes	 in	 stroma	 between	 tumour	 nests	 (stromal	 lymphocytes)	 and	
within	 tumour	nests	 (intra-tumoural	 lymphocytes,	 iTLs).	 Infiltration	was	 assessed	as	
absolute	 counts,	 as	 proportions	 of	 stromal	 area	 for	 stromal	 lymphocytes,	 and	 as	 a	
proportion	 relative	 to	number	of	 tumour	 cells	 for	 iTLs.	 Lymphocyte	 infiltrates	at	 the	
tumour	edge	were	also	assessed	separately	as	mild,	moderate,	or	heavy	infiltrate.	
Results	
The	 most	 prevalent	 cell	 types	 were	 CD4+	 lymphocytes	 in	 the	 stroma,	 and	 CD8+	
lymphocytes	 in	 the	 intra-tumoural	 compartment.	 There	were	 significant	 correlations	
between	 the	 stromal	 and	 intra-tumoural	 levels	 of	 each	 of	 the	 lymphocytes	 and	 also	
between	 different	 lymphocytes.	 There	 were	 positive	 correlations	 between	 tumour	
infiltrating	 lymphocytes	 and	hormone	negative,	 triple	negative	 and	grade	3	 tumours.	
Only	 tumour	 infiltrating	 CD8+	 lymphocytes	 correlated	 with	 the	 matched	 circulating	
levels,	 and	 this	 correlation	 was	 stronger	 in	 hormone	 negative	 and	 triple	 negative	
tumours.	 High	 stromal	 CD4+	 infiltrate	was	 associated	with	 better	 DFS	 and	OS	 in	 the	














Baker	 et	 al.,	 2011,	 Loi	 et	 al.,	 2013,	 Ali	 et	 al.,	 2014),	 but	 these	 observations	 are	 not	
entirely	 consistent	 in	 the	 literature	 (Macchetti	 et	 al.,	 2006,	 Georgiannos	 et	 al.,	 2003,	
Matkowski	et	al.,	2009).	The	International	TILs	Working	Group	(Salgado	et	al.,	2015b)	
has	recommended	a	standardised	protocol	 to	evaluate	and	report	 tumour	 infiltrating	
lymphocytes	 (TILs)	 using	 H&E	 stained	 breast	 specimens	 in	 order	 or	 increase	 the	
validity	and	reliability	of	this	potential	biomarker.	Although	TILs	are	found	both	in	the	
stroma	 and	within	 the	 tumour	 nests	 (intra-tumoural,	 iTLs),	 the	 recommendation	 by	
The	International	TILs	Working	Group	was	to	evaluate	stromal	TIL	alone	as	it	was	felt	
that	the	iTLs	were	more	difficult	to	assess	and	less	reproducible.	TILs	have,	however,	
been	evaluated	both	in	the	stroma	and	 in	 the	 intra-tumoural	compartment	 (Loi	et	al.,	
2013,	Adams	et	al.,	2014,	Dieci	et	al.,	2015,	Asano	et	al.,	2016)	and	found	to	have	good	
inter-observer	 agreement	 for	 both	 the	 stromal	 as	 well	 as	 iTLs,	 and	 some	 reports	
suggest	the	latter	to	be	a	better	prognostic	marker	(Liu	et	al.,	2012)	
	
There	 are	 numerous	 reports	 on	 TILs	 and	 their	 associations	 with	 clinical	 and	
pathological	 features	 (reviewed	 in	 Ch	 1,	 section	 1.5).	 TILs	 have	 been	 found	 to	 be	
associated	with	 highly	 proliferative	 breast	 cancers	 like	 triple	 negative	 breast	 cancer	
(TNBC)	 and	 Her2+	 breast	 cancer	 and	 their	 presence	 at	 diagnosis	 is	 associated	 with	
pathological	 complete	 response	 (pCR)	 to	 NACT	 and	 better	 disease	 free	 or	 overall	
survival	following	chemotherapy.	Denkert	et	al	(2010)	were	one	of	the	first	to	report	a	
strong	association	between	lymphocyte	predominant	breast	cancer	(LPBC)	and	pCR	in	
a	 large	 cohort	 of	 patients	 from	 the	 GeparDuo	 and	 GeparTrio	 trials	 and	 subsequently	
from	the	GeparSixto	 trial	 (Denkert	et	al.,	2015,	Dieci	et	al.,	2015).	There	are	multiple	
other	 reports	 showing	 association	 of	 TILs	 with	 pCR	 or	 better	 survival	 (West	 et	 al.,	
2011a,	Adams	et	al.,	2014,	Nabholtz	et	al.,	2014)	(reviewed	in	Chapter	1,	section	1.5.1).	
TILs	have	also	been	found	to	be	associated	with	high	tumour	grade	tumours,	hormone	






on	 immunohistochemistry	 to	 assess	 specific	 lymphocyte	 types,	 and	 there	 is	 evidence	
that	different	 lymphocyte	 subtypes	may	have	different	prognostic	 value.	While	CD8+	
lymphocytes	infiltrate	has	been	associated	with	better	survival	(Mahmoud	et	al.,	2011a,	
Ali	 et	 al.,	 2014),	 there	 are	 conflicting	 results	 regarding	 prognostic	 significance	 of	
FoxP3+	infiltrate.	Most	studies	have	found	high	FoxP3+	infiltrate	to	be	associated	with	




There	 is	 heterogeneity	 in	 the	 studies	 with	 regards	 to	 the	 sample	 size,	 method	 of	
detection	of	lymphocytes	(IHC	versus	H&E),	area	scored	(tissue	microarray	cores	–	so	a	
very	 limited	 piece	 of	 tissue	 -	 versus	 whole	 section),	 lymphocytes	 considered	 (all	
lymphocytes	versus	CD4+,	CD8+,	CD20+	or	FoxP3+	 lymphocytes),	 site	of	 lymphocytic	
infiltrate	 within	 the	 tumour	 tissue	 (stromal	 versus	 intra-tumoural),	 the	 scoring	
methodology	and	the	cut	offs	used	for	defining	high	versus	low	infiltrate	(range	of	0-3,	







lymphocytes.	 It	 is	 possible	 that	 TILs	 simply	 reflect	 the	 circulating	 levels,	 suggesting	
their	accumulation	may	not	be	as	a	result	of	local	tumour	effects	but	rather	associated	
with	 systemic	 influences.	Alternatively,	 it	 is	possible	 that	TIL	 levels	 could	be	 entirely	
unrelated	 to	 the	circulating	levels,	 suggesting	a	true	 local	 interaction.	Finally,	 it	 could	
even	 be	 postulated	 that	 TILs	 might	 correlate	 negatively	 with	 circulating	 levels,	
suggesting	that	accumulation	in	tumour	depletes	the	circulating	levels.	
	
4.3 Experimental	 aim	 and	 design,	 and	 technical	
validation	
Since	 the	 presence	 of	 lymphocytes	within	 the	 tumour	 has	 previously	 been	 shown	 to	
correlate	with	 tumour	 characteristics	 and	 outcomes,	 I	wanted	 to	 determine	whether	
this	 was	 also	 true	 for	 the	 breast	 cancer	 patients	 I	 had	 recruited	 to	 my	 study.	 In	
particular,	 this	 would	 provide	 the	 opportunity	 to	 analyse	 whether	 these	 tumour-
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infiltrating	 levels	 reflect	 the	 circulating	 levels	 described	 in	 Chapter	 3.	 Therefore,	
paraffin	blocks	of	the	resection	specimen	for	patients	who	underwent	adjuvant	therapy	
and	resection	as	well	as	the	biopsy	specimens	for	patients	who	underwent	NACT	were	




lymphocytes	 with	 circulating	 lymphocytes	 at	 a	 time	 point	 closest	 to	 the	 surgical	
resection,	 and	 the	 baseline	 pre-chemotherapy	 blood	 samples	 was	 available	 only	 for	





tumour	 cell	 count.	 Lymphocyte	 infiltrate	 at	 the	 tumour	 edge	 was	 graded	 as	 mild	
moderate	or	heavy	in	cases	where	the	tumour	edge	was	well	defined	and	present	in	the	





CD20+	B	cells	 Primarily	 responsible	 for	 humoral	 immunity	 by	
producing	antibodies.	
CD4+	helper	T	cells	 Help	 the	 activity	 of	 other	 immune	 cells	 by	 producing	
cytokines.	They	also	help	in	activating	B	cells.	
CD8+	cytotoxic	T	cells		 Can	directly	 kill	 cells	 infected	by	other	 organisms	and	
also	kills	the	cancer	cells.	
FoxP3+	regulatory	T	cells	 Component	of	CD4+	T	 cells	 and	help	 in	 regulating	 the	
immune	response.	
Table	14.	Lymphocytes	assessed	using	IHC		
Representative	 staining	 of	 each	 of	 the	 four	 antibodies	 is	 shown	 in	 Figure	 48,	
demonstrating	clear	brown	staining	of	each	lymphocyte	marker	allowing	identification	











CD4+,	 CD8+	 and	 FoxP3+	 lymphocytes.	 Clinical	 and	 pathological	 characteristics	 of	
patients	included	were	listed	previously	in	Table	7,	section	3.2,	cohort	A.	
	
To	 assess	 whether	 the	 histopathological	 assessments	 I	 performed	were	 reliable	 and	
that	the	data	were	reproducible,	an	experienced	histopathology	consultant	also	scored	
more	than	10%	of	the	slides	in	parallel,	evenly	spread	throughout	the	different	antigens	
assessed	 (8	 slides	 per	 antibody,	 total	 32	 slides).	 Spearman’s	 correlation	 tests	 were	
performed	 to	 assess	 correlations	 between	 the	 two	 scorers.	 There	 was	 very	 high	
correlations	 (Harris,	 2014)	 between	 separate	 counts	 for	 both	 stromal	 and	 the	 intra-








staining,	 namely	 stromal	 proportion	 of	 lymphocytes,	 stromal	 lymphocyte	 count,	 intra-
tumoral	 lymphocyte	 count	 and	 tumour	 cell	 count	 by	 the	 author	 RV.	 A	 breast	
histopathology	 consultant	 EV	 also	 scored	 8	 cases	 per	 antigens.	 	 Scatter	 plots	 showing	
correlation	 between	 the	 scores	 of	 EV	 (x	 axis)	 against	 RV	 (y	 axis)	 for	 each	 of	 the	 4	
measures	 are	 shown	here.	 Spearman’s	 rho	 correlation	 coefficients	 (rs)	 and	p	 values	 are	





generally	 the	statistical	 test	of	choice	 for	 testing	 the	agreement	between	two	scorers.	
To	perform	kappa	test,	continuous	data	had	to	be	changed	to	ordinal	data	by	stratifying	
them	 into	 different	 groups	 as	 shown	 in	 Table	 15.	 For	 each	 of	 the	 variables	
(lymphocytes	or	tumour	cells)	scored	by	the	two	scorers,	the	stratification	groups	were	
determined	 based	 on	 the	 actual	 variable	 and	 the	 expected	 density	 of	 variable	 in	




































































































lymphocyte	 count	 (absolute	 lymphocyte	 count	 within	 stromal	 area),	 intra-tumoural	
lymphocyte	 (absolute	count	of	 lymphocytes	within	 tumour	nests)	count	and	tumour	cell	
count.	 The	 stratification	 groups	 were	 made	 for	 performing	 kappa	 test	 to	 assess	 the	
agreement	between	the	two	scorers	and	were	determined	based	on	actual	variable	and	its	
density	in	the	tumour	compartment	being	assessed.		
Kappa	 tests	 showed	 that	 there	 was	 very	 good	 agreement	 between	 the	 two	 sets	 of	








	 Stromal%	 Stromal	count	 ITL	count	 Tumour	 cell	
count	
Kappa	 1.00	 0.813	 0.712	 0.847	
P	value	 <0.001	 <0.001	 <0.001	 <0.001	
Table	16.	Agreement	between	the	scores	of	RV	and	EV	
Agreement	 between	 the	 scores	 of	 the	 two	 scorers	was	 assessed	 using	 Kappa	 test.	 Test	
performed	 for	 the	 four	 variables	 that	 were	 scored	 namely,	 stromal	 proportion	 of	
lymphocytes,	 stromal	 count,	 intra-tumoural	 lymphocyte	 count	 and	 total	 number	 of		
tumour	 cells.	 Table	 shows	 the	 result	 of	 Kappa	 test	 for	 each	 of	 the	 variables	 and	 the	 p	
value.	
4.4 Results	




50)	 and	 at	 the	 tumour	 edge	 (Figure	 51).	 There	 was	 considerable	 variation	 in	 the	
presence	 of	 all	 four	 lymphocyte	 types	 in	 both	 tissue	 compartments	 throughout	 the	
different	patient	samples,	as	reflected	in	the	large	boxes	and	whiskers	on	the	plots	of	
Figure	50.	The	most	prevalent	cell	type	was	CD4+	lymphocytes	in	the	stroma,	and	CD8+	
lymphocytes	 in	 the	 intra-tumoural	 compartment,	 implying	 that	 local	 influences	 do	
impact	on	lymphocyte	infiltration	to	some	extent.	The	CD4+	stromal	lymphocyte	count	
was	 significantly	 higher	 when	 compared	 to	 CD20+	 (p=0.001)	 or	 FoxP3+	 (p<0.001)	
lymphocyte	 count.	 The	 CD4+	 stromal	 lymphocyte	 count	 was	 also	 higher	 than	 CD8+	
stromal	 lymphocyte	 counts	 but	 the	 result	 was	 not	 statistically	 significant.	 Similar	
results	were	seen	for	stromal	proportion	of	lymphocytes	with	the	difference	between	
stromal	 proportions	 of	 CD20+	 and	 CD4+	 lymphocytes	 and	 the	 difference	 between	
stromal	 proportions	 of	 FoxP3+	 and	 CD4+	 lymphocytes	 being	 statistically	 significant	
(p=0.009	 &	 p<0.001	 respectively).	 In	 the	 intra-tumoural	 compartment,	 the	 CD8+	
lymphocyte	count	was	significantly	higher	when	compared	to	CD20+	(p<0.001),	CD4+	
(p=0.005)	and	FoxP3+	(p<0.001)	lymphocytes	and	similar	results	were	seen	with	the	
intra-tumoural	 proportion	 of	 lymphocytes	 relative	 to	 the	 tumour	 cells	 with	 CD8+	
lymphocyte	 proportion	 being	 significantly	 higher	 than	 CD20+	 (p<0.001),	 CD8+	
(p=0.005)	 and	 FoxP3+	 (p<0.001)	 lymphocytes.	 There	 were	 relatively	 few	 FoxP3+	
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lymphocytes	 in	 the	 stroma	 or	 within	 the	 tumour	 nests.	 Box	 plots	 showing	 the	







namely	 stromal	 lymphocyte	 count	 (A)	 stromal	 proportion	 of	 lymphocytes	 (B),	 intra-
tumoural	lymphocyte	count	(C),	and	intra-tumoural	proportion	of	lymphocytes	relative	to	
the	 tumour	cells	 (D	Boxes	represent	 50%	of	 the	data	with	medians	 (line),	 interquartile	




The	 presence	 of	 lymphocytes	 at	 the	 tumour	 edge	 was	 also	 assessed	 as	 a	 separate	
measure	 on	 the	 basis	 that	 the	 region	 might	 represent	 the	 most	 potent	 area	 of	
interaction	between	tumour	 and	host	 immune	 system.	Lymphocyte	 infiltration	of	 the	
edge	 was	 graded	 as	 mild,	 moderate,	 or	 heavy	 infiltrate	 based	 on	 the	 extent	 of	
















































































Lymphocyte	 infiltrate	 of	 CD20,	 CD4,	 CD8	and	FoxP3+	 lymphocytes	 at	 tumour	 edge	was	
assessed	and	graded	as	mild,	moderate	or	heavy	in	all	cases	where	the	tumour	edge	could	
be	 visualised	 along	 with	 the	 main	 tumour.	 The	 frequency	 of	 mild,	 moderate	 or	 severe	
infiltrate	at	the	tumour	edge	for	each	of	the	antibodies	is	represented	as	pie	chart.	
4.4.2 Infiltration	 with	 CD20+,	 CD4+,	 CD8+	 or	 FoxP3+	
lymphocytes	 correlates	 between	 stromal	 and	 intra-
tumoural	 compartments,	 and	 with	 tumour	 edge,	 both	
within	each	and	across	different	lymphocyte	types		
Spearman’s	 correlation	 tests	were	performed	 to	assess	associations	between	 stromal	
and	 intra-tumoural	 infiltrates,	both	 for	 each	 individual	lymphocyte	 type	(for	example	
whether	the	extent	of	CD20+	lymphocyte	infiltration	of	the	stroma	correlates	with	the	
same	cell	type	infiltrating	the	tumour	nests)	(Table	17),	and	between	lymphocyte	types	
(for	 example	 whether	 the	 extent	 of	 CD20+	 lymphocyte	 infiltration	 of	 the	 stroma	
correlates	with	infiltration	of	other	lymphocyte	types	in	any	location)	(Table	18).	There	
























%	 values	 (correlation	 coefficient	 range	 0.435-0.676;	 all	 p<0.001).	 There	 were	 no	
correlations	between	stromal	or	intra-tumoural	lymphocyte	infiltrate	and	lymphocyte	
infiltrate	 at	 the	 tumour	 edge	 in	 the	 case	 of	 CD20+,	 CD4+	 and	 FoxP3+	 lymphocytes,	
although	 this	 was	 weakly	 correlated	 for	 CD8+	 lymphocytes	 between	 intra-tumoural	
count	 and	 infiltrate	 at	 tumour	 edge	 (correlation	 coefficient	 0.298,	 p=0.022).	 On	
applying	the	Bonferroni	correction,	the	significant	p	value	was	reduced	to	0.003	and	all	
correlations	 between	 stromal	 and	 intra-tumoural	 lymphocytes	 remained	 significant.	
The	 correlation	 between	 intra-tumoural	 CD8	 count	 and	 distribution	 of	 CD8	 at	 the	











CD20	 0.676	 0.593	 NS	 NS	
CD4	 0.609	 0.692	 NS	 NS	
CD8	 0.487	 0.565	 NS	 0.298	*	
FoxP3	 0.675	 0.435	 NS	 NS 
Table	17.	Correlation	between	lymphocyte	infiltrates	at	different	sites	
Spearman’s	correlation	tests	were	performed	to	assess	associations	between	lymphocyte	





strong	 positive	 correlations	 between	 the	 numbers	 of	 lymphocytes	 of	 different	 types	
(CD20+,	 CD4+,	 CD8+	 and	 FoxP3+)	 in	 each	 of	 the	 different	 locations	 and	 using	 the	
different	 assessment	 metrics	 (stromal	 count,	 stromal	 proportions,	 intra-tumoural	
counts,	 intra-tumoural	 proportions,	 edge	 infiltration)	 (correlation	 coefficients	 range	
0.427	 to	0.827,	 p<=0.001,	 except	between	CD20	and	CD8	 ITL	 count	where	p=0.002).	
Table	 18	 shows	 the	 correlation	 coefficients.	 This	 implied	 some	 influences	 driving	











































































4.4.3 Hormone	 negative	 and	 triple	 negative	 breast	 cancers	
contain	 higher	 proportions	 of	 tumour	 infiltrating	
lymphocytes			
Various	clinico-pathological	features	have	been	reported	to	correlate	with	the	location	
and	 subtypes	 of	 tumour	 infiltrating	 lymphocytes.	 Next,	 I	 tested	 whether	 clinico-
pathological	features	of	the	patients	or	their	tumours	correlated	with	differences	in	the	





CD4+	 and	 FoxP3+	 lymphocytes	 in	 the	 stromal	 compartment	 as	 compared	 to	 ER/PR	
positive	tumours	(p=0.024,	0.023	and	0.008	respectively)	(Figure	52A).	This	trend	was	














(C)	 and	 absolute	 count	 (D).	 Boxes	 represent	 50%	 of	 the	 data	 with	 medians	 (line),	
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stromal	 CD20+,	 CD4+	 and	 FoxP3+	 lymphocytes	 showed	 significance	 (p=0.042,	 0.048	
and	 0.022	 respectively)	 and	 intra-tumoural	 CD4+	 and	 CD8+	 lymphocytes	 showed	
significance	 (p=0.032	 and	 0.046	 respectively).	 However,	 notably,	 differential	
infiltration	was	not	 found	when	dichotomising	 the	cohort	on	 the	basis	of	her2	status	



























status	 and	 the	 distribution	 of	 lymphocytes	 in	 the	 stromal	 and	 intra-tumoural	
compartments	assessed	in	the	triple	negative	(ER/PR/Her2	negative)	group	versus	group	
with	either	hormone	receptor	positivity	or	HER	2	positivity.	Figure	shows	the	distribution	
of	 lymphocytes	 in	 the	 stromal	 and	 intra-tumoural	 compartment	 of	 the	 two	 as	 a	
proportion	 of	 stromal	 area	 (A)	 and	 absolute	 count	 (B)	 and	 in	 the	 intra-tumoural	
compartment	as	a	proportion	relative	to	tumour	cells	(C)	and	absolute	count	(D).	Boxes	
represent	 50%	 of	 the	 data	 with	 medians	 (line),	 interquartile	 range	 (whiskers)	 and	
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in	 the	 grade	 2	 and	 grade	 3	 tumours	 were	 evident	 (Figure	 55),	 with	 higher	 grade	
tumours	generally	showing	greater	infiltration	of	stromal	CD20+	(p=0.006	for	stromal	
count	and	0.017	 for	stromal	proportion),	CD8+	(p=0.048	 for	stromal	proportion)	and	
FoxP3+	 lymphocytes	 (p=0.001	 for	 stromal	 count	 and	 0.002	 for	 stromal	 proportion)	
(Figure	 55,	 A-B),	 and	 intra-tumoural	 CD20+	 lymphocyte	 count	 (p=0.042),	 CD8+	

































contain	any	grade	1	 tumours.	 Figure	 shows	 the	distribution	of	 different	 lymphocytes	 in	
Grade	2	and	3	tumours	in	the	stroma	as	absolute	count	(A)	and	as	a	proportion	(B)	and	in	
the	 intra-tumoural	 compartment	as	 absolute	 count	 (C)	 and	as	 a	 proportion	 relative	 to	
tumour	cells	(D	Boxes	represent	50%	of	the	data	with	medians	(line),	interquartile	range	
(whiskers)	and	outliers	 (circles).	All	statistically	 significant	differences	 (p<0.05)	 selected	
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4.4.5 Tumour	 size	 and	 nodal	 status	 do	 not	 correlate	 with	
differences	in	infiltrating	lymphocytes	in	stromal	or	intra-
tumoural	compartments	
The	 patients	 were	 then	 categorised	 based	 on	 tumour	 size	 (<2	 cm,	 2-5	 cm,	 >5	 cm).	
Although	 smaller	 tumours	 (<2	 cm)	 tended	 to	 have	 higher	 stromal	 lymphocytic	
infiltrate,	 there	 were	 no	 statistically	 significant	 differences	 in	 the	 distribution	 of	
lymphocytes	in	the	stromal	or	intra-tumoural	compartment	based	on	tumour	size.		The	
difference	 in	 the	stromal	proportion	of	CD4+	T	cells	had	a	p	value	of	0.047,	however,	
this	 single	weak	 result	may	well	 have	been	associated	with	multiple	 testing	and	was	
therefore	 not	 considered	 further	 (Appendix	 3,	 Section	 6.3.4,	 Table	 38).	 The	 study	
cohort	was	also	split	into	lymph	node	positive	and	lymph	node	negative	patients.	There	








latter	 was	 of	 particular	 interest	 as	 this	 had	 proved	 to	 correlate	 with	 circulating	
lymphocytes	in	the	previous	chapter	(Ch	3,	section	3.4.7.2).	The	cohort	was	divided	into	
2	groups	based	on	age	(20-49	and	50-79)	and	analyses	as	above	were	performed.	There	
were	 no	 significant	 differences	 in	 the	 distribution	 of	 lymphocytes	 based	 on	 age	
(Appendix	 3,	 Section	 6.3.6,	 Table	 40).	 Similarly,	 when	 the	 cohort	 was	 divided	 into	
smokers	 and	 non-smokers	 there	 were	 no	 statistically	 significant	 differences	 in	 the	
distribution	of	lymphocytes	(Appendix	3,	Section	7.3.7,	Table	41).	
4.4.7 Some	 subtypes	 of	 tumour-infiltrating	 lymphocytes	
correlate	 with	 their	 respective	 circulating	 levels,	 in	
specific	tumour	subtypes	only	
One	key	question	not	addressed	in	the	literature,	is	how	TIL	levels	and	types	relate	to	
the	 circulating	 levels.	Here,	 I	 have	quantified	TILs	(of	 different	 types	and	 in	different	
locations),	 and	 also	 have	 access	 to	 data	 on	 circulating	 levels	 (Chapter	 3).	 I	 was	
therefore	 interested	 to	 assess	 correlations	between	TILs	and	 the	 circulating	 levels	 of	
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lymphocytes	assessed	at	 the	 time	point	closest	 to	 the	 time	of	surgical	 removal	of	 the	
tumour	 –	 ie,	 the	 pre-chemotherapy	 time-point	 for	 the	 patients	 undergoing	 adjuvant	
chemotherapy.	 It	 should	 be	 emphasized	 that	 this	 time	 point	 for	 assessment	 of	
circulating	 levels	 was	 typically	 around	 2	 weeks	 after	 surgery	 –	 so	 the	 infiltrating	
lymphocyte	 assessment	 and	 circulating	 lymphocyte	 assessment	 are	 not	 perfectly	
matched	in	terms	of	timing.	Spearman’s	correlation	tests	were	performed	to	check	for	
correlations	 between	 tumour-infiltrating	 CD20+,	 CD4+	 and	 CD8+	 lymphocytes	 and	





There	 was	 a	 significant	 positive	 correlation	 between	 circulating	 levels	 of	 CD8+	
lymphocytes	 and	 a	 number	 of	 different	 measures	 of	 tumour-infiltrating	 CD8+	
lymphocytes,	with	correlation	coefficients	ranging	from	0.313	to	0.375	(Table	19).	For	
completion,	the	scatter	plots	for	this	are	shown	in	Appendix	3	(section	6.3.8,	Figure	68).	
On	 applying	 the	 Bonferroni	 correction	 (corrected	 p=0.01),	 correlations	 between	
circulating	 CD8+	 T	 cells	 and	 intra-tumoural	 proportion	 of	 CD8+	 T	 cells	 remained	
significant.	 There	 were	 no	 correlations	 between	 TILs	 (stromal	 or	 intra-tumoural	 by	
either	proportion	or	absolute	counts,	or	lymphocyte	infiltrate	at	the	tumour	edge)	and	























CD8+	 T	 lymphocytes	 and	 intra-tumoural	 CD8+	 T	 lymphocytes.	 Table	 shows	 the	






cells,	 CD19+CD27+IgD+	 non	 switched	 memory	 B	 cells,	 CD19+CD27+IgD-	 switched	
memory	 B	 cells,	 CD19+CD24hiCD38hi	 transitional	 B	 cells;	 for	 T	 cells:	
CD3+CD4+CD45RA+CD45RO-/CD3+CD4+CD45RA+CD62L+	 naïve	 T	 cells,	 CD3+CD4+CD45RA-
CD45RO+	memory	 T	 cells,	 CD4+CD45RA+CD31+	 recent	 thymic	 emigrants).	 The	 levels	 of	
each	of	these	subtypes	were	also	tested	for	correlations	with	tumour-infiltrating	levels	
on	 the	 basis	 of	 the	 hypothesis	 that	 any	 one	 of	 these	 might	 be	 predisposed	 to	
preferential	 accumulation	 within	 tumours	 or	 could	 be	 specifically	 excluded	 from	
tumours.	However,	there	were	no	significant	correlations	between	these	circulating	B	




their	 respective	 circulating	 levels	 are	 strongest	 in	 the	 tumour	
subtypes	with	the	heaviest	infiltrate	
Since,	 the	 receptor	 status	 and	 grade	 of	 tumours	 correlated	 with	 the	 extent	 of	
lymphocyte	 infiltration	 (sections	 4.4.3	 and	 4.4.4	 above),	 I	 next	 tested	whether	 these	
factors	impacted	on	the	correlations	between	TILs	and	circulating	lymphocyte	levels.		I	
split	the	cohort	into	ER	negative	and	ER	positive	groups.	Within	the	ER	positive	group,	




total	 cohort.	 In	 the	 ER	 negative	 group,	 there	 were	 positive	 correlations	 between	
circulating	 CD8	 counts	 and	 stromal	 proportion	 of	 CD8+	 lymphocytes	 (rs	 0.550,	
p=0.010),	stromal	count	(rs	0.545,	p=0.011),	intra-tumoural	CD8+	lymphocyte	count	(rs	
0.435,	 p=0.049)	 and	 intra-tumoural	 proportion	 of	 CD8+	 lymphocytes	 (rs	 0.466,	
p=0.033)	 (Table	 20;	 scatter	 plots	 in	 Appendix	 3,	 Section	 6.3.9,	 Figure	 69-70).		
Furthermore,	 some	 correlations	 that	 had	 not	 been	 evident	 between	 circulating	 and	
tumour-infiltrating	 levels	 in	 the	 whole	 cohort	 were	 revealed	 within	 only	 the	 ER	
negative	 group.	Circulating	CD25+FoxP3+	 lymphocytes	 (regulatory	T	 cells)	 showed	a	
negative	 correlation	 with	 intra-tumoural	 FoxP3+	 lymphocyte	 counts	 (rs	 -0.574,	 p=	
0.025)	and	lymphocyte	proportion	relative	to	tumour	cells	(rs	-0.524,	p=0.045)	(Table	
20).	 No	 correlation	 between	 circulating	 and	 tumour	 infiltrating	 lymphocytes	 were	
evident	in	either	ER	positive	or	ER	negative	groups	for	CD4+,	CD20+	or	CD25hiFoxP3+	
lymphocytes.	On	 applying	 the	Bonferroni	 correction,	 the	 significant	p	 value	was	0.01	
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Similar	 results	 were	 seen	 when	 examining	 triple	 negative	 cancers,	 which	 also	 have	
increased	infiltration	(section	4.4.3),	as	compared	to	cancers	showing	positivity	for	one	
or	 more	 of	 the	 receptors	 ER,	 PR	 or	 Her2.	 The	 group	 positive	 for	 at	 least	 one	 of	
ER/PR/Her2+	 demonstrated	 no	 correlations	 between	 circulating	 levels	 and	 their	
respective	 tumour	 infiltrating	 lymphocytes.	 In	 the	 triple	 negative	 cohort,	 significant	
correlations	were	again	seen	between	circulating	levels	and	tumour-infiltrating	levels	
for	 CD8+	 lymphocytes	 (positive	 correlations)	 and	 regulatory	 T	 cells	 (negative	
correlations)	(Table	21).	On	applying	the	Bonferroni	correction,	correlations	between	
circulating	CD8+	T	cells	and	stromal	proportions	of	CD8+	T	cells	remained	significant.	










































The	 influence	 of	 tumour	 grade	 was	 less	 clear.	 Grade	 3	 tumours	 were	 more	 heavily	
infiltrated	 than	grade	2	 tumours	(section	4.4.4),	but	 in	 this	case	both	groups	showed	
some	significant	correlations	between	circulating	and	tumour-infiltrating	levels	(Table	
22).	Some	of	these	correlations	were	consistent	with	those	previously	seen,	such	as	a	
positive	 correlation	 between	 circulating	 CD8+	 lymphocytes	 and	 tumour-infiltrating	
CD8+	 lymphocytes,	 while	 other	 were	 unique	 to	 this	 analysis,	 for	 example	 a	 positive	
correlation	 between	 CD20+	 lymphocytes	 in	 the	 circulation	 and	 stromal	 counts	 for	
grade	 2	 tumours	 only	 or	 a	 positive	 correlation	 between	 CD4+	 lymphocytes	 in	 the	
circulation	and	at	the	tumour	edge	for	grade	3	tumours	only.	 	It	 is	tempting	to	regard	
some	 of	 these	 correlations	 as	 potentially	 chance	 events,	 particularly	 considering	 the	
large	 number	 of	 tests	 performed,	 and	 the	 borderline	 significance	 of	 some	 results.	 In	
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CD20,	 CD4,	 CD8	 and	 CD25+FoxP3+	 T	 lymphocytes	 and	 the	 corresponding	 tumour	
infiltrating	lymphocytes	in	patients	with	grade	2	and	grade	3	tumours.	Table	shows	the	






chemotherapy	 from	individuals	who	were	 treated	with	neo-adjuvant	chemotherapy.	 I	
assessed	 matched	 diagnostic	 biopsy	 specimens	 (pre-chemotherapy)	 and	 the	 final	
surgical	specimens	(post-chemotherapy)	of	the	small	group	of	patients	who	underwent	
neo-adjuvant	 chemotherapy	 within	 my	 cohort	 (n=10).	 There	 were	 no	 statistically	
significant	 differences	 between	 the	 pre	 and	 post-chemotherapy	 levels	 of	 tumour	
infiltrating	lymphocytes	at	any	site	for	any	of	the	subtypes	tested	(lymphocytes	positive	
for	CD20,	CD4,	CD8	or	FoxP3).	This	is	most	likely	due	to	the	small	sample	size	(n=10).	




I	 then	 tried	 to	 see	 if	 there	 was	 any	 difference	 in	 TILs	 based	 on	 response	 to	
chemotherapy.	There	was	no	 statistically	 significant	difference	 in	 the	 lymphocytes	 in	
any	 compartment	 when	 the	 cohort	 was	 divided	 into	 3	 groups	 based	 on	 clinical	 and	
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pathological	 assessment	 as	 follows:	 no	 response,	 partial	 response	 or	 complete	
response.	 The	 ‘no	 response’	 group	 (n=4)	 contained	 patients	 who	 had	 disease	
progression	on	chemotherapy.	Partial	responders	(n=4)	were	those	who	had	minimal	





There	 is	 considerable	 evidence	 that	 levels	 of	 TILs	 correlate	 with	 survival	 in	 breast	
cancer	patients	(reviewed	in	Chapter	1,	section	1.5.1).	I	therefore	wanted	to	assess	this	
in	my	 study	 cohort.	 Follow	 up	 data	 relating	 to	 survival	was	 collected	 for	 the	 cohort.		










There	was	 a	 significant	 negative	 correlation	 between	 occurrence	 of	 death	 and	 CD4+	
stromal	count	(rs	=	-0.301,	p=0.019),	CD4+	stromal	lymphocyte	proportion	(rs	=	-0.253,	
p=0.049),	 CD20	 infiltrate	 at	 tumour	 edge	 (rs	 =-0.331,	 p=0.025)	 and	 there	 was	 also	
negative	 correlation	 between	 tumour	 recurrence	 and	 CD20+	 lymphocyte	 infiltrate	 at	
tumour	edge	(rs=-0.437,	p=0.002)	and	CD8+	lymphocyte	infiltrate	at	tumour	edge	(rs	=	-
0.314,	 p=0.045).	 On	 univariate	 analysis,	 these	 were	 not	 predictors	 of	 death	 or	
recurrence	when	 they	were	 used	 as	 continuous	 variables.	 However,	when	 used	 as	 a	
categorical	 variable	 by	 splitting	 the	 cohort	 into	 high	 and	 low	 lymphocyte	 infiltrate	
using	 a	 cut	 off	 value	 determined	 by	 ROC	 curve	 analysis,	 CD4	 stromal	 count	 was	 a	
predictor	of	tumour	recurrence	(p=0.010,	HR	6.3,	CI	1.542	to	25.732,	with	patients	with	
low	CD4	 infiltrate	 at	 higher	 risk	of	 recurrence).	 Similarly,	 CD8	 stromal	 infiltrate	 as	a	
categorical	 variable	 predicted	 tumour	 recurrence	 (p=0.039,	 HR	 3.985,	 CI	 1.075	 to	
14.769)	with	patients	with	low	CD8	infiltrate	at	greater	risk	of	recurrence.	Significant	
predictors	of	death	were	CD4	 stromal	proportion	(p=0.025,	HR	8,	 CI	 0.020	 to	0.773)	
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and	CD4	stromal	 count	 (p=0.006,	HR	13.714,	CI	0.011	 to	0.475)	with	 those	with	 low	
CD4	stromal	count	and	stromal	proportion	at	greater	risk	of	death.		
	
In	 a	multivariate	 analysis model	 containing	 CD4	 stromal	 count	 (continuous	 variable)	
CD4	stromal	proportion	(continuous	variable),	tumour	grade,	hormone	receptor	status,	
chemotherapy	 type	 and	 chemotherapy	 regimen	 the	 following	 variables	 proved	 to	 be	
significant	predictors	of	recurrence:	CD4	stromal	count	(p=0.044,	HR	0.989,	CI	0.978	to	
1)	CD4	stromal	proportion	(p=0.029,	HR	1.110,	CI	1.011	to	1.219)	and	chemotherapy	
type	 (ACT	vs	NACT)	 (p=0.039,	HR	0.109,	CI	 0.013	 to	0.894).	Difficult	 to	 explain	why	
CD4	 stromal	 count	 had	 a	HR	<1	 and	 stromal	proportion	 had	HR>1.	 One	 explanation	
could	be	 that	the	stromal	count	 is	confounded	by	the	amount	of	stroma	 in	the	region	
assessed	–	so	as	well	as	a	measure	of	TILs	it	is	also	a	measure	or	more	or	less	stroma.		













but	 the	 latter	 did	 not	 reach	 statistical	 significance	 (Figure	 56).	 The	 percentage	 of	
recurrence	 and	 death	was	 lower	 in	 those	with	 higher	 stromal	 infiltrate	 of	 CD8+	and	
CD20+lymphocytes	but	these	results	did	not	reach	statistical	significance.	In	the	case	of	







of	 CD4+	 T	 cells.	 Disease	 free	 survival	 (DFS)	 and	 Overall	 Survival	 (OS)	 was	 compared	










shown	 in	 Tables	 43-46	 (Appendix	 3,	 Section	 6.3.11).	 Patients	 with	 stromal	 counts	
above	 the	 cut	 off	 for	 CD4+	 T	 cells	 showed	 better	DFS	 (10%	 versus	 45%	 recurrence,	
p=0.029)	in	ER/PR	positive	group,	while	patients	with	stromal	counts	above	the	cut	off	
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from	 ROC	 curve	 analysis	 for	 stromal	 counts	 of	 CD4+	 and	 CD8+	 T	 cells.	 Disease	 free	
survival	 (DFS)	was	 compared	 between	 these	 two	 groups	 of	 patients	 in	 ER/PR	negative	
and	ER/PR	positive	patients	using	log	rank	tests.	Figure	shows	DFS	in	patients	with	high	
and	low	stromal	counts	of	CD4+	T	cells	in	ER/PR	negative	(A-left)	and	ER/PR	positive	(A-
right)	 (cut	 off	 value	 108)	 and	 high	 and	 low	 stromal	 counts	 of	 CD8+	 T	 cells	 in	 ER/PR	






(0%	 versus	 33%	 mortality,	 p=0.014)	 while	 high	 stromal	 proportions	 of	 CD4+	
lymphocytes	were	associated	with	better	OS	in	ER/PR	negative	patients	only	(0	versus	
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from	 ROC	 curve	 analysis	 for	 stromal	 counts	 and	 stromal	 proportions	 of	 CD4+	 T	 cells.	
Overall	 survival	 (OS)	 was	 compared	 between	 these	 two	 groups	 of	 patients	 in	 ER/PR	




positive	 (B-right)	 (cut	 off	 value	 1.4).	 Y-axis	 shows	 the	 cumulative	 survival	 and	 x-axis	
shows	the	 time	 to	recurrence.	P	value	 from	 log-rank	 test	 is	 shown	on	 the	plots.	NS=	not	
significant.	
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from	ROC	curve	analysis	 for	 stromal	proportions	of	CD20+	B	cells.	Overall	 survival	 (OS)	
was	 compared	 between	 these	 two	 groups	 of	 patients	 in	 ER/PR	 negative	 and	 ER/PR	
positive	 patients	 using	 log	 rank	 tests.	 Figure	 shows	 OS	 in	 patients	 with	 high	 and	 low	
stromal	counts	of	CD20+	B	cells	in	ER/PR	negative	(left)	and	ER/PR	positive	(right)	(cut	
off	 value	 0.90).	 Y-axis	 shows	 the	 cumulative	 survival	 and	 x-axis	 shows	 the	 time	 to	
recurrence.	P	value	from	log-rank	test	is	shown	on	the	plots.	NS=	not	significant.	
	
Surprisingly,	 high	 intra-tumoural	 CD8+	 T	 cells	 in	 ER/PR	 positive	 patients	 was	
associated	 with	 poor	 OS	 (33%	 versus	 6%	 mortality,	 p=0.013	 for	 intra-tumoural	
proportion	of	CD8+	 lymphocytes	and	43%	versus	6%	mortality,	p=0.013	 for	absolute	
counts	 (Figure	 60).	 High	 intra-tumoural	 FoxP3+	 T	 cell	 infiltrate	 in	 ER/PR	 positive	
patients	was	 associated	with	worse	OS	 (36%	 versus	 6%	mortality,	 p=0.005)	 (Figure	
61).	 In	 the	 ER/PR	 negative	 patients,	mortality	 rate	 appeared	 to	 be	 lower	 in	 patients	
with	high	FoxP3+	infiltrate	but	the	results	did	not	reach	statistical	significance.	
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from	 ROC	 curve	 analysis	 for	 intra-tumoural	 CD8+	 T	 cells.	 Overall	 survival	 (OS)	 was	
compared	between	these	 two	groups	 of	 patients	 in	ER/PR	negative	 and	ER/PR	positive	
patients	using	log	rank	tests.	Figure	60-A	shows	OS	in	patients	with	high	and	low	intra-
tumoural	counts	of	CD8+	T	cells	in	ER/PR	negative	(A-left)	and	ER/PR	positive	(A-right)	
(cut	 off	 value	 63.5)	 and	 Figure	 60-B	 shows	 OS	 in	 patients	 with	 high	 and	 low	 intra-
tumoural	proportions	of	CD8+	T	cells	 in	ER/PR	negative	(B-left)	and	ER/PR	positive	(B-
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from	 ROC	 curve	 analysis	 for	 intra-	 tumoural	 proportions	 of	 FoxP3+	 T	 cells.	 Overall	
survival	(OS)	was	compared	between	these	two	groups	of	patients	in	ER/PR	negative	and	
ER/PR	positive	patients	using	 log	rank	 tests.	Figure	shows	OS	in	patients	with	high	and	
low	 intra-tumoural	 proportions	 of	 FoxP3+T	 cells	 in	 ER/PR	 negative	 (left)	 and	 ER/PR	
positive	(right)	(cut	off	value	1.9).	Y-axis	shows	the	cumulative	survival	and	x-axis	shows	
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significant	heterogeneity	in	all	 these	studies	with	regards	 to	 the	sample	size,	 staining	
used	for	detection	of	lymphocytes	(IHC	versus	H&E),	area	scored	(TMA	versus	biopsy	
versus	whole	section)	lymphocytes	considered	(lymphocytes	in	general	on	H&E	versus	
CD4,	 CD8,	 CD20	 or	 FoxP3),	 site	 of	 lymphocytic	 infiltrate	 within	 the	 tumour	 tissue	
(stromal	vs	intraepithelial),	the	scoring	methodology	and	the	cut	offs	used	for	analysis	
and	 to	define	 lymphocyte	predominant	breast	 cancer	 (reviewed	 in	 chapter	1,	 section	




represent	 the	 lymphocyte	distribution	of	 the	 tumour.	 In	 fact,	 this	lack	of	reliability	 in	
scoring	 lymphocytes	 is	 probably	 one	 of	 the	main	 reasons	why	 the	majority	 of	 panel	
members	at	the	14th	St	Gallen	International	Breast	conference	did	not	believe	that	TILs	
could	be	used	as	a	prognostic	or	predictive	marker	(Coates	et	al.,	2015).	Subsequently	
the	 International	 TIL	 working	 group	 published	 a	 standardised	 methodology	 for	




similar,	 and	 that	 since	 scoring	 of	 stromal	 lymphocytes	 is	 more	 reproducible	 and	





section	4.4.1).	The	 levels	of	CD4+	and	CD8+	T	cells	 in	the	stromal	and	 intra-tumoural	
compartments	 respectively	were	 significantly	higher	 compared	 to	other	 lymphocytes	
assessed,	implying	that	local	influences	probably	impact	on	lymphocyte	infiltration	to	




showed	 generally	mild	 to	moderate	 infiltrate	 at	 the	 tumour	 edge	 (Figure	 51,	 section	
	 152	




edge	was	 therefore	 an	 indication	of	 better	prognosis.	 There	was	a	 strong	 correlation	
between	 the	 distribution	 of	 lymphocytes	 in	 the	 stromal	 and	 intra-	 tumoural	
compartment	 (Table	 17,	 Section	 4.4.2),	 implying	 that	 the	 distribution	 in	 the	 stromal	
and	intra-tumoural	compartment	is	similar	for	each	of	the	lymphocytes.	There	was	also	
a	 strong	 correlation	between	 the	different	 lymphocytes	 assessed	both	 in	 the	 stromal	
and	 intra-tumoural	compartment	(Table	18,	Section	4.4.2).	Further	subgroup	analysis	
of	 hormone	 negative	 and	 triple	 negative	 breast	 cancers	 showed	 strong	 correlation	
between	 TILs	 and	 hormone	 negative	 and	 triple	 negative	 tumours	 (Figures	 52-53,	
section	4.4.3)	and	also	between	high	grade	tumours	and	TILs	(Figure	55,	section	4.4.4).	
This	 is	 consistent	 with	 other	 published	 data	 on	 TILs	 (reviewed	 in	 section	 1.5).	
Compared	 to	 ER/PR	 positive	 tumours,	 ER/PR	 negative	 tumours	 had	 significantly	
higher	 proportions	 of	 CD20+,	 CD4+	 and	FoxP3+	 lymphocyte	 infiltrate	 in	 the	 stromal	
compartment	 (Figure	 52,	 section	 4.4.3).	 Similarly,	 triple	 negative	 tumours	 showed	 a	
higher	proportion	of	CD20+,	CD4+,	CD8+	and	FoxP3+	lymphocytic	infiltrate	both	in	the	
stromal	and	within	the	 intra-tumoural	compartment	when	compared	to	 tumours	 that	
were	 ER/PR	 or	 Her2	 positive	 (Figure	 53,	 section	 4.4.3).	 When	 the	 cohort	 was	 split	
based	 on	 Her2	 status	 and	 the	 TILs	 compared	 in	 the	 two	 groups,	 there	 were	 no	
significant	differences	(Fig	54,	section	4.4.3).	This	is	contrary	to	what	has	been	shown	





tumours.	 Tumour	 size	 did	 not	 present	 consistent	 significant	 correlations	 with	 TILs,	
which	 may	 represent	 the	 fact	 that	 larger	 size	 may	 reflect,	 in	 part,	 relatively	 late	
diagnosis	 rather	 than	 a	 true	 difference	 in	 tumour	 biology.	 On	 the	 other	 hand,	 nodal	
status,	 which	 is	 often	 accepted	 to	 reflect	 a	 transition	 to	 a	 more	 aggressive	 disease	
behaviour,	also	 failed	 to	correlate	with	TILs.	One	 interpretation	of	 this	would	be	 that	





how	 TIL	 levels	 and	 types	 relate	 to	 the	 circulating	 levels.	 It	 is	 possible	 that	 their	
accumulation	may	 not	 be	 because	 of	 local	 tumour	 effects	 but	 rather	 associated	with	
simple	 systemic	 influences	 reflecting	 overall	 levels.	 Alternative	 hypotheses	would	 be	
that	 tumour-infiltrating	 lymphocyte	 levels	 could	 be	 entirely	 unrelated	 to	 circulating	
levels,	 suggesting	 a	 true	 local	 interaction,	 or	 could	 even	 correlate	 negatively	 with	
circulating	levels,	suggesting	tumour	recruitment	equates	to	depletion	of	the	circulating	
lymphocytes.	 I	 found	a	positive	correlation	of	 the	 tumour	 infiltrating	CD8+	cells	with	
circulating	 levels	 of	 CD8+	 T	 cells	 (Table	 18,	 section	 4.4.7.1).	 To	 the	 best	 of	 my	
knowledge	 there	 are	 no	 published	 reports	 comparing	 circulating	 and	 tumour	
infiltrating	 lymphocytes	 in	 breast	 cancer.	 Ling	 et	 al.,	 (2007)	 reported	 increased	
frequency	 of	 regulatory	 FoxP3	 cells	 both	 in	 the	 tumour	 environment	 as	 well	 as	 in	
circulation	 in	 patients	 with	 colorectal	 cancer,	 however,	 no	 comparison	 was	 made	
between	the	 tumour	 infiltrating	and	circulating	 lymphocytes.	My	results	showed	that	
there	was	no	correlation	between	tumour	infiltrating	CD20+	B	cells,	CD4+	or	FoxP3+	T	
cells	 with	 circulating	 levels	 of	 B	 cells,	 CD4+	 T	 cells	 and	 CD25+FoxP3+	 /	
CD25hiFoxP3+regulatory	T	cells	respectively.	Interestingly,	the	positive	correlation	seen	
with	 the	 CD8+	 T	 cells	 between	 these	 compartments	 was	 even	 stronger	 in	 the	 ER	
negative	and	triple	negative	groups,	while	no	correlation	was	seen	 in	the	ER	positive	
group	(Table	20-21,	section	4.4.7.2).	The	clinical	significance	of	this	is	unclear	as	there	
are	 no	 previous	 studies	 comparing	 circulating	 and	 tumour	 infiltrating	 lymphocytes.	
However,	 if	 this	 is	 reproducible	 in	larger	cohorts,	 it	may	not	only	eliminate	a	tedious	




There	 are	 also	 no	 reports	 of	 lymphocyte	 infiltrate	 at	 the	 tumour	 edge	 as	 a	 separate	
entity	 as	 most	 of	 the	 studies	 are	 on	 patients	 undergoing	 NACT	 where	 the	 biopsy	
specimen	has	been	used	 to	 evaluate	 the	 lymphocyte	 infiltrate,	 or	 are	based	on	TMAs	
where	a	small	area	is	assessed	that	would	not	allow	the	assessment	of	tumour	edge.	I	
evaluated	 the	 distribution	 of	 lymphocytes	 at	 the	 tumour	 edge	 in	 all	 cases	where	 the	
tumour	 edge	 was	 present	 in	 the	 same	 section	 as	 the	 tumour.	 My	 results	 of	 the	
lymphocyte	 infiltrate	 at	 the	 tumour	 edge	 are	 therefore	 novel	 in	 this	 field.	 I	 found	
negative	correlations	between	CD20	 infiltrate	at	 tumour	edge	and	tumour	recurrence	
as	 well	 as	 death.	 There	 was	 also	 a	 negative	 correlation	 between	 CD8	 infiltrate	 at	
tumour	 edge	 and	 tumour	 recurrence	 (section	 4.4.9.1).	 It	 is	 possible	 that	 a	 high	
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lymphocytic	 infiltrate	at	 the	 tumour	edge	 is	an	 indication	of	 the	 immune	response	 to	
the	 tumour	 and	an	 attempt	 to	 contain	 the	 tumour	 or	 eliminate	 the	 tumour	 cells.	 On	







Unfortunately,	 my	 results	 for	 this	 cohort	 of	 patients	 were	 not	 adequately	 powered	





subtype	 also	 influences	 outcome.	While	 increase	 in	 CD8+	 lymphocytic	 infiltrate	 post	
NACT	 is	associated	with	better	prognosis,	 increase	 in	FoxP3+	 lymphocytes	have	been	





with	 nodal	 involvement	 suggesting	 that	 known	 poor	 prognostic	 tumours	 have	 high	
infiltrates	 of	 lymphocytes.	 Despite	 this,	 survival	 analysis	 has	 shown	 that	 TILs	 are	
associated	with	better	prognosis.	This	appears	to	be	a	bit	of	a	paradox.	In	my	study	as	
well,	I	found	higher	TIL	infiltrate	in	high-grade	tumours	as	well	as	ER/PR	negative	and	
triple	 negative	 tumours	 (Figures	 51-54,	 section	 4.4.3	 and	 4.4.4).	 These	 features	 are	
known	 to	 be	 poor	 prognostic	 features.	 However,	 in	 these	 groups	 of	 patients,	 high	
lymphocytic	 infiltrate	 was	 generally	 associated	 with	 better	 survival,	 although,	 there	
were	slight	differences	based	on	location	of	lymphocytes	and	the	lymphocyte	subtype	
assessed	(section	4.4.9.3).	Since	 I	used	 IHC	to	evaluate	 the	 lymphocytes	and	assessed	
both	stromal	and	intra-tumoural	lymphocytes,	I	could	assess	the	effect	of	stromal	and	
intra-tumoural	lymphocytes	on	survival	individually.	Although,	there	was	a	significant	




lymphocytes	 in	 the	 immediate	 vicinity	 of	 the	 tumour	 cells	 (intra-tumoural	
lymphocytes)	 influences	 the	 tumour	cells	differently	compared	 to	 the	 lymphocytes	 in	
the	 stromal	 compartment	 or	 in	 the	 periphery	 of	 the	 tumour.	 There	 was	 also	 a	
significant	difference	based	on	 the	 type	of	 lymphocytes.	High	CD4+	T	cell	 infiltrate	 in	
the	 stroma	 was	 associated	 with	 significantly	 better	 DFS	 and	 OS	 (Figure	 55,	 section	
4.4.9.2).	High	CD8+	and	CD20+	lymphocytes	also	showed	the	same	trend	but	the	results	
did	not	reach	statistical	significance.	However,	high	levels	of	FoxP3+	lymphocytes	in	the	
stroma	 was	 associated	 with	 higher	 recurrence	 rates,	 although	 the	 results	 were	 not	
statistically	 significant	 (Table	 42,	 Appendix	 3).	 Similar	 trends	 were	 seen	 with	
lymphocyte	infiltrate	in	the	intra-tumoural	compartment	but	the	results	did	not	reach	
statistical	 significance.	A	 larger	 study	population	may	have	helped	 to	 get	 a	definitive	
answer.	 When	 the	 cohort	 was	 split	 based	 on	 hormone	 receptor	 status,	 survival	






Surprisingly,	 high	 intra-tumoural	 CD8+	 T	 cells	 in	 ER/PR	 positive	 patients	 was	
associated	with	poor	OS.	This	is	contrary	to	what	has	been	shown	so	far	(reviewed	in	
section	 1.5,	 chapter	 1).	 Although	 there	 have	 been	 a	 few	 reports	 in	 the	 past	 which	
showed	that	high	CD8+	T	cell	infiltrate	was	associated	with	poor	prognosis	(Macchetti	
et	al.,	2006,	Georgiannos	et	al.,	2003,	Matkowski	et	al.,	2009),	the	methodology	used	in	
these	 studies	 was	 different.	 Moreover,	 these	 studies	 did	 not	 differentiate	 between	
stromal	and	intra-tumoural	lymphocytes.	On	univariate	analysis,	CD4	and	CD8	stromal	
counts	 were	 found	 to	 be	 significant	 predictors	 of	 tumour	 recurrence	 and	 on	
multivariate	 analysis,	 CD4	 stromal	 count	 alone	 was	 an	 independent	 predictor	 of	
tumour	recurrence	(section	4.4.9.1).	However,	more	work	needs	to	be	done	 to	clarify	










only	 20%	 of	 the	 breast	 specimens	 were	 positive	 for	 FoxP3	 expression	 (Zou,	 2006),	
others	have	found	expression	of	FoxP3	in	a	much	higher	percentage	of	samples,	ranging	
upto	70%	(Merlo	et	al.,	2009).	The	difference	is	partly	related	to	the	ways	in	which	the	
scoring	was	 done.	 Zuo	 et	 al.	 (2006)	 only	 included	 nuclear	 staining	while	Merlo	 et	 al	
included	both	cytoplasmic	as	well	as	nuclear	staining.		I	included	nuclear	staining	and	
found	 a	 substantially	 higher	 proportion	 of	 stromal	 FoxP3+	 lymphocytes	 in	 ER/PR	
negative	patients.		My	results	also	showed	high	intra-tumoural	FoxP3+	lymphocytes	to	
be	associated	with	poor	prognosis	in	ER/PR	positive	patients	(Fig	61,	section	4.4.9.3).	
There	 are	 conflicting	 results	 regarding	prognostic	 significance	of	 FoxP3+	TILs.	While	
most	 studies	 have	 found	 high	 FoxP3+	 T	 cells	 infiltrate	 to	 be	 associated	 with	 poor	
prognosis,	others	have	not	found	them	to	be	of	prognostic	value	and	some	have	found	
them	 to	 be	 associated	 with	 better	 prognosis	 (reviewed	 in	 Chapter	 1,	 section	 1.5).	
Larger	 studies	 based	 on	 IHC	 evaluating	 different	 lymphocyte	 subtypes	 both	 in	 the	
stroma	 and	 in	 the	 intra-tumoural	 compartment	 may	 help	 clarify	 these	 ambiguities	
regarding	 prognostic	 significance	 of	 different	 lymphocytes.	 Despite	 the	 difference	 in	




My	results,	as	well	as	evidence	 from	 literature,	suggest	 that	 the	presence	of	different	
lymphocytes	 in	 the	 tumour	 microenvironment	 appears	 to	 be	 associated	 with	 poor	
prognostic	 tumours	 and	 may	 influence	 patient	 outcome.	 TILs	 therefore	 remain	 a	
potential	 biomarker	 but	 more	 work	 is	 required	 looking	 at	 different	 subtypes	 using	
immunohistochemistry	 (rather	 than	 H&E)	 and	 there	 is	 also	 potential	 for	 even	more	
subtle	examination	of	TILs	by	flow	cytometry	to	further	identify	the	specific	subtypes	of	
B	or	T-lymphocytes	and	assess	their	role	as	prognostic	markers.	There	has	been	some	
association	 between	 tumour-infiltrating	 CD45RO+	memory	 effector	 T	 cells	 and	 good	










5.1 The	 influence	 of	 breast	 cancer,	 and	 breast	 cancer	
therapy	on	lymphocytes	
The	 immune	system	clearly	responds	 to	 the	presence	of	 tumour,	as	evident	 from	the	
presence	of	lymphocytic	infiltrate	in	the	tumour	microenvironment	and	its	association	
with	certain	poor	prognostic	features	of	cancer	and	also	its	association	with	prognosis	








was	 significantly	 less	 compared	 to	 CD8+	 T	 cells	 and	NK	 cells	 even	at	9	months	 post	
chemotherapy.	The	phenotypes	of	repopulating	B	and	T	cells	are	also	different.	While	
repopulating	B	 cell	 consisted	of	 higher	proportion	of	naïve	 cells,	 repopulating	T	 cells	
consisted	 of	 memory	 T	 cells.	 	 The	 chemotherapy	 regimen	 influenced	 the	 extent	 of	
depletion	and	repopulation	of	lymphocytes	with	patients	on	EC/FEC	regimen	showing	
significantly	 lower	levels	of	 lymphocytes	at	2	weeks	post-chemotherapy	compared	to	
those	who	had	taxanes	 in	addition	 to	EC/FEC	regimen.	The	 levels	at	9	months	 in	 the	
former	 group	 showed	 better	 recovery	 compared	 to	 those	 who	 received	 taxanes.	
Smoking	 also	 had	 significant	 effect	 on	 levels	 of	 repopulating	 B	 lymphocytes	 with	
smokers	showing	significantly	lower	levels	of	B	lymphocytes	at	3,	6	and	9	months	post	
chemotherapy.	 Further	 subtype	 analysis	 of	 repopulating	 B	 cells	 in	 smokers	 showed	
significantly	 low	 levels	 of	 naïve	 B	 cells	 but	 significantly	 higher	 levels	 of	 switched	
memory	 B	 cells	 compared	 to	 non-smokers.	 Titres	 of	 anti-pneumococcal	 and	 anti-
tetanus	antibodies	were	significantly	reduced	post-chemotherapy	and	did	not	return	to	
normal	 even	 at	 9	 months	 post-chemotherapy.	 Regression	 analysis	 showed	
chemotherapy	 type	 (ACT	 versus	 NACT),	 chemotherapy	 regimen	 (EC/FEC	 versus	
EC+Taxanes)	and	levels	of	B,	CD4,	CD8	and	NK	cells	at	2	weeks	post	chemotherapy	to	
be	 independent	 predictors	 of	 tumour	 recurrence	 and/or	 death	 with	 better	 outcome	
associated	with	ACT,	EC/FEC	chemotherapy	and	levels	of	lymphocytes	below	the	cut	off	
value	 as	 determined	 using	 ROC	 curve	 analysis.	 Survival	 analysis	 also	 showed	 that	
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patients	 with	 lymphocyte	 levels	 below	 the	 cut	 off	 at	 2	 weeks	 post	 chemotherapy	
showed	 less	 recurrence	 and	 better	 survival.	 At	 9	months	 post	 chemotherapy,	 those	
with	 levels	 above	 the	 cut	 off	 value	 showed	 less	 recurrence	 and	 better	 survival.	
Although	B	cells	subtypes	did	not	have	any	influence	on	survival,	patients	with	naïve	T	
cells	 and	 recent	 thymic	 emigrants	 above	 the	 cut-off	 value	 at	 2	weeks	 and	 9	months	
post-chemotherapy	showed	less	recurrence	and	better	survival.	Conversely	those	with	
memory	 T	 cells	 below	 the	 cut-off	 value	 showed	 less	 recurrence	 and	 better	 survival.	
High	levels	of	regulatory	T	cells	at	6	months	were	associated	with	high	recurrence	rates	
and	higher	mortality	rates.	Surprisingly,	 I	 failed	 to	demonstrate	a	significant	effect	of	
chemotherapy	on	the	immune	response	within	the	tumour	microenvironment,	in	terms	
of	levels	or	location	of	different	types	of	tumour-infiltrating	lymphocytes,	although	this	
may	 have	 been	 due	 to	 the	 small	 cohort	 of	 patients	 for	 whom	 the	 pre	 and	 post-
chemotherapy	tissue	were	available	for	analysis.		
Analysis	 of	 tumour	 infiltrating	CD4+,	CD8+,	CD20+	and	FoxP3+	 lymphocytes	 showed	
that	 the	most	 prevalent	 lymphocyte	was	 CD4+	 lymphocytes	 in	 the	 stroma	 and	 CD8+	
lymphocyte	 in	 the	 intra-tumoural	 compartment.	 There	 were	 significant	 correlations	
between	 the	 stromal	 and	 intra-tumoural	 levels	 of	 each	 of	 the	 lymphocytes	 and	 also	
between	 different	 lymphocytes.	 There	 were	 positive	 correlations	 between	 tumour	
infiltrating	 lymphocytes	 and	hormone	negative,	 triple	negative	 and	grade	3	 tumours.	
Only	 tumour	 infiltrating	 CD8+	 lymphocytes	 correlated	 with	 the	 matched	 circulating	
levels,	 and	 this	 correlation	 was	 stronger	 in	 hormone	 negative	 and	 triple	 negative	
tumours.	 High	 stromal	 CD4+	 infiltrate	was	 associated	with	 better	 DFS	 and	OS	 in	 the	






lymphocytes	 in	 the	 tumour	 microenvironment	 appears	 to	 be	 associated	 with	 poor	
prognostic	 tumours	 and	 may	 influence	 patient	 outcome.	 TILs	 therefore	 remain	 a	
potential	 biomarker	 but	 more	 work	 is	 required	 looking	 at	 different	 subtypes	 using	





It	 is	 important	 to	 consider	 some	 of	 the	 limitations	 of	 this	 study.	 Sample	 size	 was	
probably	the	most	significant	limitation.	My	results	showed	some	correlation	between	




The	 comparison	 of	 tumour	 infiltrating	 lymphocytes	 and	 circulating	 lymphocytes	was	
made	with	 the	 levels	of	circulating	 lymphocytes	prior	 to	chemotherapy.	This	was	 the	
closest	time	point	to	the	time	of	resection.	However,	for	a	more	accurate	analysis,	blood	
collected	on	the	day	of	surgery	would	be	more	ideal.	The	levels	of	lymphocytes	in	blood	




I	 followed	 up	 the	 patients	 for	 9	months	 post-chemotherapy	 and	 at	 this	 point	 B	 and	
CD4+	 T-lymphocyte	 levels	 were	 still	 significantly	 different	 from	 their	 pre-
chemotherapy	 levels.	 Longer-term	 follow	 up	 was	 not	 feasible	 due	 to	 funding	 issues,	
logistics,	 and	 my	 own	 employment	 circumstances.	 However,	 follow-up	 until	 the	
lymphocytes	 returned	 to	 normal	 may	 be	 informative	 in	 establishing	 whether	 these	
patients	 have	 suffered	 permanent	 changes	 to	 their	 immune	 systems.	 I	 also	 did	 not	
evaluate	 the	 clinical	 implications	 of	 altered	 lymphocyte	 levels	 post-chemotherapy	 in	
terms	 of	 increased	 susceptibility	 to	 infections.	 I	 did	 attempt	 to	 gather	 data	 from	
patients	at	 the	 end	of	 the	 follow	up	period	(9	months	post-chemotherapy)	 regarding	




function	 of	 the	 residual	 lymphocytes.	 I	 have	 evaluated	 the	 lymphocyte	 counts	 and	
extrapolated	 this	 to	 identify	 deficiency	 in	 immunity	 post-chemotherapy.	 I	 did	 not	






general	 data	 regarding	 the	 effect	 of	 chemotherapy	 on	 white	 blood	 cells	 (WBC).	
Although	I	performed	detailed	analysis	of	lymphocytes,	I	did	not	collect	data	regarding	




the	 slides	 for	 lymphocytes,	 this	 scoring	was	 difficult	 and	 subjective	 especially	when	
assessing	 the	proportion	of	 stromal	 lymphocytes,	 and	 in	 choosing	 the	 representative	
fields	 for	 analysis.	 The	 scoring	 of	 the	 slides	would	 have	 been	 better	with	 the	 Aperio	
Imagescope	software,	which	allows	objective	quantification	of	the	exact	percentage	of	
stained	lymphocytes.	However,	there	were	issues	with	the	licencing	of	this	software	at	
the	 University	 of	 Leeds	 and	 hence	 this	 could	 not	 be	 used.	 In	 any	 event,	 subjective	
classifications	of	intra-tumoural,	stromal,	or	tumour	edge	would	still	be	required.	There	
were	 other	 limitations	 with	 Webscope,	 as	 it	 does	 not	 allow	 saving	 the	 annotations	
made	 on	 the	 slides.	 Screen	 shots	 therefore	 had	 to	 be	 taken	 and	 used	 by	 the	 second	
scorer.	 A	 more	 objective	 way	 of	 assessing	 the	 lymphocyte	 infiltrate	 would	 certainly	
increase	the	reliability	of	such	studies.	
5.3 Future	directions	






T	 cell	 subsets,	 I	 did	 not	 evaluate	 these	 in	 the	 tissue	 specimens,	 as	 such	 subtle	
phenotyping	is	not	possible	retrospectively	using	archival	samples.	 
	
Despite	 the	 limitations	of	 this	 study,	 there	 is	 enough	evidence	 to	 suggest	 that	 cancer	
and	chemotherapy	 for	 treatment	of	cancer	have	some	effects	on	 the	 immune	system.	
The	clinical	implications	of	this,	however,	remain	poorly	understood	and	are	worthy	of	
further	 study	 and	 assessment	 in	 a	 larger	 cohort	 of	 patients	 in	 order	 to	 improve	 the	
management	of	breast	cancer	patients.	
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Effect of Breast Cancer Chemotherapy on Immunity 
 
Information Sheet For Study Participants 
 
You are invited to take part in a research study. Before you decide whether to do so it is 
important for you to understand why the research is done and how it could affect you. Please 
take time to read this information carefully. If anything is not clear or you would like more 
information please do not hesitate to contact us. Thank you for reading this. 
 
What is the purpose of this study? 
Breast Cancer is the most common cancer in women in the UK. Many patients with breast 
cancer require chemotherapy as part of their treatment. Chemotherapy is the use of anti-
cancer drugs to destroy cancer cells. The aim of chemotherapy is to do the maximum 
damage to cancer cells while causing the minimum damage to healthy tissue.  We have 
previously observed that chemotherapy results in the loss of certain white blood cells (B 
lymphocytes) that are a critical part of the immune system - the body’s defence against 
infections. We think that these cells return after the end of chemotherapy but we are not sure 
how quickly they return or whether they are fully functional. We aim to study the return of 
these cells in breast cancer patients being treated with chemotherapy to allow us to see 
whether the immune system of these patients recovers fully after chemotherapy. We will also 
test whether there is a need for revaccination against some common diseases for which 
vaccinations are available. 
 
Why have I been chosen? 
You have been invited to take part because you are going to have chemotherapy for breast 
cancer. 
 
Do I have to take part? 
No, it is up to you to decide whether or not to take part. If after reading this information 
sheet and asking as many questions as you wish, you decide to take part we will ask you to 
sign a consent form and to keep the information sheet for future reference. You are still free 
to withdraw at any time and without giving any reason. A decision to withdraw at any time 
or a decision not to take part will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
If you decide to take part, a series of extra blood tests will be taken from you during your 
treatment.  These blood tests will be taken at the start of chemotherapy and after the 
completion of your chemotherapy. You will have further blood tests when you come for your 
routine follow up clinic appointments up to 2 years after treatment. Each blood test will 
require about 10mLs of blood and will be taken from a needle placed into your arm. In total 
we expect that you will have up to four extra blood tests that would not normally be taken as 
part of standard treatment for breast cancer.  These blood tests will be done during your 
routine visits to the hospitals. 
 
What is my blood tested for? 
Your blood will be tested for various cells, proteins and molecules many of which are 
important components of your immune system and protect you from infection. 
 
What other information will be collected in the study? 
If you agree to take part, information routinely available from your medical notes will be 
used in the study. This includes medication that you are currently taking, the type of 
operation carried out, the pathology findings from the tissue removed and a description of 
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your post-operative recovery. Extra tests may be carried out in the laboratory on the tissue 
that was removed from you at the time of your operation. We will also collect all details 
regarding the drugs used for your chemotherapy and any reactions and side effects of the 
chemotherapy that may affect your immune system. 
 
What do I have to do? 
During your routine visits to the hospital before and after your chemotherapy, you will have 
some extra blood tests if you agree to participate. 
 
What are the possible disadvantages of taking part? 
Extra blood tests will be taken during the study period that would not normally form part of 
the standard treatment for breast cancer. These blood tests will always be taken by authorised 
trained professionals to minimise any discomfort or disruption to yourself. 
 
What are the possible benefits of taking part? 
There is no direct benefit to you but it may provide us with important information to help 
identify people who are more likely to develop problems after their chemotherapy for breast 
cancer in the future. 
 
Will the information obtained in the study be confidential? 
All information collected from you in the study will be kept strictly confidential. This 
information will be securely stored at the LGI on paper and electronically under the 
provision of the 1998 Data Protection Act. Anything you say will be treated in confidence, 
no names will be mentioned in any report of the study, and care will be taken so that 
individuals cannot be identified from details in reports from the results of the study. Only 
appropriately-qualified members of the Breast Research Team may confidentially review 
your medical records. This is to ensure that the study is carried out to the highest possible 
scientific standards. In order to be able to check your notes we will need to hold some 
information, such as your date of birth and hospital number, so that we can identify your 
notes accordingly. We will also hold a copy of your signed consent form. 
 
What will happen to the results of the study? 
We would hope to publish the results of the study in a quality medical journal.  
 
Who is organising and funding the research? 
The study is under the supervision of Mr K Horgan (Clinical Director for Breast Diseases, 
United Leeds Teaching Hospital) and funded from a Breast Cancer Course Trust Fund. 
Neither the hospital nor any of the study organisers receive any payment for your 
participation in the study. 
 
Contact for further information. 
If you have problems or questions, please do not hesitate to get in touch. Please use one of 
the following contact numbers: 
 
Miss Rashmi Verma (Surgical Research Fellow)  0113 3923624 / 07727097304 
Sue Hartup, Amy Henson, Ruth Thorpe (Breast Research Nurses) 0113 3928838 
 

























PATIENT CONSENT FORM -  
 
Title of Project: Effect of Breast Cancer Chemotherapy on Immunity 
 
Consent for additional blood samples to be taken pre and post chemotherapy 
 
           please initial boxes 
 
1. I confirm that I have read and understand the information sheet dated ............................      
for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals from the research staff or from regulatory authorities where it is relevant to my 
taking part in research; I give permission for these individuals to have access to my records. 
 
4. I understand that my medical data will be collected for this study and may be used to help 
develop new research, and that data protection regulations will be observed and strict 
confidentiality maintained. 
 
5. I consent to the storage, including electronic, of personal information for the purposes of 
this study.  I understand that any information that could identify me will be kept strictly 
confidential and that no personal information will be included in the study report or other 
publication. 
 
6. I agree to take part in the above study.  
 
________________________ ________________ _______________ 
Name of Patient Date Signature 
 
_________________________ ________________ _______________ 



































































6.2.2 Proportions	 of	 lymphocytes	 post-chemotherapy	
compared	to	the	matched	pre-chemotherapy	level	
	 2	w	 3	m		 6	m	 9	m	
B	 5.38	 32.60	 68.10	 68.76	
CD4	 41.64	 48.71	 59.75	 60.11	
CD8	 59.17	 83.81	 93.58	 93.40	





















6.2.3 Repopulating	 B	 and	 CD4	 cells	 as	 proportions	 of	 pre-

















1st	tertile	 153.50	 6.04	 31.46	 76.92	 64.33	
2nd	tertile	 237.13	 4.25	 37.12	 75.66	 88.57	
3rd	tertile	 403.00	 5.69	 35.82	 63.11	 63.36	




















1st	tertile	 752.00	 44.25	 53.70	 73.50	 72.06	
2nd	tertile	 1030.00	 40.53	 52.86	 66.90	 58.95	
3rd	tertile	 1677.00	 41.65	 46.24	 48.49	 53.02	








B	cells	 Pre		 2	w		 3m	 6m	 9m	
1st	tertile	 153.50	 7.00		 46.00		 80.00		 100.00		
2nd	tertile	 237.00	 11.00	 82.00	 161.00	 207.50	




<0.001	 0.030	 <0.001	 <0.001	 <0.001	
CD4	 Pre	 2w	 3m	 6		 9		
1st	tertile	 752.00	 342.00		 387.00		 513.00		 544.00		
2nd	tertile	 1030.00	 432.50	 532.00	 635.00	 663.00	









6.2.4 Correlation	 between	 B	 and	 CD4+	 T	 cell	 proportions	
relative	 to	 pre-chemotherapy	 level	 and	 clinico-
pathological	factors	
	 2w	 3m	 6m	 9m	
Age	 NS	 NS	 NS	 NS	
Tumour	grade	 NS	 NS	 NS	 NS	
Tumour	size	 NS	 NS	 NS	 0.300	(p=0.029)	
LN	
involvement	




NS	 NS	 NS	 NS	
ER/PR	status	 NS	 NS	 NS	 NS	














Recurrence	 NS	 NS	 NS	 NS	




	 2w	 3m	 6m	 9m	
Age	 NS	 NS	 NS	 NS	
Tumour	grade		 NS	 NS	 NS	 NS	
Tumour	size	 NS	 NS	 NS	 NS	
LN	
involvement	




NS	 NS	 NS	 NS	
ER/PR	status	 NS	 NS	 NS	 NS	






Radiotherapy	 NA	 NS	 NS	 -0.292	(p=0.034)	
Smoking	 NS	 NS	 NS	 NS	
Recurrence	 NS	 NS	 NS	 NS	





6.2.5 Correlations	 between	 B	 and	 CD4+	 T	 cell	 absolute	 counts	
and	clinic-pathological	factors	
	 Pre	 2w	 3m	 6m	 9m	
Age	 NS	 NS	 NS	 NS	 NS	
Tumour	
grade	
NS	 NS	 NS	 NS	 NS	
Tumour	size	 NS	 NS	 NS	 NS	 NS	
LN	
involvement	




NS	 NS	 NS	 NS	 NS	












Radiotherapy	 NA	 NA	 NS	 NS	 NS	






Death	 NS	 NS	 NS	 NS	 NS 
Table	29.	Correlations	between	B	cell	absolute	counts	and	clinic-pathological	factors	






NS	 NS	 NS	 NS	 NS	
Tumour	size	 NS	 NS	 NS	 NS	 NS	
LN	
involvement	




NS	 NS	 NS	 NS	 NS	
ER/PR	status	 NS	 NS	 NS	 NS	 NS	













Recurrence	 NS	 NS	 NS	 NS	 NS	





6.2.6 Multivariate	 analysis	 to	 determine	 predictors	 of	 B	 and	
CD4+	T	cell	counts	post-chemotherapy	
B	cell	count	at	2w	 R2	 p	 F	(DF)	 Sig	 F	
change	
95%	CI	








B	cell	count	at	3m	 	 	 	 	 	








B	cell	count	at	6m	 	 	 	 	 	








B	cell	count	at	9m	 	 	 	 	 	























CD4+	 T	 cell	 count	 at	
2w	
R2	 p	 F	(DF)	 Sig	 F	
change	
95%	CI	








CD4+	 T	 cell	 count	 at	
3m	
	 	 	 	 	








CD4+	 T	 cell	 count	 at	
6m	
	 	 	 	 	








CD4+	 T	 cell	 count	 at	
9m	
	 	 	 	 	













	 Time	 EC/FEC	 EC+Taxane	 p	
Anti-tetanus	
antibody	
2w	 81.46	 72.03	 0.497	
3m	 94.07	 94.07	 0.705	




2w	 68.36	 55.94	 0.086	
3m	 66.58	 64.10	 0.782	
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0.354	 0.552	 246	 3/35	(9%)	
4/27(15%)	
0.613	 0.434	




































































































































































































































1.358	 0.244	 3.04	 3/40	
4/38	
0.443	 0.511	
Table	 36.	 .	 Effect	 of	 the	 extent	 of	 depletion	 or	 repopulation	 of	 B	 cell	 subtypes	 post-
chemotherapy	on	survival	




















































































































































































































































Table	 37.	 Effect	 of	 the	 extent	 of	 depletion	 or	 repopulation	 of	 T	 cell	 subtypes	 post	 -
chemotherapy	on	survival	
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from	 log	 rank	 test	 comparing	 survival	 in	 the	 two	 groups	 (above	 and	 below	 the	 cut	 off	
value	 of	 lymphocytes).	 RA+CD62L+	 Naïve	 T	 cell	 was	 analysed	 mainly	 in	 post-
chemotherapy	 samples	 and	 very	 few	 pre-chemotherapy	 samples.	 Therefore,	 there	 was	
































































































rs =0.676, p<0.001 rs =0.609, p<0.001




Scatter	 plot-showing	 correlation	 between	 the	 stromal	 proportion	 and	 intra-tumoural	











CD4 ITL proportion (%)















CD8 ITL proportion (%)















FoxP3 ITL proportion (%)















CD20 ITL proportion (%)

















rs =0.593, p<0.001 rs =0.692, p<0.001
rs =0.565, p<0.001 rs =0.435, p<0.001
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rs = 0.522, p<0.001 rs = 0.514, p<0.001 rs = 0.523, p<0.001























































































































rs = 0.649, p<0.001 rs = 0.505, p<0.001 rs = 0.568, p<0.001
rs = 0.585, p<0.001 rs = 0.626, p<0.001 rs = 0.472, p<0.001
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6.3.3 	Correlation	 between	 intra-tumoural	 lymphocyte	 counts	
and	proportions	of	different	lymphocytes	
	
Figure	 66.	 Correlation	 between	 intra-tumoural	 lymphocyte	 counts	 of	 different	
lymphocytes	














































































































rs = 0.507, p<0.001 rs = 0.388, p=0.002 rs = 0.517, p<0.001
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CD8 ITL proportion (%)
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rs = 0.604, p<0.001 rs = 0.593, p<0.001 rs = 0.622, p<0.001































































































































































































































































































































































































































































Scatter	 plot-showing	 correlation	 between	 circulating	 CD8+	 T	 cells	 count	 pre-	





















































































rs= 0.313, p=0.024 NS
rs= 0.322, p=0.020 rs= 0.375, p=0.006
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6.3.9 Correlations	between	circulating	CD8+	T	cells	and	tumour	






Scatter	 plot-showing	 correlation	 between	 circulating	 CD8+	 T	 cells	 count	 pre-	
chemotherapy	and	stromal	count	(A),	stromal	proportion	(C),	in	ER/PR	negative	patients	






































































rs= 0.550, p=0.010 NS







Scatter	 plot-showing	 correlation	 between	 circulating	 CD8+	 T	 cell	 count	 pre-
chemotherapy	and	intra-tumoural	CD8+	T	cell	count	(A)	and	intra-	tumoural	proportion	
of	CD8+	T	cells	(C)	in	ER/PR	negative	patients	and	intra-tumoural	CD8+	T	cells	count	(B)	
































































































































































































































































































































































































































































































































































































2.010	 0.156	 1.9	 1/29	(3%)	
4/11	(36%)	
7.831	 0.005	
Table	46.	Effect	of	high	and	low	FoxP3+	TILs	on	survival	in	ER/PR	-ve	and	+ve	patient	
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